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Resumo 
 
O glicosilfosfatidilinositol (GPI) é um complexo glicolipídico utlizado por dezenas 
de proteínas, o qual medeia a sua ancoragem à superfície da célula. Proteínas de 
superfície celular ancoradas a GPI apresentam várias funções essenciais para a 
manutenção celular. A deficiência na síntese de GPI é o que caracteriza 
principalmente a deficiência hereditária em GPI, um grupo de doenças 
autossómicas raras que resultam de mutações nos genes PIGA, PIGL, PIGM, PIGV, 
PIGN, PIGO e PIGT, os quais sao indispensáveis para a biossíntese do GPI.  
Uma mutação pontual no motivo rico em GC -270 no promotor de PIGM impede a 
ligação do factor de transcrição (FT) Sp1 à sua sequência de reconhecimento, 
impondo a compactação da cromatina, associada à hipoacetilação de histonas, e 
consequentemente, impedindo a transcrição de PIGM. Desta forma, a adição da 
primeira manose ao GPI é comprometida, a síntese de GPI diminui assim como as 
proteínas ligadas a GPI à superficie das células. Pacientes com Deficiência 
Hereditária em GPI-associada a PIGM apresentam trombose e epilesia, e ausência 
de hemólise intravascular e anemia, sendo que estas duas últimas características 
definem a Hemoglobinúria Paroxística Nocturna (HPN), uma doença rara causada 
por mutações no gene PIGA. 
 
Embora a mutação que causa IGD seja constitutiva e esteja presente em todos os 
tecidos, o grau de deficiência em GPI varia entre células do mesmo tecido e entre 
células de tecidos diferentes. Por exemplo nos granulócitos e linfócitos B a 
deficiência em GPI é muito acentuada mas nos linfócitos T, fibroblastos, plaquetas 
e eritrócitos é aproximadamente normal, daí a ausência de hemólise intravascular.  
Os eventos transcricionais que estão na base da expressão diferencial da âncora GPI 
nas células hematopoiéticas são desconhecidos e constituem o objectivo geral desta 
tese.  
 
x 
Em primeiro lugar, os resultados demonstraram que os níveis de PIGM mRNA 
variam entre células primárias hematopoiéticas normais. Adicionalmente, a 
configuração dos nucleossomas no promotor de PIGM é mais compacta em células 
B do que em células eritróides e tal está correlacionado com os níveis de expressão 
de PIGM, isto é, inferior nas células B. A presença de vários motivos de ligação 
para o FT específico da linhagem megacariocítica-eritróide GATA-1 no promotor 
de PIGM sugeriu que GATA-1 desempenha um papel regulador na sua transcrição. 
Os resultados mostraram que muito possivelmente GATA-1 desempenha um papel 
repressor em vez de activador da expressão de PIGM. Resultados preliminares 
sugerem que KLF1, um factor de transcrição restritamente eritróide, regula a 
transcrição de PIGM independentemente do motivo -270GC.    
 
Em segundo lugar, a investigação do papel dos FTs Sp demonstrou que Sp1 medeia 
directamente a transcrição de PIGM em ambas as células B e eritróide. 
Curiosamente, ao contrário do que acontece nas células B, em que a transcrição de 
PIGM requer a ligação do FT geral Sp1 ao motivo -270GC, nas células eritróides 
Sp1 regula a transcrição de PIGM ao ligar-se a montante e não ao motivo -270GC. 
Para além disso, demonstrou-se que Sp2 não é um regulador directo da transcrição 
de PIGM quer nas células B quer nas células eritróides.    
Estes resultados explicam a ausência de hemólise intravascular nos doentes com 
IGD associada a PIGM, uma das principais características que define a HPN.  
 
Por último, resultados preliminares mostraram que a repressão da transcrição de 
PIGM devida à mutação patogénica -270C>G está associada com a diminuição da 
frequência de interacções genómicas em cis entre PIGM e os seus genes “vizinhos”, 
sugerindo adicionalmente que a regulação de PIGM e desses genes é partilhada. 
 
No seu conjunto, os resultados apresentados nesta tese contribuem para o 
conhecimento do controlo transcricional de um gene housekeeping, específico-de-
tecido, por meio de FTs genéricos e específicos de linhagem. 
 
 
 
 
xi 
Abstract 
 
Glycosylphosphatidylinositol (GPI) is a complex glycolipid used by dozens of 
proteins for cell surface anchoring. GPI-anchored proteins have various functions 
that are essential for the cellular maintenance. Defective GPI biosynthesis is the 
hallmark of inherited GPI deficiency (IGD), a group of rare autosomal diseases 
caused by mutations in PIGA, PIGL, PIGM, PIGV, PIGN, PIGO and PIGT, all 
genes indispensable for GPI biosynthesis.  
A point mutation in the -270GC-rich box in the core promoter of PIGM disrupts 
binding of the transcription factor (TF) Sp1 to it, imposing nucleosome compaction 
associated with histone hypoacetylation, thus abrogating transcription of PIGM. As 
a consequence of PIGM transcriptional repression, addition of the first mannose 
residue onto the GPI core and thus GPI production are impaired; and expression of 
GPI-anchored proteins on the surface of cells is severely impaired. Patients with 
PIGM-associated IGD suffer from life-threatening thrombosis and epilepsy but not 
intravascular haemolysis and anaemia, two defining features of paroxysmal 
nocturnal haemoglobinuria (PNH), a rare disease caused by somatic mutations in 
PIGA. 
Although the disease-causing mutation in IGD is constitutional and present in all 
tissues, the degree of GPI deficiency is variable and differs between cells of the 
same and of different tissues. Accordingly, GPI deficiency is severe in granulocytes 
and B cells but mild in T cells, fibroblasts, platelets and erythrocytes, hence the lack 
of intravascular haemolysis. 
The transcriptional events underlying differential expression of GPI in the 
haematopoietic cells of PIG-M-associated IGD are not known and constitute the 
general aim of this thesis.  
 
Firstly, I found that PIGM mRNA levels are variable amongst normal primary 
haematopoietic cells. In addition, the nucleosome configuration in the promoter of 
PIGM is more compacted in B cells than in erythroid cells and this correlated with 
the levels of PIGM mRNA expression, i.e., lower in B cells. The presence of 
several binding sites for GATA-1, a mega-erythroid lineage-specific transcription 
xii 
factor (TF), at the PIGM promoter suggested that GATA-1 has a role on PIGM 
transcription. My results showed that GATA-1 in erythroid cells is most likely a 
repressor rather than an activator of PIGM expression. Preliminary data suggested 
that KLF1, an erythroid-specific TF, regulates PIGM transcription but 
independently of the -270GC motif.  
Secondly, investigation of the role of the Sp TFs showed that Sp1 directly mediates 
PIGM transcriptional regulation in both B and erythroid cells. However, unlike in B 
cells in which active PIGM transcription requires binding of the generic TF Sp1 to 
the -270GC-rich box, in erythroid cells, Sp1 regulates PIGM transcription by 
binding upstream of but not to the -270GC-rich motif. Additionally, I showed that 
Sp2 is not a direct regulator of PIGM transcription in B and erythroid cells. 
These findings explain lack of intravascular haemolysis in PIGM-associated IGD, a 
defining feature of PNH. 
 
Lastly, preliminary work shows that transcriptional repression of PIG-M by the 
pathogenic -270C>G mutation is associated with reduced frequency of in cis 
genomic interactions between PIGM and its neighbouring genes, suggesting a 
shared regulatory link between these genes and PIGM. 
 
Altogether, the results presented in this thesis provide novel insights into tissue-
specific transcriptional control of a housekeeping gene by lineage-specific and 
generic TFs. 
 
Chapter 1 - Introduction 
 
1 
Chapter 1 – Introduction 
 
1.1 Regulation of gene expression 
 
 
Gene expression is the fundamental process by which the genetic information is 
converted to messenger RNA (mRNA) that is ultimately translated into functional 
proteins essential to the cell.  
Control of gene expression has to be dynamic and highly regulated in order that 
spatial and temporal patterns that ensure cell and tissue development and function 
are achieved. For this purpose, gene expression is fine-tuned at different levels 
starting with transcription. RNA Polymerase II (RNA PolII) binding and active or 
repressed gene transcription is regulated by the integration of in cis DNA 
sequence information (promoters, enhancers and insulators), DNA elements with 
processes that determine chromatin packaging, histone and DNA modification 
(epigenetic marks). Next, I will provide an overview of transcriptional regulation 
of gene expression. 
 
1.1.1 Transcriptional regulation of gene expression 
 
 
Typically, protein-coding genes contain two distinct modules of cis-acting DNA 
elements: i) a promoter, which is composed by a core promoter and nearby (or 
proximal) promoter, and ii) distal regulatory elements, which can be enhancers, 
silencers, insulators or locus control regions (LCR) (Fig.1). 
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Fig. 1 - Schematic representation of a typical gene regulatory region (adapted from 
Maston, G.A. et al, 2006). The promoter region comprises the proximal and the core 
promoter and usually spans ≤ 1Kb. The core promoter normally encompasses the 
transcription start site (TSS), from where transcription is initiated (black arrow).  
 
 
Whereas the core promoter directs the initiation of transcription at precise sites by 
nucleating the Pre-initiation complex (PIC) and the RNA PolII, the proximal 
promoter and distal regulatory elements can activate or repress transcription. 
Distal regulatory elements, like enhancers or LCR, dispersed over tens to 
thousands of kilobases from the transcription start site (TSS), regulate gene 
transcription by forming DNA loops, in which distal DNA-bound proteins are 
nucleated to the core promoter. A very well-studied example is the β-globin locus 
where the distal elements - deoxyribonuclease I (DNase I) hypersensitive sites 
(DHSs) – in the LCR physically interact with the β-globin gene, HBB, by 
chromosomal looping (1, 2). This mechanism of gene regulation has also been 
demonstrated in transitional states of α-globin expression during erythroid 
differentiation (3).  
 
The method most used to study intrachromosomal interactions between cis-acting 
elements is called 3C (chromosome conformation capture) (4) and recently, 
methods derived from this technique have been developed (5, 6) and applied at the 
single cell level (7). 
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Alterations in DNA regulatory elements have been associated with human 
diseases and in fact, it is estimated that between 1 to 2% of disease-causing point 
mutations are in regulatory regions of the genome, the majority located within 
1Kb of the TSS (8). Nevertheless, cis-acting mutations do not necessarily affect 
the nearby gene. In agreement, a genome-wide association study (GWAS) has 
recently linked single nucleotide polymorphisms (SNPs) within DHSs not only to 
adjacent genes but also to new distant gene targets. Interestingly, most SNPs 
within DHSs overlapped with a transcription factor recognition sequence further 
suggesting the disruption of common transcriptional networks in disease (9). 
 
As reviewed by Butler J. et al (10), the core promoter is the minimal DNA 
sequence encompassing the TSS (extending approximately 35 nucleotides 
upstream and downstream), that is sufficient to direct initiation of transcription by 
“docking” the basal transcriptional machinery; the proximal promoter, 
immediately upstream of the core promoter, spans a few hundred nucleotides. 
Proximal promoters, as well as distal regulatory elements, contain short DNA 
sequences known to anchor specific transcription factors (TFs), proteins that bind 
DNA and modulate transcription. TFs can be subdivided into two groups: generic 
and cell-type specific. Generic TFs are ubiquitously expressed in all cell types 
whereas cell-type specific TFs have restricted expression.  
The DNA sequences bound by TFs, called transcription factor binding sites 
(TFBS), are typically constituted by 6 to 12 nucleotides although binding 
specificity is usually determined by 4 to 6 positions within the site (11).  
 
 
1.1.2 The transcriptional machinery 
 
Protein-coding genes are transcribed by RNA PolII which generates mRNA 
transcripts from a template DNA. Accurate and efficient transcription initiation 
involves various factors which can be classified in three groups: general 
transcription factors (GTFs) that include TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and 
TFIIH; activators and co-activators. GTFs assemble in the core promoter in an 
ordered manner together with RNA PolII at the TSS. Transcriptional activity 
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derived from binding of the general factors and RNA PolII at the core promoter - 
basal transcription -, is usually low but can be potentiated by transcription factors 
that once recruited stabilize the transcriptional machinery. Accordingly, 
transcriptional activity is greatly stimulated or repressed by co-activators or co-
repressors, respectively, localised upstream at the core promoter. Co-factors lack 
DNA binding properties and therefore interact physically with the DNA through 
bound TFs. For instance, Mediator, a multiprotein complex, is a co-activator 
known to target RNA PolII and recently, various crucial aspects of transcriptional 
regulation have been assigned to it (12). RNA PolII core promoters are 
functionally and structurally diverse. A small proportion contains a TATA box 
located 30 base pairs (bp) upstream of the TSS that guides RNA PolII to initiate 
transcription (“sharp” promoters). Usually, TATA promoters exhibit a low GC 
dinucleotide content and are associated with tissue-specific transcription. On the 
other hand, the majority of the promoters contain long (on average 1000bp) GC-
rich DNA sequences called CpG island (CGIs) and correlate with the presence of 
multiple TSSs (“broad” promoters) (13-15). CGIs-associated promoters have been 
linked for long to housekeeping (ubiquitously expressed) genes, but is now clear 
that tissue-specific genes also contain CGI promoters (16, 17). Interestingly, some 
promoters contain both a TATA box and a CpG island, like in the erythropoietin 
gene (18, 19) and new studies have suggested that promoters of this type are 
capable of both TATA-dependent and TATA-independent transcriptional 
initiation (20). Therefore, the initial distinction between high and low-CpG 
promoters tends to fall in disuse and as suggested by Lenhard, B et al, 2012, (21) 
dividing promoters into “sharp” and “broad” may provide a better functional 
classification. 
Apart from the TATA box, core promoters also contain other functional elements 
including initiator (INR), TFIIB recognition element (BRE), downstream core 
promoter element (DPE), amongst others (10). 
 
Defining the boundaries of core promoters is challenging due to their complexity. 
Most genes use more than one core promoter (alternative promoter usage), 
typically located hundreds or thousands of nucleotides apart, and most promoters 
contain a cluster of TSSs rather than a single, well defined TSS. The use of 
alternative promoters entails the generation of at least two different mRNA 
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isoforms that might generate distinct protein products and moreover, it is 
associated with patterns of gene expression, i.e., ubiquitous or tissue-
specific/developmental stage-specific (22).  There are examples in the literature in 
which the generation of a new promoter element causes disease by interfering 
with normal gene expression (23).  
 
1.1.3 Epigenetic control of transcription 
 
TFs usually are part of multiprotein complexes. Beyond recruiting co-activators 
and co-repressors, TFs also recruit histone-modifying enzymes and remodelling 
complexes that modify the nucleosomes, the basic unit of chromatin, in a dynamic 
manner. The term Epigenetics refers transferable regulatory information that 
controls gene transcription by processes other than changes in the underlying 
DNA sequence.  
 
The nucleosome, the basic unit of chromatin, is composed by an octamer of four 
core histones H2A, H2B, H3 and H4, wrapped around a string of 147 base pairs of 
DNA. Consecutive nucleosomes are regularly arranged and connected by the 
DNA linker histone H1 and once compacted in higher-order structures originate 
the chromosome (Fig. 2). 
 
 
 
 
Fig. 2 – Levels of structural organization of the DNA and histone proteins. DNA 
wrapped around a globular structure of the histone octamer constitutes the nucleosome. 
The chromatin fiber consists in the higher order of chromatin organisation; further 
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packaging of the chromatin fiber originates the chromosome. (Adapted from image on the 
National Human Genome Research Institute website; author - Darryl Leja). 
 
 
In the genome, the type and positioning of the nucleosomes is determined by a 
variety of factors including, DNA sequence, activators, nucleosome remodelers 
and the RNA PolII transcription machinery (24). 
The histones that constitute the nucleosomal unit are proteins with a globular 
domain and an N-terminal “tail”. Whilst the globular domains interact with each 
other in order to form the octameric core, the histone “tails” undergo post-
translational modifications (PTM) at specific aminoacid residues. Those 
modifications, mediated by histone-modifying enzymes, include acetylation, 
methylation, phosphorylation, ubiquitylation, sumoylation, ADP ribosylation, 
deamination and proline isomerization. Acetylation of histone “tails” is one of the 
best studied modifications. Usually, acetylation of histone “tails” by histone 
acetyltransferases (HATs) is associated with active gene expression whereas 
hypoacetylation at specific promoters by histone deacetylases (HDACs) is 
associated with repressed genes (25). Nevertheless, HDACs have been also found 
at active genes suggesting that gene expression results from a dynamic, balanced 
process between acetylation and deacetylation (26). 
Another epigenetic mark that modulates gene expression is DNA methylation. 
DNA methylation occurs at the cytosine nucleotides that constitute the CpG 
modules and it is typically associated with gene silencing (27).  
 
1.1.4 Transcription factors and DNA-binding specificity 
 
 
It is estimated that there are approximately 1,400 transcription factors containing 
sequence specific DNA-binding properties (28). 
The DNA binding specificity of a TF is primary defined by the  DNA binding 
domain (DBD) and according to it, TFs can be classified in different families: 
cysteine-rich zinc finger, homeobox, helix-loop-helix (HLH), basic leucine zipper 
(bZIP), forkhead, ETS, Pit-Oct-Unc (POU) (11). In addition to the DBD, TFs also 
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contain a transactivation domain (TAD) which by recruiting the other elements 
of the transcriptional machinery stimulates transcription.  
 
Whereas the DBD of TFs has been studied in vitro for many decades by 
techniques such as Electrophoretic Mobility Shift Assay (EMSA), full-length 
transcription factor occupancy has been studied in vivo only in the past few years 
by methods including Chromatin Immunoprecitipation (ChIP) and its derivatives 
(ChIP-chip, ChIP-seq and ChIP-exo) and DamID. DNase I hypersensitivity and 
Formaldehyde-Assisted Isolation of Regulatory Elements (FAIRE) have been also 
extensively used to investigate chromatin structure. The former is based on the 
principle that TF binding to the DNA generates a remodelled chromatin state 
more permissive to nuclease digestion. Studies have recently suggested the use of 
DHSs profile as quantitative benchmark in lineage specification (29-31). 
 
Across the genome, only a small fraction of predicted consensus motifs is 
occupied by TFs (32, 33) suggesting that the presence of a consensus motif is not 
always sufficient to explain TF binding. Understanding what determines TF 
occupancy at particular consensus motifs is a very interesting and emerging area 
of research in the field of regulation of gene expression.  
The sequence flanking the core motif (34), cofactor binding (35) and the 
chromatin landscape (DHSs and histone marks) (36, 37) are known to influence 
TF binding and consequently gene expression. Additionally, spacing and 
orientation between dimeric sites also influence TF binding specificity (34).  
Conversely, TF binding also influences the chromatin landscape (29, 38).   
 
In what respects cell-type specific TF binding preferences, studies in the field are 
even less numerous. The contribution of DNase accessibility along with DNA 
sequence and histone modifications in cell type-specific TF binding was recently 
investigated genome-wide by using a computational approach. DNase 
accessibility not always explains cell-type specific TF binding as in sites where 
binding sites were accessible in both erythroid and lymphoid cell lines, TFs, such 
as JUND and YY1, occupied their cognate motifs only in one cell type. Cell-type 
specific TF binding was therefore more reliable on the “preferential” sequence 
(determined by the presence of heterodimer motifs for example) rather than on 
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chromatin accessibility (39). Another study, using as a model the estrogen 
receptor (ER) compared, in multiple cell types, the properties of the cell-type 
specific and shared TF binding sites. Most shared sites contained high-affinity 
cognate sequences and did not show a dependency on open chromatin. On the 
other hand, cell specific sites harboured low-affinity sequence elements and were 
associated with chromatin accessibility (40). Other investigations suggest that the 
quantitative difference in TF-binding between cell types, rather than an ON/OFF 
event, should be taken into account when studying TF binding properties (41).  
 
Together, these studies highlight the importance of the underlying DNA sequence 
in TF binding specificity. They reveal the complexity of TF binding and the 
importance in understanding DNA binding properties of individual TFs in a cell-
type specific context in vivo. 
Overall, the functional importance of differential and cell type-specific 
preferences of TF binding to regulatory DNA at a single gene level in health and 
in disease has not been determined. In my PhD project, I took advantage of a 
pathogenic promoter mutation that causes Inherited Glycosylphosphatidylinositol 
(GPI) Deficiency, i.e, IGD, to address these issues.  
 
1.1.5 Deregulation of transcription in disease 
 
Many diseases and syndromes have been linked to alterations in components of 
transcriptional regulation. Apart from mutations in regulatory elements, mutations 
in transcription factors, co-factors, chromatin regulators, and non-coding RNAs 
have been also reported.  
Regarding TFs, alterations in their levels, structure or function impact changes in 
wide gene regulatory networks and not surprisingly, have implications in various 
human diseases, including cancer (42, 43), autoimmunity and inflammation (44, 
45), cardiovascular disease (46) amongst others. Importantly, a vast number of 
TFs has been associated with developmental defects, revealing their importance 
during early stages of development (47-49). The capacity of some TFs in auto-
regulate their own expression also highlights their importance in maintaining 
appropriate gene expression (50, 51).  
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The majority of the alterations in TFs relate by far with loss of function of the 
protein. Some others relate with generation of a fusion protein or de-regulated 
expression due to translocations, mutations in promoters or enhancers and very 
few are associated with gain of function or amplification (reviewed by Lee and 
Young, 2013 (52)).  
Changes in gene regulatory regions normally alter transcription either by gaining 
or loss of a transcription factor binding site. For instance, a SNP in the α-globin 
cluster generates a new GATA-1 binding site, which by recruiting an erythroid-
specific complex to the new promoter causes α-thalassemia (23). In the Pierre 
Robin syndrome, a heterozygous point mutation alters binding of the TF MSX1, 
abrogating the enhancer function, thus causing cleft palate (53). 
 
One of the best studied Mendelian disorders caused by a mutation affecting TF 
binding is the PIGM-associated Inherited GPI Deficiency. It is caused by a 
hypomorphic C>G point mutation in the core promoter of the GPI 
mannosyltransferase I (GPI-MTI), PIGM, abrogating binding of the TF Sp1 (38).  
 
In the subsequent sections, first, I will give an overview of the GPI biosynthetic 
pathway and the diseases associated with it followed by a more extensive 
description of the clinical, cellular, biochemical and ‘transcriptional’ phenotype of 
PIGM-associated GPI deficiency. 
 
1.2 The Glycosylphosphatidylinositol (GPI) biosynthetic pathway  
 
1.2.1 GPI-mediated anchoring of proteins in the cell membrane 
 
 
Whereas a large number of proteins are embedded in the phospholipid bilayer of 
the cell membrane through a transmembrane arrangement, some surface proteins 
are anchored on the cell membrane through covalent linkage to GPI (54). 
Glycosylphosphatidylinositol (GPI)-anchored proteins (GPI-APs) constitute a 
unique class of proteins associated with the cell membrane, intersecting only the 
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external monolayer of the cell membrane. The GPI anchor, a complex glycolipid 
consisting of a phosphatidylinositol (PI) moiety and a glycan core, can be attached 
to the C- terminus of dozens of proteins. GPI-APs have various functions in the 
cell, including enzymes, complement regulatory proteins, and signal transduction 
(summarised on Table 1). 
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Table 1 – Examples of GPI-APs and respective function in mammalian cells [adapted 
from (55)] 
 
GPI-anchored protein Function 
Alkaline phosphatase 
5’-nucleotidase 
Acetylcholinesterase 
Dipeptidase 
Enzymes 
LFA-3 
NCAM 
Cell-cell interaction and 
adhesion 
CD55 (DAF) 
CD59 
Complement regulation 
Thy-1 
CD14 
Carcinoembryonic antigen 
(CEA) 
CD52 
Mammalian antigens 
CD16b 
Folate-binding protein 
Others 
 
 
The GPI backbone structure EtN-P-6Manα1-2Manα1-6Manα1-4GlcNα1-
6myoInositol-phospholipid (where EtN-P is ethanolamine phosphate; Man is 
mannose and GlcN is glucosamine) (Fig. 4) is shared among various eukaryotic 
GPI-APs, such as those in yeast (Sacccharomyces cerevisiae), protozoan parasites 
where they are highly abundant (Trypanosoma brucei and Plasmodium 
falciparum) and plants (Pyrus communis).  
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Fig. 3 – Structure of the GPI anchor common core. Adapted from Mayor and 
Riezman, 2004 (56). 
 
 
Despite their common core, there is variability in both glycan and lipidic 
components of the GPI anchors, which might occur either before or after 
attachment to the proteins (56). Those variations are believed to have a biological 
significance, namely, in the lateral mobility of GPI-APs and in trafficking. 
However, the evolutionary purpose of this structurally diverse manner of 
expressing proteins, as well as the functional role of GPI itself, beyond the 
physical anchoring, remain unknown. The importance of GPI anchoring in 
mammals has been highlighted by the fact germ line disruption of GPI 
biosynthesis is embryonic lethal. For instance, Pig-a knock out mice presented 
neurodevelopmental defects and failed to develop beyond the ninth day of 
gestation (57).  
 
The function of the enzymes involved in the biosynthesis of the GPI has been well 
characterised. In striking contrast, the mechanisms driving their regulation have 
been less studied. Proteins involved in the GPI biosynthesis will be described 
next.  
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1.2.2 Biosynthesis of the GPI-anchor moiety 
 
The biosynthesis of the GPI-anchor moiety occurs at least in eleven sequential 
steps in the endoplasmic reticulum (ER) by a series of more than 20 enzymes 
located in its membrane (Fig.3) 
 
 
 
Fig. 4 – Biosynthetic pathway of the Glycosylphosphatidylinositol (GPI) anchor. 
Assembly of the GPI occurs in the Endoplasmic Reticulum and once assembled the 
anchor is attached to a protein containing the appropriate GPI attachment signal. The 
complex GPI-anchor protein (GPI-AP) is then exported to the cell surface via Golgi. 
Mutations in genes highlighted in red cause Inherited GPI Deficiency.   
 
The steps in the biosynthesis of GPI are as follow: 
 
Step 1: The synthesis of GPI is initiated by the addition of N-acetylglucosamine 
(GlcNAc) from UDP-GlcNAc to free PI on the cytosolic face of the ER. This 
reaction is mediated by GPI-GlcNAc, a large enzymatic complex constituted by 
PIGA (58-60), PIGC (61), PIGH (62), PIGQ (63), PIGY (64), PIGP (65) and two 
other additional components, PIGP and DPM2 (65). PIGA is the catalytic subunit 
of the complex. 
 
Steps 2: De-acetylation of GlcNAc-PI is catalysed by PIGL, resulting in GlcN-PI 
(66). 
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Step 3: GlcN-PI is flipped to the luminal side of the ER by mediation of a yet 
unidentified enzyme, generally called “flippase”. 
 
Step 4: An acyl chain is transferred from an acyl-CoA to the 2-position of the 
inositol by PIGW, originating GlcN-(acyl)PI. The acylation of the inositol is 
indispensable for the attachment of the Etn-P to the terminal mannose later in the 
pathway (step 9) (67). 
 
Steps 5, 6 and 8 – Constitute the addition of mannose residues. Three mannose 
residues from dolichol-phosphate-mannose (DPM) are subsequently added to 
GlcN-(acyl)PI through the action of specific GPI mannosyltransferases (GPI-MT), 
namely PIGM/PIGX (68, 69), PIGV and PIGB. GPI-MTI consists of two 
subunits: the catalytic subunit, PIGM, and the subunit required for its stabilisation, 
PIGX. The second and the third mannose residues are transferred by the GPI- 
MTII and the GPI-MTIII, PIGV and PIGB, respectively. A fourth mannose 
residue can also be added to the GPI intermediate by PIGZ (also called SMP3), 
depending on the mammalian cell type and tissue (68, 70-72). 
 
Steps 7, 9 and 10 – Comprise Etn-P modification of mannose residues. The three 
mannose residues are modified by the addition of three Etn-Ps from 
phosphatidylethanolamine. The enzymes responsible for these modifications are 
the GPI-ethanolamine (GPI-ET) phosphate transferases. PIGF constitutes the 
stabilising element whereas PIGN, PIGO and PIGG have catalytic activity (73). 
Only the modification in the terminal mannose (Man-3) is essential for GPI 
expression in mammals (74). 
 
Step 11 – Transamidation reaction. In the last step, a GPI transamidase complex 
composed by PIGK, PIGS, PIGT, PIGU and GAA1 cleaves the GPI attachment 
signal in the C-terminus of the precursor protein. The precursor protein in then 
bridged with the GPI anchor by the Etn-P attached to the terminal mannose (75-
77). 
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Once assembled, GPI-APs are transported to the Golgi via secretory vesicles. 
Whereas in some circumstances of GPI deficiency, precursor proteins are retained 
in the ER and undergo ER-associated degradation, in others, even if they form an 
intermediate complex with GPI transamidase, they are hydrolysed and secreted in 
its soluble form. One such example is the secretion of free alkaline phosphatase 
(ALP) seen in patients with hyperphosphatasia mental retardation syndrome 
(HPMR) (78). 
 
Recently, new sequencing technologies such as whole-exome sequencing analysis 
have allowed high throughput screening of potential disease-associated genes (79) 
and as a result, several novel diseases associated with GPI deficiency have been 
identified and characterised. 
GPI- associated diseases comprise acquired- and inherited- GPI deficiency. 
Whereas acquired deficiency results from mutations in somatic cells, inherited 
deficiency is caused by germline mutations. By definition, a mutation is a 
pathogenic alteration in the DNA sequence typically with a population frequency 
of < 1% (80).  
 
1.2.3 Acquired-GPI deficiency 
 
Paroxysmal nocturnal haemoglobinuria (PNH), clinically defined in 1882, was the 
first identified GPI-associated disease (81). PNH is an acquired clonal disorder 
that usually arises from somatic mutations in the X-linked PIGA gene in one or 
more haematopoietic stem cells (HSCs) (60, 82), and therefore affects all blood 
cell lineages. So far, more than 100 somatic mutations in PIGA have been 
identified (83). Consistent with a clonal disorder, GPI deficiency is partial and 
presents in a multimodal fashion. Accordingly, three types of blood cells can co-
exist: cells with normal GPI expression and cells with partial or complete GPI-
deficiency (84). The expansion of GPI- clones in PNH suggests that other 
abnormalities in addition to PIGA mutations are involved in the pathogenesis of 
the disease and understanding how GPI- clones expand has been a subject of 
research in the last decades. 
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In PNH, the most dramatic effect is seen in the erythrocytes, where deficiency in 
the GPI-anchored complement inhibitors CD55 and CD59 triggers an unopposed 
activation of the complement cascade, leading to red cell destruction manifesting 
as intravascular haemolysis. The other defining features of PNH are venous 
thrombosis and bone marrow failure (BMF). The reason for bone marrow failure 
still remains unknown but various interesting findings have been made. The close 
association between PNH and aplastic anaemia (AA), in which stem cells in the 
bone marrow are destroyed by the autoimmune system has suggested that both 
diseases share a similar mechanism. Based on this hypothesis, selective targeting 
of GPI+ HSCs by autoreactive T –cells would permit GPI- HSCs to escape the 
immunological attack and to expand. In line with this, the analysis of the T-cell 
repertoire of PNH patients showed a high usage of the T-cell antigen receptor BV 
when compared to normal, age-matched controls (85) and more recently, 
Gargiulo, L. and collaborators, have shown the presence in PNH patients at 
frequencies higher than controls of a novel CD1d-dependent, GPI-reactive T-cell 
population, enriched in an invariant TCRα chain (86).  
These findings support the hypothesis that GPI itself is a target of autoreactive T-
cells in PNH and help to explain the pathogenetic mechanism driving BMF in 
PNH. 
 
Defective GPI biosynthesis also constitutes the hallmark of inherited GPI 
deficiency (IGD), a group of rare autosomal recessive diseases caused by 
germline mutations in PIGM, PIGA, PIGL, PIGV, PIGN, PIGO and PIGT (Fig. 
4). 
 
1.2.4 Inherited-GPI deficiency (IGD) 
 
Identified in 2006, PIGM-associated IGD was the first characterised inherited 
disorder of the GPI pathway (87). The disease results from a mutation in the core 
promoter of the first mannosyltransferase encoding-gene PIGM and so far, 
constitutes the only GPI-associated disorder resultant from an alteration in a 
regulatory region. Considering that my project relies on PIGM-associated IGD as 
a disease-model, I will describe it in more detail.   
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1.2.4.1 PIGM-associated IGD 
 
PIGM-associated IGD was identified in two unrelated consanguineous families of 
Middle Eastern and Turkish origin (see Fig. 9), in which the probands presented 
in infancy with abdominal vein thrombosis and later developed absence seizures. 
Haematological investigations showed a normal thrombophilia screen in all 
affected children apart from an intermittently low-positive Ham test, indicating 
some degree of CD59 absence from the erythrocyte surface. Intriguingly, none of 
the affected children exhibited clinical evidence of significant intravascular 
haemolysis or bone marrow failure, defining features of PNH. Moreover, an 
unusual expression pattern of GPI-linked proteins and GPI itself on blood cells 
was observed. Whereas in PNH, distinct populations of cells resulting from 
normal, complete or intermediate loss of GPI are observed, in PIGM-associated 
IGD the expression pattern of GPI-anchored proteins varied according to the cell 
type. Red blood cells of the affected children presented near normal expression of 
CD59, with a small proportion of cells (<5%) being variably deficient while 30-
50% of platelets were CD59 negative. Granulocytes were mostly GPI negative as 
assessed by fluorescein-labeled proaerolysin (FLAER), CD59 and CD24 
antibodies. The constitutional nature of the disease was demonstrated by staining 
primary fibroblasts from one affected child with CD59 antibody and FLAER, in 
which there was a clear reduction in the expression of GPI.  
By employing homozygosity mapping and genome-wide linkage search using 
SNP in both families, PIGM was identified as the only common candidate gene. 
As described above, PIGM along with PIGX, constitute the enzymatic complex 
GPI-MTI which is responsible for transferring the first mannose to GPI on the 
luminal side of the ER (68). 
The block in GPI biosynthesis at the biochemical level was directly demonstrated 
by substrate labelling of patient-derived EBV-transformed lymphoblastoid B cell 
lines (LBCLs), followed by glycolipid extraction and high performance thin layer 
chromatography. Whereas the first steps of the biosynthetic pathway were intact, 
incorporation of H-D-mannose in GPI-enriched glycolipids was impaired in both 
families.  
Altogether, those findings indicated that the defect arose at the addition of the first 
mannose moiety, pointing PIGM as the likely disease gene. This was further 
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confirmed in rescue experiments in which biosynthesis and expression of GPI at 
the cell surface were restored after transfection of PIGM-deficient LBCLs with 
PIGM WT cDNA. 
 
Genetic defect in PIGM-associated IGD and its impact on transcription 
 
In order to investigate the origin of the defect at the sequence level, Sanger 
sequencing analysis covering the single-exon of PIGM, its 3’- untranslated region 
(UTR) and 2kb region upstream of the ATG was performed. Sequencing analysis 
identified a single nucleotide substitution (C>G) at position -270 from ATG 
which was the cause of drastic reduction of PIGM mRNA levels in PIGM-
deficient LBCLs (1% of normal controls). In heterozygous parental LBCLs, 
PIGM mRNA expression was about half of the normal levels which was 
consistent with a typical recessive trait.  
TF binding motif prediction algorithms anticipated the presence of several 
putative transcription factor (TF) binding sites at the promoter of PIGM and very 
importantly, they predicted a putative Sp1-binding site encompassing the 
pathogenic -270C>G mutation (Fig. 5). Disruption of the Sp1-binding site by this 
mutation was further confirmed in EMSA and super-shift assays. 
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Fig. 5 - Predicted Sp1 binding sites at the PIGM promoter. Apart from the -270GC 
box, four putative Sp1binding sites were predicted at the promoter. -270C>G mutation 
(red arrowhead) abrogates Sp1 binding. Black arrow indicates the putative TSS. 
 
The impact of the Sp1-binding mutation on promoter activity of PIGM was 
directly assessed in reporter assays. By transfecting PIG-M-deficient and 
heterozygous LBCLs with plasmids containing either the WT or the MUT 
promoter upstream of a luciferase reporter gene, a decrease of 80 to 90% in PIGM 
promoter activity was observed in the presence of the mutation (87). 
Altogether, these findings identified the biochemical and genetic defect in PIGM-
associated IGD and very importantly, they showed the importance of precise 
transcription factor binding and regulation of gene expression. 
 
Sp1 belongs to the Sp/Kruppel family of transcription factors which are critical 
regulators of gene expression of many housekeeping and inducible genes (88-90). 
Mutations generating or abolishing Sp1 binding sites in regulatory regions are not 
novel and they have been reported in several human diseases (45, 91-94).  
Further the molecular characterisation of PIGM-associated IGD, a therapy to treat 
patients was investigated.  
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From molecular characterisation to targeted therapy 
 
Apart from interacting with the basal transcriptional machinery (95, 96) , Sp1is 
also known to influence transcription by recruiting and stimulating histone 
modifying enzymes, such as HATs (97, 98) and HDACs (99-101) to the gene 
promoter regions. The regulatory role of Sp1/Sp3 associated with the effect of the 
HDACs in promoting histone deacetylation and preventing high-order 
organization of the chromatin and the importance of the acetylation status during 
development prompted the authors to investigate whether PIGM promoter would 
contain responsive elements to butyrate and if so, how transcription of PIGM 
would be modulated. 
By chromatin immunoprecipitation (ChIP) it was shown that in the presence of 
the -270 C>G mutation, histone 4 (H4) was hypoacetylated at the promoter in 
PIGM-deficient LBCLs and acetylated in heterozygous LBCLs. Treatment with 
3mM sodium butyrate (NaBu), a pan- HDAC inhibitor, resulted in restoration of 
H4 acetylation at the MUT promoter, a 20-fold increase of the PIGM mRNA 
levels and restoration of GPI expression at the cell surface, as measured by 
FLAER. More importantly, in a child treated with sodium phenylbutyrate, 
peripheral blood cell PIGM mRNA levels drastically increased (from 0.15% 
before treatment to 60.77% after treatment), cell-surface GPI expression in 
granulocytes was restored to nearly normal levels and strikingly the child became 
seizure-free (102).  
Altogether these results demonstrated that the -270C>G mutation disrupts a Sp1-
dependent butyrate responsive element which is associated with histone 
hypoacetylation at the PIGM promoter. Further investigations regarding the 
molecular mechanism of transcriptional regulation in PIGM-associated IGD will 
be summarised in the next section.  
 
As mentioned above, germline mutations in genes of the GPI pathway, other than 
PIGM, cause GPI deficiency. Remarkably, the main features shared between 
patients with IGD are the neurological abnormalities, including mental retardation 
and epilepsy. These features, frequently associated with an incomplete diagnosis, 
reinforce the significance of GPI and GPI-APs in normal neurodevelopment and 
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strengthen the importance of genetic screening and biochemical analysis of genes 
associated with glycosylation and in particular with the biosynthesis of GPI.  
 
Interestingly, in this group of rare inherited disorders the severity of the disease 
not only correlates with the type of mutation but also with the location of the gene 
in the biosynthetic pathway. Accordingly, mutations in PIGO are more severe 
than mutations in PIGV since they cause a more pronounced growth delay in 
patients (103). Other very interesting evidence in this group of disorders is the 
absence of haemolysis in patients, suggesting normal GPI expression in the 
surface of the erythrocytes. Understanding how those genetic abnormalities 
contribute to different phenotypic patterns in the haematopoietic cells still remains 
to be elucidated. The contribution of somatic events in this group of rare diseases 
should be also start taken into account. 
 
The genetic abnormalities identified so far in genes of the GPI biosynthetic 
pathway as well as the associated clinical features are summarized below. 
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Table 2 – Genetic abnormalities identified in the GPI biosynthetic genes and 
associated clinical features  
 
Gene Mutation Disease  Clinical features  References 
PIGM Homozygous g.-270G>C 
PIGM-
associated 
IGD 
 
Epilepsy, thrombosis of the 
hepatic veins 
 (87) (102) 
PIGA c.1234C>T 
X-linked 
disease  
 
Cleft palate, neonatal seizures, 
contractures and central 
nervous system (CNS) 
malformations 
 (104) 
PIGL 
Compound heterozygous 
c.500T>C + c.274delC, 
c.652C>T, c.427-1G>A 
or del17p12-p11.2 
CHIME  
Coloboma, heart defects, 
ichthyosiform dermatosis, 
mental retardation and ear 
anomalies with hearing loss 
 
 
(105) (106) 
(107) 
(108) 
(109) 
PIGV 
Homozygous 
c.1022C>A or 
c.766C>A; compound 
heterozygous 
c.1022C>A+c.1154A>C; 
c.1022C>A+c.1022C>T 
HPMR  
Mental retardation and elevated 
alkaline phosphatase (ALP) 
levels  
 
(78) (110) 
(111, 
112) 
 
PIGN 
c.2126G>A 
MCAHS 
(multiple-
congenital-
anomalies-
hypotonia-
seizures 
syndrome) 
 
Developmental delay, cardiac, 
genitourinary and 
gastrointestinal anomalies, 
severe neurological impairment 
with chorea and seizures 
 (113) 
PIGO 
Compound heterozygous 
c.2869C>T+ c.2361dup; 
c.2869C>T+ 
c.3069+5G>A 
-  
Mental retardation, elevated 
alkaline phosphatase TNAP 
gene, intractable seizures 
Growth delay, malformations 
of the urinary system and heart 
 (103) 
PIGT 
Homozygous c.547A>C 
 
Compound 
heterozygous:c.1401-
2A>G; 8-MB deletion 
 
PNH 
 
Distinct facial features, 
intellectual disability, 
hypotonia and seizures, 
abnormal skeletal, endocrine 
and ophthalmologic findings 
Hemolytic crisis, abdominal 
pain, diarrhea, headache, 
arthralgia, dyspnea and fatigue 
 
(114) 
 
 
 
 
(115) 
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1.2.4.2 Deregulation of PIGM transcription 
 
Gene silencing of CGI promoters is achieved through dense CpG methylation as 
mentioned before, or Polycomb (PcG) recruitment. Whether CpG methylation is 
the primary event in gene silencing is still a matter of debate. The PcG complex in 
mammals comprises polycomb-repressive complex 1 (PRC1) and 2 (PRC2). 
PRC2 is recruited to CGIs and then trymethylates H3K27 which is recognised by 
PRC1 complexes that impede transcriptional elongation, thus repressing gene 
expression by further modifying the histone tails (H2A-K119 ubiquitination) 
(116-118). The hierarchy of functional regulators that is responsible for Polycomb 
recruitment is still under investigation. Most results have arisen from studies in 
embryonic stem (ES) cells in which gene expression activation and repression has 
to be properly controlled.  
 
Taking advantage of the -270C>G mutation at the CGI-PIGM promoter, the 
transcriptional mechanism driving repression of the housekeeping gene was 
investigated in more detail. 
 
Having seen that in B cells Sp1 binding was required for PIGM transcription and 
histone acetylation, the role of the CGI in the nucleosome dynamics was further 
evaluated. CGIs are intrinsically associated with nucleosome destabilization, 
accessible and nucleosome-free chromatin and therefore with transcriptional 
activation of gene expression (116, 117). The binding motifs of several TFs, 
including of Sp1, Nfr-1, E2F and Ets, are GC-rich and overlap with GCIs (119).  
Restriction enzyme accessibility assay (REAA) showed that the MUT promoter 
was less accessible than the WT promoter, consistent with nucleosome 
compaction. Nucleosome positioning, determined by micrococcal nuclease 
(MNase) protection assay followed by RQ-PCR showed low levels of protection 
in the WT promoter, particularly in the area encompassing the TSS and the -
270GC box thus defining the nucleosome-depleted region (NDR). In the MUT 
promoter, high levels of protection seen across the NDR were reduced by 
restoration of Sp1 binding following NaBu treatment, and most likely by histone 
re-acetylation. Together, the results suggested that the CGI was not sufficient to 
impose a nucleosome depleted region (NDR) at the PIGM promoter and intact 
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Sp1 binding and recruitment of HATs were required for nucleosome relaxation 
and normal transcription. 
Repression of gene expression by nucleosome compaction is usually associated 
with DNA and histone methylation. Accordingly, the MUT promoter was 
enriched for the H3K27me3 mark, characteristic of developmentally 
regulated/poised genes, and suggestive of PcG recruitment and transcriptional 
repression. Further analysis showed that the CGI promoter was not methylated. 
Surprisingly, the co- presence of the active mark, H3K4me3 in the MUT promoter 
suggested the presence of a bivalent chromatin state. Altogether, the findings 
indicated that active TF binding “protects” against silencing by PcG, instructing a 
permissive chromatin state. Contrary, absence of active TF binding in CGIs 
directs Polycomb recruitment and deposition of bivalent histone methylation 
marks thus explaining the repression, yet reversible, of PIGM transcription and 
GPI deficiency in B cells (38). 
 
Understanding the mechanism by which erythroid cells overcome the pathogenic 
C>G mutation and express near normal levels of GPI and GPI-APs demanded 
further investigation.  
Below, as a prelude to the experimental work I plan to address this aspect of the 
molecular pathogenesis of PIGM-associated IGD, I provide a brief overview of 
the erythropoiesis and its transcriptional control. Before, a summary of the role of 
Sp TFs in transcriptional regulation is presented. 
1.3 The Specificity Protein (Sp) transcription factor family 
 
The Specificity Protein/Krüppel-like Factor (Sp/KLF) transcription factor family 
shares a highly conserved DNA binding domain of C2H2-type zinc fingers. 
Members of this family bind to CACCC/GC/GT boxes, which are very common 
in the regulatory regions of many cellular genes.  
The Sp subgroup favours GC-rich boxes and so far, nine members have been 
identified, Sp1 to Sp9. The glutamine-rich subfamily is constituted by Sp1, Sp2, 
Sp3 and Sp4. Whereas Sp1 and Sp3 are ubiquitously expressed, Sp4 is cell-type 
specific and presents distinct functional properties from Sp1 and Sp3. Sp4 is 
highly enriched in the brain tissue (120, 121) and therefore, Sp4 deficiency results 
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in abnormalities more prominent in the nervous system (122). In fact, alterations 
in the Sp4 and Sp1 levels have been associated to neuropsychiatric disorders (123) 
(124) and a very recent study proposes these proteins as potential biomarkers of 
early-stages of psychotic diseases (125).   
 
Depending on the promoter architecture and cellular context, Sp1 and Sp3 
compete for DNA binding and it has also been suggested that Sp1 and Sp3 are 
functional redundant. However, results derived from developmental studies in 
mice are not in agreement and suggest they might have functional redundant roles 
only in early stages of development. Accordingly, Sp1 knockout mice are not 
viable and die around embryonic day 11 (126) whereas Sp3 knockout mice are 
viable and die from respiratory abnormalities (127). 
 
Sp2 contains the least conserved DNA binding domain within the Sp family and 
mainly recognises GC box promoter elements. A recent study has identified 
various Sp2 gene targets in mouse embryonic fibroblasts (MEFs) and human 
embryonic kidney (HEK) 293 cells, defining Sp2 as a major regulator of genes 
involved in various cellular pathways (128).   
 
Sp1 was the first identified member of the Sp family and many of its functions 
have been revealed by in vitro experiments.  Sp1 has two isoforms and it is 
constituted by four domains. Two transactivation domains, that are localised in 
the N-terminus and are required for Sp1 transactivation potential; an internal 
domain and a carboxyl-terminus domain required for synergistic transactivation 
(Fig. 6). The N-terminus domains directly contact elements of the transcriptional 
machinery, such as TBP (TATA-binding protein)/TFIID (95, 96), thus activating 
transcription initiation. It is possible that in this way Sp1 directly recruits TFIID 
that potentiates Sp1-mediated transcription of TATA-less genes. Interestingly, 
Sp1 also has the ability to regulate gene expression by mediating chromatin loops 
between enhancer and promoter regions (129). 
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Fig. 6 – Schematic representation of Sp1. Sp1 is constituted by four domains (A, B, C 
and D). Domains A and B comprise the transactivation domains (TADs). Sp1 binds to the 
DNA through their zinc-fingers (Zn). 
 
 
Sp1 is a very versatile protein, regulating expression of genes involved in various 
cellular processes, such as cell differentiation (130), apoptosis (131), angiogenesis 
and cancer (132). The posttranslational modifications of Sp1 affect its 
transcriptional activity and stability and therefore contribute for the complexity of 
its regulatory functions (133). Among those modifications are phosphorylation, 
acetylation, sumoylation, ubiquitylation and glycosylation. 
For a long time, Sp1 was recognised as an activator of transcription of 
housekeeping and TATA-less genes. However, it is now known that Sp1 can also 
activate transcription of tissue-specific genes by interacting with tissue specific 
TFs such as GATA-1 (134, 135). Interactions with signal-induced factors, like 
SREBP-1a have also been reported (136). 
As mentioned before, Sp1 interacts with HATs and HDACs. 
 
Mutations in DNA sequences causing disruption of Sp binding sites have been 
reported in a growing body of literature. Notably, these mutations have an impact 
in normal gene expression and are in the basis of various human diseases.  
In 1991, Toshiyuki et al. (137) described for the first time a Sp1-binding site 
mutation in the retinoblastoma gene. Koivisto et al. showed in 1994 that a 
mutation (-43C>T) in the core promoter of the low density lipoprotein (LDL) 
receptor gene abolishes binding of Sp1 and causes familial hypercholesterolemia 
(138). Posteriorly, another study identified a mutation in a Sp1 binding site in the 
5’-upstream region of the DKC1 gene, causing multisystem disorder dyskeratosis 
congenita (DKC) (91), associated later on with decreased promoter activity and 
thus, gene expression (92). More recently, it has been shown that a mutation (-
250G>C) in the promoter of the ferrochelatase gene (FECH) abrogates binding of 
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Sp1 and impairs promoter activity causing erythropoietic protoporphyria (EPP) 
(93).  
Abrogation of Sp1 binding in the regulatory region of the NME4 gene impairs 
binding of the erythroid specific TF SCL/Tal1 localised 55bp apart. Consequently, 
NME4 expression is altered in erythroid cells but is not affected in nonerythroid 
cells (139).  
These results constitute a remarkable evidence of how alterations in gene 
regulatory regions have a functional impact in TF regulatory networks of the cell, 
affecting gene expression in a more broad or cell-type specific manner.  
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1.4 Haematopoiesis 
 
 
Haematopoiesis is the biological process in which a pluripotent haematopoietic 
stem cell (HSC) gives rise to haematopoietic progenitor cells which in turn 
differentiate in different blood cell types. In mammals, haematopoiesis occurs 
sequentially in the yolk sack, fetal liver and bone marrow.  
A pluripotent HSC is highly proliferative and capable of self-renewal, or in other 
words, to produce new HSCs. After differentiation, a long-term HSC ((LT)-HSC) 
originates an HSC with lower self-renewal potential, designated short term (ST)-
HSC.  
(ST)-HSC has the ability to differentiate into a multipotent progenitor cell–MPP, 
which in turn differentiates into a common myeloid progenitor (CMP) or common 
lymphoid progenitor (CLP) cell. CMP then differentiates into 
megakaryocyte/erythroid progenitor, called MEP or into granulocyte/macrophage 
progenitor, GMP; CLP originates B and T lymphocytes. MEPs give rise to red 
blood cells (RBC) and megakaryocytes and GMPs give rise to mast cells, 
eosinophils, neutrophils and monocytes/macrophages (Fig. 7). The specific 
pathway that gives rise to red blood cells is called erythropoiesis and it will be 
described next. Specific markers at the cell surface of the different haematopoietic 
cell types allow their identification and selection. For instance, CD34, c-kit, IL-
6R, Thy-1 and CD45RA constitute cell surface markers of HSCs (140).  
External signals such as cytokines (SCF, TPO, Flt3 and GM-CSF) produced by 
stromal bone marrow cells, are known to play a critical role in the status of HSC 
and therefore influence haematopoiesis.  
 
During the haematopoietic development, TFs play a crucial role by influencing 
the transcriptional programmes in both the formation of the HSC and maintenance 
of its function and in the blood cell lineage specification. In addition to binding to 
DNA, haematopoietic TFs interact with each other and also interact with 
chromatin-associated factors. 
Haematopoietic TFs have to be expressed in an ordered specific manner. Amongst 
the transcription factors essential for the survival and proliferation of HSCs are 
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MLL (mixed lineage-leukemia gene), RunX1, TEL/ETV6, SCL/Tal-1 and LMO2 
(141). SCL/Tal-1 and LMO2 are essential in the early stages of haematopoiesis as 
mice null embryos die from the complete absence of embryonic blood (142). 
 
 
 
 
Fig. 7 – Haematopoietic hierarchy. The long-term HSC (LT-HSC) origins a short-term 
(ST-HSC) which in turn gives rise to common-myeloid progenitor (CMP) and common-
lymphoid progenitor (CLP). CMP can origin the megakaryocyte/erythrocyte progenitor 
(MEP) and granulocyte/macrophage progenitor (GMP) precursor cells. Whereas MEP 
origins megakaryocytes and erythroid precursors, GMP gives rise to granulocytes, mast 
cells, eosinophils and monocytes/macrophages. CLP differentiates into B and T 
lymphocytes (adapted from(141)).  
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In what respects lineage specification, TFs play a dual role. They promote lineage 
differentiation and at the same time they act against factors favouring other 
choices. Accordingly, PU.1, a key TF for the monocytic and B lymphoid 
commitment, interacts and antagonizes GATA-1, which is essential in the 
megakaryocytic and erythroid development (143); the contrary is also true (144).  
Direct evidence of the importance of TFs in haematopoiesis has arisen from 
genetic studies using knock-out mice. One such example is the master regulator of 
erythropoiesis, GATA-1. Disruption of GATA-1 in a murine embryonic stem cell 
line failed to give rise to red blood cells in chimaeric mice (145) and in its 
absence, erythroid precursor cells arrest at the proerythroblast stage and undergo 
apoptosis (146).  
Forced expression studies and reprogramming, also revealed the importance of 
master TFs in lineage specification. For instance, exogenous expression of 
GATA-1 in cell lines of monocytes induced the expression of erythroid-
megakaryocyte lineage markers and down-regulation of monocytic markers (147, 
148). Overexpression of C/EBP-α, was also shown to commit B- and T-cell 
progenitors into functional macrophages (149, 150). 
 
Not surprisingly, de-regulation of TFs and chromatin-modifying enzymes in the 
haematopoietic cells is largely associated with the onset of a variety of 
haematological malignancies. For instance, heterozygous mutations in PU.1 have 
been linked to acute myeloid leukemia (151) and overexpression of Tal-1, and its 
consequent abnormal auto-regulation cause T- cell acute lymphoblastic leukemia 
(T-ALL) (152). 
 
1.4.1 Erythropoiesis 
 
Erythropoiesis is the process in haematopoietic cell lineage specification that 
gives rise to erythrocytes. As the erythroid precursor cells undergo differentiation 
their numbers increase and their proliferative potential decreases. During fetal life, 
erythropoiesis occurs in the fetal liver and following birth, switches to the bone 
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marrow. In adult life, erythroid precursors are mainly produced in the bone 
marrow and once they mature, they expel their nucleus and enter the bloodstream.  
The growth of burst forming unit-erythroid (BFU-E), the more immature 
erythroid progenitors, depends of cytokines such as stem cell factor (SCF), 
thrombopoietin (TPO), interleukin 3 (IL3) and 11 (IL11), and Flt-3 ligand. Under 
normal conditions these cells differentiate into colony-forming unit-erythroid 
(CFU-E) cells which are highly dependent of erythropoietin (EPO) and give rise 
to the erythroid precursors. At this stage, pro-erythroblasts undergo four to five 
cell divisions and sequentially originate morphologically distinct populations - 
basophilic, polychromatic and orthochromatic erythroblasts -, through acquisition 
of the surface markers, CD36, transferrin receptor protein 1 (CD71) and 
glycophorin A (GPA). CD71 loss anticipates enucleation, giving rise to a more 
mature and reduced in size cell, the reticulocyte (Fig. 8). Reticulocytes then enter 
the blood circulation where they mature into erythrocytes. The life-span of 
erythrocytes is 120 days (153). Erythroid gene regulation not only depends of the 
antagonising effect between haematopoietic TFs, but also depends of chromatin 
changes mediated by histone post-translational modifications (154).   
 
 
 
 
Fig. 8 – Erythroid differentiation. HSC – Haematopoietic Stem Cell; CMP – Common 
Myeloid Progenitor; MEP – Megakaryocyte-Erythroid Progenitor; Ery – Erythroblast. 
Erythroid cells are identified at the various stages by expression of CD71, GlyA and 
CD36. Adapted from (153).  
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1.4.2 Regulation of erythropoiesis by GATA-1 and KLF1 Transcription 
Factors 
 
During haematopoietic differentiation, lineage specification is largely determined 
by the coordinated expression of specific TFs, in a quantitative and temporal 
manner.    
The GATA family of TFs has been implicated in the specification of 
erythroid/megakaryocytic cells as well as in the transcriptional program of T cells 
(155). The GATA family comprises the haematopoietic and non-haematopoietic 
subfamily. The haematopoietic sub-family is constituted by GATA-1, GATA-2 
and GATA-3 and their expression is restricted to the haematopoietic system 
(156); the non-haematopoietic sub-family comprises GATA-4, GATA-5 and 
GATA-6 which are expressed in several tissues (157).  
 
GATA-1 constitutes the master regulator of erythropoiesis as it is responsible for 
survival and proliferation of erythroid cells. It is also expressed in 
megakaryocytes, eosinophils and mast cells. GATA-1 has been extensively 
studied both in mouse and human erythroid cells. GATA-1 deficient embryonic 
stem cells arrest at the proerythroblast stage and GATA-1 null mice show 
complete ablation of erythropoiesis and die from severe anaemia (158).   
 
GATA-1 is constituted by two zinc-fingers: a C-terminal zinc-finger that binds 
DNA with high-affinity and an N-terminal zinc finger responsible for stabilizing 
the interaction (159, 160). GATA-1 regulates transcription of erythroid-specific 
genes through binding to its consensus motif (T/A)GATA(A/G) in gene 
regulatory regions. Recently, ChIP-seq data in a mouse-erythroid cell line 
identified more than 2,000 GATA-1 targets spanning more than 15,000 binding 
sites (161). It usually regulates gene expression in association with FOG-1 (162), 
Scl/Tal-1 (163), LMO2 (164) and others. It also interacts with TFs like KLF1 
(165) and proteins with acetyltransferase properties like CBP/p300 (166, 167). 
 
GATA-1 and Sp1 binding sites are very often localised in close proximity in the 
promoters and enhancer of erythroid-specific genes. GATA-1 physically interacts 
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with Sp1 through their zinc finger domains and in the absence of GATA-1 
binding sites, Sp1 is able to recruit GATA-1 at the promoter (134, 135, 168). 
Studies performed in vitro revealed that depending on the promoter context, 
GATA-1 functional interacts with Sp1 or with its close associated family member, 
KLF1. Accordingly, GATA-1 cooperates with Sp1 at the pyruvate kinase 
promoter and with KLF1 at the βmaj globin-derived GCT promoter. At the 
glycophorin B promoter, GATA-1 interacts with either Sp1 or KLF1 (165). 
 
Disease associated mutations in GATA-1 have also been described, revealing the 
multifactorial role of GATA-1. A mutation in a splice site of the GATA-1 gene 
produces a truncated short-length form of the protein causing Diamond-Blackfan-
Anemia (DBA) (169). Similarly, GATA-1 mutations that originate an amino-
terminally truncated protein contribute for the onset of transient 
myeloproliferative disorder (TAM) and acute megakaryoblastic leukaemia 
(AMKL) in Down-Syndrome patients (170, 171). 
 
The KLF subgroup of the Sp/KLF transcription factor family is comprised by 16 
members (KLF1-KLF16) and preferentially binds to CACCC boxes. KLF1, also 
known as EKLF, has restricted erythroid expression and therefore regulates 
erythroid genes such as the β-globin (HBB) gene. Mutations in the CACCC box in 
the regulatory region of β-globin are a cause of β-thalassemia (172). KLF1 is 
constituted by three zinc-fingers and mutations in those have been directly 
associated with hereditary persistence of fetal haemoglobin (HPFH) (173) and 
congenital dyserythropoietic anemia (CDA) (174). In mice, KLF1 knockout cause 
defects in the late stages of fetal erythropoiesis (175, 176). The second member of 
the KLF family, KLF2 is specifically expressed in T lymphocytes.  
Similarly to Sp1 and Sp3 also KLF1 and KLF3 (BKLF) compete for the same 
sites. Interestingly, Sp1 has the ability to compete with KLF family members such 
as KLF4, KLF9 and KLF13 for the same binding sites (177). 
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1.5. Aims and Hypothesis 
 
Mutations in gene regulatory regions are less frequent than coding mutations and 
therefore less well studied. However, when they occur, they provide unique 
opportunities for elucidating mechanisms of transcriptional regulation and their 
functional impact in gene expression. 
PIGM-associated IGD provides the opportunity to elucidate the role of a cis-DNA 
element, in this case of the -270GC-rich box, in differential, tissue-specific 
transcriptional regulation of the same gene. As discussed earlier, in PIGM-
associated IGD the -270 C>G promoter mutation differentially affects expression 
of GPI in cells from the same or different tissues, as exemplified by erythrocytes 
which are mostly GPI+ and by the granulocytes which are mostly negative for 
GPI expression. 
 
The molecular events underlying differential regulation of PIGM and variable 
expression of GPI in haematopoietic cells are not known and their elucidation 
constitutes the overall aim of this thesis. 
 
The specific aims of this thesis are to:  
 Elucidate the differences at the PIGM transcriptional level between normal 
and IGD haematopoietic cells and to investigate the PIGM promoter 
architecture (nucleosome positioning and promoter accessibility) and its 
impact in gene expression; 
 Determine the role of the mega-erythroid lineage-affiliated transcription 
factors GATA-1 and KLF1 in transcriptional regulation of PIGM in 
erythroid cells and 
 Determine the role of the generic transcription factor Sp1 and other Sp 
family members on PIGM transcriptional regulation in normal and IGD 
haematopoietic cells; 
 Explore the role of the pathogenic -270C>G mutation in the interactions 
established between PIGM and other genes.
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Chapter 2 - Materials and Methods 
 
2.1 Cell lines, primary cells and treatment 
 
K562 (erythroleukemia), HL60 (myeloid), Jurkat (T-lymphocyte) and EBV-
immortalised lymphoblastoid B cells (LBCLs), detailed in Table 2, were cultured 
in RPMI-1640 medium (Sigma). 293T, Flp-In-293, HeLa and SH-SY5Y cell lines 
were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Sigma) and 
splited by trypsinisation. Both media were supplemented with 10% fetal bovine 
serum (FBS; Sigma), 1% L-Glutamine (Sigma) and 1% penicillin-streptomycin 
(Sigma). 
 
Table 3 - EBV-immortalised lymphoblastoid B cells (LBCLs) (see also family tree 
below) 
 
Cell line Genotype Family member 
N1 Homozygous WT N/A 
N2 Homozygous WT N/A 
1A Homozygous WT IV1, Family 1 
1B Homozygous MUT IV4, Family 1 
2E Heterozygous  III4, Family 2 
2A Heterozygous III5, Family 2 
2B Homozygous MUT IV2, Family 2 
2C Homozygous MUT IV3, Family 2 
2D Heterozygous IV4, Family 2 
 
N1, N2 – EBV transformed cell lines, Triose-Phosphate Isomerase (TPI) deficient. 
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Primary cells were obtained from healthy donors and from PIGM-associated IGD 
patients and their relatives, as reported in (87), from which this current study 
follows. PBMC from patients and relatives have been cryopreserved since then.   
 
 
 
 
 
Fig. 9 – Family trees of children with inherited GPI deficiency. In Family 1 the 
parents are first cousins and there are four unaffected siblings and one affected child 
(1B); her twin sibling died in utero at 8 weeks. In Family 2 the parents are first cousins 
and there are four children, two of whom are affected (2B and 2C).  
 
 
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient 
centrifugation at 1800 rpm for 30 minutes using Histopaque (Sigma). CD34+ cells 
were obtained from cord blood mononuclear cells, after density gradient 
centrifugation, by using the CD34 MicroBead cell isolation kit (Miltenyi Biotec). 
After isolation, CD34+ cells were analysed for purity in a BD LSRFortessa flow 
cytometer (BD Biosciences, USA).   
Neutrophils were obtained from peripheral blood by lysis of the erythrocyte 
fraction in sequential incubations of ice-cold ddH2O for 10 seconds, 0.6M KCl 
and ice-cold PBS, spun at 1300 rpm, 4ºC, for 8 minutes. Cell lysis was performed 
until only a clear white pellet of neutrophils remained. Cell morphology was 
monitored by May-Grünwald-Giemsa stained cytospin preparations (as described 
in 2.4). 
Mithramycin (MitA; Sigma) was dissolved in DMSO at 50µM stock solution and 
diluted prior to use at the indicated final concentrations. After 24 hours, viable 
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cells (as determined by trypan blue (Sigma) exclusion were counted in a 
hemocytometer). 
 
2.2 Bioinformatics 
 
Nucleotide sequences were obtained from the Ensembl database 
(http://www.ensembl.org/index.html) and analysis of the PIGM promoter region 
was carried out using the Transcription Element Search System (TESS) and the 
TFsearch (http://www.cbrc.jp/research/db/TFSEARCH.html) web tools. ChIP-seq 
data was retrieved from the ENCODE (http://genome.ucsc.edu/encode/) database. 
Primers were designed with NCBI Primer Blast. 
 
2.3 Bacterial transformation 
 
Chemically competent bacteria were thawed on ice and 50ηg of plasmid DNA 
was added followed by incubation on ice for 30 minutes. Transformation was 
carried out by heat-shock at 42ºC, for 45 seconds. 250µl of LB medium (Sigma) 
was added to the cells and they were shaken at 225 rpm, 37ºC for 1 hour, 
following which 50µl were plated in LB agar plates containing 100µg/ml 
ampicillin (Sigma) and incubated O/N at 37ºC. Individual colonies were picked, 
seeded into 4ml LB medium containing 100µg /ml ampicillin and shaken at 225 
rpm, 37ºC, O/N. Plasmid DNA was isolated using the GeneJET Plasmid Miniprep 
Kit (Fermentas).  
Larger quantities of plasmid DNA were obtained by seeding the bacterial cells 
into 300ml of LB medium containing 100ug/ml ampicillin, shaken at 225 rpm, 
37ºC, O/N. Plasmid DNA was isolated using the GeneJET Plasmid Maxiprep Kit 
(Fermentas). 
 
2.4 Cytospins preparations 
 
Approximately 4x104 cells were placed in a cytospin cartridge and spun at 400 
rpm for 5 minutes into a slide (Superfrost Plus,VWR). Slides were air-dried, fixed 
in methanol (Sigma) and incubated in the May-Grünwald solution (VWR) 
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previously diluted 1:2 in H2O, for 7 minutes. Slides were then incubated in the 
Giemsa solution (VWR) previously diluted 1:10 in H2O, for 20 minutes and 
washed 3 times in distilled H2O. Slides were mounted in DPX solution (Sigma) 
and analysed in a light microscope (EVOS XL Core, Fisher Scientific, USA). 
   
2.5 Chromatin Immunoprecipitation (ChIP) assays 
 
Cells lines (5x106/IP) and CD36+ primary cells (3x105/IP) were collected by 
centrifugation at 1200 rpm and cross-linked with 1% formaldehyde (Sigma) at RT 
for 10 minutes. Cross-link was quenched by addition of glycine to a final 
concentration of 125mM. According to the antibody, chromatin was prepared 
using the Shearing ChIP kit (Diagenode) or using the solutions recommended in 
the ChIP assay kit (ref 17-295, Millipore) and sheared by sonication at 4ºC for 25 
minutes in a 0.5/0.5 ON/OFF cycle, high intensity in a Bioruptor UCD-200 
(Diagenode, Belgium). Sonicated fragments of average 500bp length were 
confirmed on a 1.5% agarose gel. Preblocked (0.2mg/ml glycogen, 0.2mg/ml 
BSA) Protein G magnetic beads (Dynabeads, Invitrogen) were then incubated 
with 2-5µg each antibody (Table 4) for at least 2 hours, at 4ºC in ChIP dilution 
buffer (0.01% SDS, 1.1% Triton X-100, 1.2M EDTA, 16.7mM Tris-HCl pH8.1, 
150mM NaCl) containing protease inhibitors (PI, Sigma). Chromatin was 
subsequently diluted at least 10 times in ChIP dilution buffer (plus PI) and pre-
cleared by incubation with Protein G magnetic beads for 1 hour at 4ºC on a 
rotating wheel. Pre-cleared chromatin was incubated with the antibody-beads 
complex overnight at 4ºC on a rotating wheel. 1/10 of the amount of chromatin 
used per IP was kept as Input control. Protein-DNA complexes were then 
recovered and sequentially washed in ChIP dilution buffer, Low Salt Wash Buffer 
(50mM Hepes pH7.9, 500mM NaCl, 1mM EDTA, 1% Triton X-100), High Salt 
Wash Buffer (20mM Tris-HCl pH8, 0.1% SDS, 1% Triton X-100, 2mM EDTA, 
500mM NaCl) and TE (10mM Tris-HCl pH8, 1mM EDTA), at 4ºC for 5 minutes. 
Protein-DNA complexes were eluted by adding 150µl elution buffer (1% SDS, 
0.1M NaHCO3) at 65ºC for 4 hours and a second time for 30 minutes. Eluted 
samples and Input control were treated with 200µg/ml Proteinase K (Fermentas). 
DNA was recovered by phenol-chloroform extraction and ethanol precipitation. 
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RQ-PCR was performed using specific primers for the target regions (Table 4) 
and Maxima SYBR Green master mix (Fermentas) in an Applied Biosystems 
7500 Real-time PCR system (Applied Biosystems, USA). The PCR program used 
for amplification consisted of a denaturation step at 95ºC for 10 minutes, followed 
by 42 cycles of 2 minutes at 94ºC, 30 seconds at 60ºC and 1 minute at 72ºC and 
melting curve. Enrichment of the target sequence was calculated as % of Input 
using the formula: [(2^ -Ct IP)/(2^ -Ct Input)]*(100/DF), where DF is the dilution 
factor of the Input. Data was presented as fold enrichment relative to % Input IgG.  
 
 
Table 4. Antibodies used for ChIP 
Antibodies  
GATA-1 ab11852, abcam 
KLF1 ab2483, abcam 
Sp1 17-601, Millipore 
Sp2 sc-643, Santa Cruz 
IgG rabbit sc-2027, Santa Cruz 
IgG mouse sc-2025, Santa Cruz  
IgG goat  sc-2028, Santa Cruz 
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Table 5. ChIP-RQ primers 
Designation Forward primer Reverse primer 
8 5’–GGATGGCAACTTTGACAGAAGAAA- 3’ 5’–TTCCTTAACTTGTCAGCCCCTTA-3’ 
7 5’-TCACCTTCACCTAGGGTTGC-3’ 5’-AGTTGAAGGGGGCTGAGTGT-3’ 
6 5’-CCACAAATCCCCGGTGAATAC-3’ 5’-CTGCGCGCTACATCCTTCAG-3’ 
5 5’-TCACTCTCGGATCTCCAGC-3’ 5’-GAGATTTCTTTGTAAGTGACAGCC-3’ 
4 5’-GCTGTCACTTACAAAGAAATCTCAC-3’ 5’-CTCGCTTCCGCTTCTTCTTC-3’ 
3 5’-CAAAGAAATCTCACTCCACTCCA-3’ 5’-CGAGCCAAAAACTTGCCTTC-3’ 
2 5’-GAAGAAGCGGAAGCGAGAC-3’ 5’-CTATCACATCCGGCATGAAG-3’ 
1 5’-CTGGAGACAGGTAGCAGTACG -3’ 5’--CTTCCCTTCGGTTCTTTGCAG-3’ 
+6Kb 5’-TCTTTTGAGGGGCAGTTCTCTC-3’ 5’-TTTGGTGAGAGAGGGTTTGGAG-3’ 
HS-49 5’-TCTCCTTGTAGTTGCCACAAGCT-3’ 5-GGGTGGGCTATAAGTGACTAAAAGAG-3’ 
HS-3.5 5’-TGATCTGGCCCCACTGATTC-3’ 5’-AGAAGTCTGCGGCGACAGTT-3’ 
HS+14 5’-TTATCTCTCCGGTCCCAGCTT-3’ 5’-GCCGGTTTGTCCTCCTAATCT-3’ 
HS+15 5’-GCCGGTTTGTCCTCCTAATCT-3’ 5’-GACGCAGCCCCTTTCTCAA-3’ 
DHFR 5’-TCGCCTGCACAAATAGGGAC-3’ 5’-AGAACGCGCGGTCAAGTTT-3’ 
HBA2 5’-GGGCCGGCACTCTTCTG-3’ 5’-GGCCTTGACGTTGGTCTTGT-3’ 
GW10 5’-GGCTAATCCTCTATGGGAGTCTGTC-3’ 5’-CCAGGTGCTCAAGGTCAACATC-3’ 
Sp2 -2.5Kb 5’-TACAGGTGAGTCATGGAACC -3’ 5’ –ACCCTGCTCAAAGTCTGCAT -3’ 
Sp2 5’ –CCGTCCATCAGTGACATTGC -3’ 5’ –TACGACATCTTCCTCCCTGG -3’ 
 
2.6 Circular chromosome conformation capture (4C) 
 
Cells (1x107/condition) were centrifuged for 5 min at 1500 rpm at RT and washed 
twice with PBS. Pellet was ressuspended in 500µl of 10% (v/v) FCS/PBS and 
then cross-linked in 1% formaldehyde (Sigma) for 10 minutes at RT. Cross-link 
was quenched on ice by addition of glycine to a final concentration of 0.125M. In 
parallel, an uncross-linked sample was prepared. Cells were centrifuged for 8 min 
at 230g, 4°C, and cell pellet was ressuspended in 5 ml of cold lysis buffer (10mM 
Tris-HCl, pH7.5; 10mM NaCl; 5mM MgCl2; 0.1mM EGTA; 0.2% NP-40; 1xPI) 
and incubated for 10 min on ice. After assessing cell lysis by trypan blue, the 
lysate was centrifuged for 5 min, 400g at 4°C, and then ressuspended in 500µl of 
1.2X restriction enzyme buffer. 7.5µl of SDS was added (0.3% final 
concentration) and nuclei were incubated at 37°C for 1 hour, 1400 rpm. 50µl of 
Triton-X 100 (2% final concentration) was added to block SDS for 1 hour at 
37°C, 900 rpm. A 5µl aliquot was taken as undigested genomic DNA control. 
Digestion was carried out by adding Apo I enzyme (Fermentas) for the following 
period: 100U – 1 hour, 300U – O/N and 100U – 1 hour, at 37°C, 1400 rpm. An 
aliquot (15µl) was taken as control of digestion and verified on a 1.5% agarose 
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gel. Prior to ligation, samples were incubated with 40µl of SDS (1.6%) final 
concentration and incubated for 25 min at 65°C, 1400 rpm. The digested nuclei 
were transferred to a 50ml tube and 6.125ml of 1.15x ligation buffer was added. 
SDS inactivation was carried out by adding 375µl of Triton X-100 (1% final 
concentration) and samples were incubated for 1 hour at 37°C while shaking 
gently. Chromatin was then incubated with 100U T4 ligase, for 4 hours at 16°C 
followed by 30 min at RT. Proteinase K (300µg final) was added and DNA-
protein complexes were uncross-linked (including undigested and digested 
controls) at 65°C O/N. DNA was recovered by adding RNase (300µg final) 
followed by phenol-chloroform extraction and ethanol precipitation. DNA 
concentration of the 3C template was determined and the 2nd digestion was carried 
out with NlaIII (Fermentas), 1unit/mg DNA and 17µl of 1x appropriate buffer), 
O/N. The enzyme was heat-inactivated and the DNA was recovered as before and 
ressuspended in 100µl milli-Q H2O. Ligation was carried out in 14ml total volume 
of 1.15X with 200U of T4 ligase, for 4 hours at 16°C, plus 30 min at RT. DNA 
was recovered by phenol extraction and DNA purification. The primers used to 
verify digestion were: GAPDH-ApoIF 5’–GTATGACTGGGGGTGTTGGG-3’; 
GAPDH-ApoIR 5’–GGGGAGGCTCCTCCAGAATA-3’; ApoI-F   5’-
AGGCATAAGGGGCTGACAAG-3’; SpeI-nested 5’–
TAATCAGAGATTCAGATTTAAG-3’. The primers used for sequencing were 
BanII nested F3 5’– CACGTTTTTTGCCCTGAGCTTTG- 3’ and BanII nested 
R3 5’-CTGGAGCCACCTTCAAGTTC-3’. 
 
2.7 DNA sequencing 
 
100ηg of purified DNA was mixed with 8ρmol of forward or reverse primer and 
0.5µl of fluorescent dideoxy terminator nucleotides (BigDye, Applied 
Biosystems) in the appropriate reaction buffer.  
The PCR program used for the sequencing reaction consisted of a denaturation 
step at 96ºC for 1 min followed by 25 cycles of 10 seconds at 96ºC, 5 seconds at 
50ºC and 4 minutes at 60ºC. The PCR product was purified by using 2µl 3M Na-
acetate, 2µl 125mM EDTA and 50µl absolute EtOH, spun at 3400 rpm for 30 
minutes, washed with 70% cold EtOH at 3400 rpm for 15 minutes and dried at RT 
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for 5-10 minutes. DNA was ressuspended in 10µl Hi-Di Formamide (Applied 
Biosystems) and resolved by capillary electrophoresis on an Applied Biosystems 
3730 DNA analyser (Applied Biosystems, USA). 
 
 
Table 6. Primers used for sequencing 
hGATA-1 F 5’-ATGGGTACCATGGAGTTCCCTGGCCTGGGG-3’ 
hGATA-1 R 5’-ATGGCGGCCGCTCATGAGCTGAGCGGAGCCAC-3’ 
pCDNA5∆CMV UNIVF  5’-GCCGCAAAAAAGGGAATAAGGGC-3’ 
pCDNA5∆CMV UNIVR 5’-CACCTACTCAGACAATGCGATGC-3’ 
 
2.8 Flow-activated cell sorting (FACS) 
 
Peripheral blood mononuclear cells (PBMC) were pelleted at 1200 rpm, washed 
and ressuspended in 100µl RoboSep buffer (Stem Cell Technologies). The cells 
were incubated with the antibodies CD19-APC (BD Pharmingen), CD14-PE 
(eBioscience), CD3-efluor450 (eBioscience),  and CD59-FITC (BD Pharmingen) 
or FLAER (Alexa 488 conjugated proaerolysin; Pinewood Scientific) for 30 
minutes at 4ºC in the dark. After incubation cells were washed in PBS/2% FBS 
and sorted in a FACSAria II flow cytometer (BD Biosciences, USA). K652- and 
LBCL-GFP expressing cells were collected, washed in PBS/2% FBS and sorted. 
Dead cells were excluded by DAPI (Sigma) or 7-AAD (BD Pharmingen) staining. 
Analysis was performed using FlowJo software (Tree Star Inc., USA).  
 
2.9 Generation of FRT stable cell lines 
 
Flp-In-293 cells (Invitrogen) containing a single integrated FRT (Flp 
Recombination Target) site and stably expressing the lacZ-Zeocin fusion gene 
were co-transfected with pCDNA5-PIGM-GFP plasmid, in which the CMV 
promoter has been deleted, and the recombinase pOG44, as described in 2.16.   
After transfection, cells were maintained under selection (100µg/ml hygromycin) 
for approximately 4 weeks. Single recombinant clones (see scheme below) were 
isolated by using cloning cylinders (Sigma), trypsinised and expanded in the 
appropriate medium. In order to confirm site-specific recombination, genomic 
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DNA was extracted using the GeneJET Genomic DNA Purification Kit 
(Fermentas) and PCR was carried out using the following 3 primers in the same 
reaction: F1 5’-CTATTCCAGAAGTAGTGAGG-3’; R1 5’-
GTCGTCCATCACAGTTTGCC-3’ and R2 5’-
GATAGGTCACGTTGGTGTAG-3’. The PCR program consisted in an initial 
denaturation step of 5 minutes at 94ºC, followed by 35 cycles of 30 seconds at 
94ºC, 45 seconds at 56ºC and 2 minutes at 72ºC and concluded with a final 
extension of 8 minutes at 72ºC. The PCR product was analysed on an agarose gel. 
 
 
 
 
Fig. 10 – Schematic representation of the FRT system. 
   
 
2.10 In vitro erythroid differentiation and cytospin staining 
 
The two-phase erythroid culture system was adapted from Ohene-Abuakwa et al, 
2005 (178) and Ronzoni, L. et al, 2008 (179). 
PBMC (2x106 cells/ml) and CD34+ cells (1x106 cells/ml) derived from cord blood 
were plated in erythroid medium, consisting of Stemspan (Stem Cell 
Technologies) supplemented with 100ηg/ml stem cell factor (SCF, Peprotech), 
10ηg/ml interleukin-3 (IL-3) and 0.5 U/ml erythropoietin (EPO) during phase 1 
(day0-7) of the cultures. After 7 days, CD36+ cells were selected using anti-PE 
magnetic beads and the MiniMACS system (Miltenyi Biotec). CD36-PE cells 
Chapter 2 – Materials and Methods 
 
46 
were re-plated in erythroid medium containing 4 U/ml EPO for 2-3 more days 
(Phase 2) and then sorted (for RNA) or magnetically separated (for ChIP).  
Erythroid differentiation was monitored by flow cytometry analysis using the 
antibodies CD34-PerCP.Cy5.5 (Biolegend), CD36-APC (BD Pharmingen), 
CD71-PE (Biolegend) and GlyA-eFluor450 (eBioscience) and by May-Grünwald-
Giemsa stained cytospin preparations (as described in 2.4). 
 
2.11 Micrococcal nuclease (MNase) protection assay  
 
2x106 cells were cross-linked with 1% paraformaldehyde in PBS, for 10 minutes 
at 37ºC. Cross-link was quenched by adding glycine to a final concentration of 
125mM, and incubated on ice for 5 minutes. Cells were washed with ice-cold PBS 
and ressuspended in 1ml buffer A (25mM HEPES pH 7.4, 150mM NaCl, 0.1mM 
EDTA, 0.1% Triton-X 100, 10% glycerol, 1 mM DTT, 1x PI) followed by 
incubation for 15 minutes at 4ºC with rotation. The sample was split in two and 
centrifuged at 4ºC, 4500 rpm for 10 minutes to pellet nuclei. Nuclei were then 
ressuspended in 225µl of MNase buffer (25mM KCl, 12.5% glycerol, 50mM Tris 
pH 7.9, 10mM CaCl2, 4mM MgCl2, 1mM PMSF) and incubated with or without 
MNase (300units/ml) at the indicated concentration(s), at 37ºC for 15 minutes. 
Digestion was stopped by adding 25µl of MNase stop solution (10mM Tris pH 
7.9, 200mM EDTA) and 250µl of digestion buffer (20mM Tris pH 7.9, 200mM 
NaCl, 50mM EDTA and 1% SDS). Cross-link was reverted at 65ºC overnight. 
The samples were treated with 6µg/ml RNase A (Fermentas) for 30 minutes at 
37ºC followed by digestion with 50µg/ml Proteinase K (Fermentas), 30 minutes at 
37ºC. DNA was recovered by phenol-chloroform extraction and ethanol 
precipitation. Micrococcal digestion was analysed in a 2% agarose gel and the 
optimal MNase concentration (147bp mononucleosome units) was used in 
subsequent experiments. Nucleosome occupancy was determined by RQ-PCR by 
calculating the ratio of digested to undigested chromatin for equivalent DNA 
amounts and using the delta Ct method for determination of the relative levels. 
The length of the PIGM promoter was covered by 100bp amplicons overlapping 
by 50bp. GAPDH promoter amplicon was used as an accessibility control. 
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Table 7. MNase protection assay primers 
Designation Forward primer Reverse primer 
i 5’-CTTCAACTCATCCTGTCCTG-3’ 5’-GTAGGAGTGAAAGGAAGATAAG-3’ 
h 5’-GCGAGCTAGTGGAGTAAAGC-3’ 5’-GGCTGCGCGCTACATCCTTC-3’ 
g 5’-TTTTTCACTCTCGGATCTCC-3’ 5’-CCCCATTTCCAGTCCTCAG-3’ 
f 5’-CAGCTCGCTGCTCGTCGG-3’ 5’-GGAGTGAGATTTCTTTGTAAGTG-3’ 
*e 5’-GGAAGAGGGCGGGGGGG-3’ 5’-TCCGCTTGCCGGGAAATCc-3’ 
*d 5’-CACTCCATAAAATCCTCAAGCC- 5’-CCGCTTCTTCTTCCAGCGG-3’ 
c 5’-TCCCCTCCCACGGACCGG-3’ 5’-AGCCGCCCGAGCCAAAAAC-3’ 
*b 5’-CGAGACCGTCCATCCAGAGG-3’ 5’-CATGAAGCCCCGCCCCCG-3’ 
*a 5’-GACCGCGCGGGGCTGGAG-3’ 5’-CTCCCACCCGCCAGGCTG-3’ 
1 5’-CGGATGTGATAGTCTGCAGTC-3’ 5’-CCTTCGTACTTCTAACCTTCCC-3’ 
2 5’-TGCGGCGGCCACCTGCTG-3’ 5’-GCCCATGATCTGACCGTGCG-3’ 
GAPDH 5’-TACTAGCGGTTTTACGGGCG-3’ 5’-TCGAACAGGAGGAGCAGAGAGCGA -3’  
   
Tm=60ºC   *Tm=63ºC 
 
2.12 Plasmids and cloning 
 
A PCR-based technique was previously used to clone a 2Kb fragment (-2000/+1) 
of the human PIGM promoter from either WT or MUT gDNA of lymphoplastoid 
cell lines into the pGL3-Basic vector (Invitrogen) using the KpnI and NcoI 
restriction sites. A pair of truncated constructs (-910WT and -910MUT) of the 
5’end was then generated by PCR amplification and monitored on agarose gel.  
The 910bp fragment (-910/+1) was digested with KpnI and NcoI (Fermentas) and 
sub-cloned into the pCDNA5/FRT vector that contains a GFP reporter gene that is 
expressed under the activity of the promoter in study. The vector was linearized 
with KpnI and dephosphorylated with SAP (Fermentas). Both vector and insert 
were incubated with Klenow (Fermentas) and 1µl 10mM dNTPs for 15 minutes at 
RT and then ligated. 
 
hGATA-1 cDNA (1241bp fragment) previously cloned in the pREP4 vector was 
digested using KpnI and NotI restriction enzymes (Fermentas) and the MigR1-
ratCD2 vector (kindly donated by G.Bohn) was linearised with EcoRI. Both 
vector and insert were incubated with Klenow and 1µl 10mM dNTPs for 15 
minutes at RT and the ligated.  
Ligation reactions containing 1:6 (fragment:vector) molar ratio were performed by 
using T4 DNA ligase (Fermentas) in a final volume of 10µl, O/N at 4ºC .  
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Sp1-DNA binding domain (DBD) was amplified by PCR from pEBGN-Sp1 
(kindly donated by Dr.Gerald Thiel) using BglII and EcoRI restriction sites. The 
fragment was sub-cloned into the MigR1-GFP plasmid and ligation was carried 
out as described above. 
 
5µl of each ligation were used to transform chemically competent cells (as 
described in 2.3). All plasmids were verified by restriction enzyme digestion and 
monitored in an agarose gel. Plasmids were also verified by direct sequencing (see 
Tables 6 and 8). 
 
Scramble shRNA, GATA-1 shRNA and Sp1 shRNA oligonucleotides were 
designed in the Mission shRNA web tool (http://www.sigmaaldrich.com/life-
science/functional-genomics-and-rnai/shrna.html) and purchased from Sigma. 
Oligonucleotides were phosphorylated with PNK (Fermentas) for 1 hour at 37ºC 
followed by annealing for 5 minutes at 95ºC and slowly cooled to room 
temperature (RT). Annealed oligonucleotides were then ligated into the lentiviral 
plasmid pLKO.1-GFP previously digested with AgeI and EcoRI restriction 
enzymes (Fermentas). Ligation reaction was carried out by T4 DNA ligase, O/N 
at 4ºC and 5µl of the ligation reaction were used to transform chemically 
competent cells (as described in 2.3). Plasmids were verified by restriction 
enzyme digestion using EcoRI and NcoI (see Appendix A, Fig. A6). 
 
 
Table 8. Primers used for cloning 
-910 KpnI F 5’-CTAATGGTACCAAATACAGAGATACTGAGGCAT-3’ 
+1 NcoI R 5’-TAATCCATGGATCTGACCGTGCGACAGCTGC-3’ 
DNSp1BglII F 5’-ATAATAGATCTATGCCTCCTAAAAAGAAGCGCAAGGTAG-3’ 
DNSp1EcoRI R 5’-ATAATGAATTCATGCCTCCTAAAAAGAAGCGCAAGGTAG-3’ 
shRNA GATA1 F1 5’-CCGGCGGCCCAAGAAGCGCCTGATTCTCGAGAATCAGGCGCTTCTTGGGCCGTTTTT-3’ 
shRNA GATA1 R1 5’-AATTCAAAAACGGCCCAAGAAGCGCCTGATTCTCGAGAATCAGGCGCTTCTTGGGCCG-3’ 
shRNA Sp1 F1 5’-CCGGGCAGCAACTTGCAGCAGAATTCTCGAGAATTCTGCTGCAAGTTGCTGCTTTTTG-3’ 
shRNA Sp1 R1 5’-AATTCAAAAAGCAGCAACTTGCAGCAGAATTCTCGAGAATTCTGCTGCAAGTTGCTGC-3’ 
shRNA Sp1 F2 5’-CCGGCCCAAGTTTATTTCTCTCTTACTCGAGTAAGAGAGAGAAATAAACTTGGGTTTTT-3’ 
shRNA Sp1 R2 5’-AATTCAAAAACCCAAGTTTATTTCTCTCTCTTACTCGAGTAAGAGAGAAATAAACTTGG-3’ 
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2.13 Rapid amplification of cDNA ends (RACE) 
 
The 5’-RACE analysis was carried out using the ExactSTART Eukaryotic mRNA 
5’- & 3’-RACE kit (Epicentre). 2ug of total RNA was treated with Apex Heat-
Labile alkaline phosphatase to remove the 5’-phosphates of truncated mRNA, at 
37ºC for 15 minutes. After extraction by phenol-chloroform and ethanol 
purification, RNA was treated with tobacco acid pyrophosphatase (TAP) to 
remove the 5’-cap structure from intact, full-length mRNA, at 37ºC for 30 
minutes. 5’-RACE acceptor oligo was ligated to the 5’end of the mRNA by 
adding 1µl TAP stop buffer, 1µl 2mM ATP solution and 1µl T4 RNA Ligase, at 
37ºC for 30 minutes. 3’-polyadenylated RNAs were then reverse transcribed into 
first-strand cDNA by adding 1µl cDNA synthesis primer (oligo d(T) sequence 
with a PCR priming site sequence at its 5’ end), 2µl dNTP, 2µl MMLV RT Buffer 
and 1µl MMLV reverse transcriptase. The reaction was incubated at 37ºC for 1 
hour followed by 10 minutes at 85 ºC to inactivate the enzyme. Second-strand 
cDNA was synthesised by adding 5µl PCR primer 1 (which anneals to the PCR 
priming site at the 5’-RACE acceptor oligo), 5µl oligo d(T) (instead of PCR 
primer2) and 2.5U of DNA polymerase enzyme with the appropriate buffer 
following the conditions: 95ºC for 30 seconds (initial denaturation); 95ºC for 20 
seconds, 60ºC for 20 seconds and 72ºC for 3 minutes, repeated for 21 cycles. The 
PCR reactions were carried out by using PCR Primer 1 and β-actin reverse primer 
(5’-AGGTGTGGTGCCAGATTTTC-3’) or PIGM reverse primer (5’-
CTTCTAACCTTCCCTTCGGTTCTTT–3’). 
Both PCR products were analysed on a 2% agarose gel. The PIGM PCR product 
was then cloned into the pJET- vector according to the manufacturer’s 
instructions.  Following bacterial transformation, the plasmid DNA was 
sequenced. 
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Fig. 11 – Schematic representation of RACE. 
 
2.14 Reporter assays  
 
Adherent cells were seeded in a 24 well plate at a concentration of 1.5x105-
2x105cells/well and transfected with 450ηg of plasmid DNA expressing the 
luciferase reporter gene and 50ηg of pRL (renilla) used for normalisation (see 
2.16).  
Suspension cells were transfected with 1.8µg luciferase reporter gene and 0.2 µg 
of renilla by electroporation. 
48 hours after transfection cells were washed with PBS and lysed in 100ul of 1X 
Passive Lysis Buffer (PLB; Promega) under agitation at 300rpm for 15 minutes at 
RT. Cell lysate was collected and spun at 14.000rpm for 5 minutes at 4ºC, to 
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remove cell debris. 20µl of the cell lysate were used to measure luciferase activity 
by using the Dual-luciferase reporter assay system (Promega), on a Fluoroskan 
Ascent Luminometer (Thermo Scientific), for 100ms. Measurements were 
performed in triplicate and luciferase reporter activity was normalised with 
respect to renilla. 
 
2.15 RNA extraction, cDNA synthesis and quantitative reverse transcriptase-
PCR (qRT-PCR) 
 
Total RNA from cell lines was extracted using the GeneJet RNA purification kit 
(Fermentas) and total RNA from primary cells in small number was extracted 
using the NucleoSpin RNA XS kit (Macherey-Nagel). When appropriated, gDNA 
was digested by DNase treatment (1U/ug RNA; Fermentas). RNA was reverse-
transcribed into cDNA in a thermocycler using the RevertAid First strand cDNA 
synthesis kit (Fermentas). Briefly, 100 to 500ng of RNA was incubated with 1µl 
oligo d(T) primers at 65 ºC for 5 minutes and after cooled down a reaction mix 
containing 2µl 10mM dNTPS, 200 units Revert Aid, and 20 units RNAse 
inhibitor (Ribolock) was added and samples were left at 42ºC for 60 min. cDNA 
was diluted according to the initial amount of RNA and gene expression was 
measured with specific primers and Maxima POWER SYBR Green master mix 
(Fermentas) in a AB 7500 Real-time PCR system. The PCR program is described 
above (see 2.5). All primers were first tested for linearity by using serial dilutions 
of cDNA. Single PCR product was verified by melting curve dissociation and 
expression values were obtained by using the ∆ Ct method (2-(Ct gene-Ct reference)). 
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Table 9. qRT-PCR primers 
 
Designation Forward primer Reverse primer 
RT-GATA-1 5’- ACACCAGGTGAACCGGCCAC-3’ 5’- CCTTCGGCTGCTCCTGTGCC-3’ 
RT-γ EX2 5’- TGGCAAGAAGGTGCTGACTTC-3’ 5’-GCAAAGGTGCCCTTGAGATC-3’ 
RT-γ EX3 5’-AATCCATTTCGGCAAAGAATTC-3’ 5’-CCACTCCAGTCACCATCTTCTG-3’ 
RT-PIGM 5’- CAGAGTCGCCCTGGTTTTCT-3’ 5’- TTCCAAAGAGCTCGCTGAGG-3’ 
RT-PIGX 5’–CTTCCCATAACCCTCCACCT-3’ 5’-GGAGCTCGTACAAACAAGCC-3’ 
RT-Sp1 5’-CTGGTCCGCCCTCTGACCAAGA-3’ 5’-TCGAGCCTGTGAAAAGGCACCA-3’ 
GFP 5’-GTTCATCTGCACCACCGGC-3’ 5’-CGGGTCTTGTAGTTGCCGTC-3’ 
GAPDH 5’-GAAATCCCATCACCATCTTCCAGG-3’ 5’-GAGCCCCAGCCTTCTCCATG-3’ 
DHFR 5’-GAGCTCGAGCCCAAGGGATA-3’ 5’-ATGAGCTCCTTGTGGAGGTTC-3’ 
α-globin 5’-GAGGCCCTGGAGAGGATGTTCC-3’ 5’-ACAGCGCGTTGGGCATGTCGTC-3’ 
 
 
2.16 Transfections 
 
In order to obtain 293 PIGM promoter-GFP cells, Flp-In-293 cells were seeded in 
10cm2 plates (2x106cells/plate). On the day after, cells were co-transfected with 
1µg of pCDNA5-∆CMV-FRT containing the PIGM promoter and 9µg of the Flp 
recombinase expression plasmid, pOG44 (Invitrogen) using the CaCl2 method. 
Briefly, the plasmid solution was made up to a final volume of 450µl with low TE 
buffer and 50µl of 2.5M CaCl2 was added to the plasmid mixture. Following 5 
minutes incubation, 500µl of 2x HBS was added drop wise to the 500µl DNA-TE-
CaCl2 complex while vortexing at full speed. Immediately after vortexing, the 
precipitate was added drop wise to the 293T cells. After 14-16 hours, cell media 
was replaced. 
HeLa, 293 cells and 293 PIGM promoter-GFP clones were seeded in 6-well plates 
at a concentration of 1.5x105 cells/well and 2.5x105 cells/well, respectively, and 
transfected with  plasmid DNA (typically 2µg) by lipofection (Lipofectamine 
2000, Invitrogen). 4 hours after transfection, cell media was replaced.     
K562 cells were transfected by electroporation in 0.4cm cuvettes, using a Gene 
Pulser II Electroporation System (BioRad ,USA). 
 
 
 
Chapter 2 – Materials and Methods 
 
53 
2.17 Viral production and transduction 
 
Lentiviruses were generated by co-transfection of 3x106 293T cells with plasmids 
encoding gag-pol (5µg pMDLg/pRRE), Rev (2.5µg of pRSV-REV), envelope 
plasmid (3µg VSV-G) and shRNA-pLKO.1 GFP (12µg). For retroviral 
production, cells were co-transfected with gag-pol (12µg pMDLg/pRRE), 
envelope plasmid (3µg VSV-G) and MigR1GFP or hGATA-1 (10µg). The 
plasmid solution was made up to a final volume of 450µl with low TE buffer. 
Finally, 50µl of 2.5M CaCl2 was added to the plasmid mixture. Following 5 
minutes incubation of the plasmid mixture, 500µl of 2x HBS was added dropwise 
to the 500µl DNA-TE-CaCl2 complex while vortexing at full speed. Immediately 
after vortexing, the precipitate was added dropwise to the 293T cells. After 14-16 
hours, cell media was replaced and cell supernatants were collected 24 and 48 
hours after changing the media and spun for 2 hours at 23000 rpm in a 
ultracentrifuge. Pellet was ressuspended in culture medium and stored at –80°C. 
Before freezing, viral supernatant was taken to infect 293T cells in order to 
determine viral titre (see Appendix A, Fig. A7). 
K562 were transduced using a spin-infection method and polybrene (8ug/ml final 
concentration). The cells were spun down for 1 hour at 2000 rpm, 32ºC and then 
kept at 37ºC overnight. Medium was changed 12 hours thereafter. 
 
2.18 Western-blot 
 
Cells were lysed with RIPA lysis buffer (buffer composition) and protein 
concentration was determined by employing the method of Bradford, following 
the kit manufacturer’s instructions (BioRad). BSA standards (BioRad) were used 
to generate a standard curve. Typically, 25µg of whole cell protein extracts were 
size-fractionated by electrophoresis on 12% SDS-polyacrilamide gel and 
transferred onto PVDF membranes (BioRad) using the Trans-Blot SD Semi-Dry 
Transfer system (BioRad) with constant voltage of 12V for 45 min. Membranes 
were blocked for 1h30 at RT with PBS/0.1% Tween20 containing 5% non-fat dry 
milk and then washed three times with PBS/0.1% Tween20.  
Specific antibodies for GATA1 (ab11852, abcam), GFP (2555, Cell Signaling), 
and β-actin (sc-1616, Santa Cruz) were diluted in the appropriate solution and 
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used to detect the protein of interest, O/N at 4ºC.  Next, the membranes were 
washed three times with PBS/0.1% Tween20 before incubation for 2 hours at RT 
with the HRP-conjugated secondary antibody (Santa Cruz). ECL (enhanced 
chemiluminescence) solution (Amersham) was used for signal detection. ImageJ 
software was used to determine % of protein expression. 
 
2.19 Statistical analysis 
 
Results are expressed as mean ± standard error of the mean (SEM) unless 
otherwise stated. Data was analysed using the unpaired two-tailed student’s t test 
or one-way ANOVA with Bonferroni correction for multi-comparison test 
(GraphPad Prism5, CA, USA). P values < 0.05 were considered statistically 
significant.  
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Chapter 3 – Results 
 
 
3.1 Elucidating the role of PIGM transcription in PIGM-
associated IGD 
 
3.1.1 Introduction 
 
In PIGM-associated IGD, the expression of GPI at the surface of haematopoietic 
cells varies in a cell-type specific manner. The differential expression of GPI is 
observed not only between different haematopoietic lineages but also between 
cells belonging to the same lineage. Regarding the lymphoid lineage, as I will 
show later, the majority of B lymphocytes are mostly GPI negative (GPI-) with a 
small proportion of cells being GPI positive (GPI+), whereas the T lymphocytes 
are mostly GPI+. In striking contrast with PNH, the erythrocytes are mostly GPI+ 
(Fig. 12), hence the absence of significant haemolysis in patients (87).  
 
 
 
Fig. 12 – Flow cytometric profile of the red blood cells (RBC) from a normal donor 
and affected child (-270C>G homozygous) stained with the GPI-linked antigen CD59. 
 
Although the differential expression of GPI has been linked to the -270C>G 
mutation in the regulatory region of PIGM (87), a direct correlation between 
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PIGM mRNA levels and expression of GPI in patient cells has not been 
shown. Additionally, the contribution of PIGX, the component of the GPI 
MT-I that stabilises PIGM, has not been investigated. 
 
It is known that gene expression is influenced by nucleosome positioning at 
functional regulatory regions such as promoters. The underlying DNA sequence 
and binding of generic and tissue-specific TFs constitute some of the elements 
that determine the occupancy of the nucleosomes, which therefore affect 
chromatin accessibility and transcription output.  
Another important aspect in gene regulation is the presence of a single or multiple 
TSSs, with multiple TSSs often associated with highly GC-rich promoters (21) 
like that of PIGM.  
 
Characterising the architectural organization of the PIGM promoter in terms 
of nucleosome occupancy and determining the position of the TSS(s) in cells 
from different haematopoietic lineages might be relevant for better 
understanding of the regulatory mechanism(s) driving PIGM transcription. 
  
The aims of this chapter are to investigate a) PIGM and PIGX mRNA expression 
in normal haematopoietic cells b) the correlation between PIGM mRNA levels 
and GPI in cells from patients with PIGM-associated IGD, c) the impact of the -
270C>G mutation on the promoter activity of PIGM in erythroid cells, d) the 
promoter accessibility in terms of nucleosome occupancy and TSS(s) positioning. 
   
3.1.2 Experimental design 
 
Gene expression was evaluated in cell lines and primary haematopoietic cells by 
qRT-PCR. For this purpose, primary haematopoietic cells from peripheral blood 
samples were obtained from normal donors and patients with IGD and isolated by 
FACS sorting. After isolation, cells were assayed for mRNA expression or 
maintained under appropriate culture conditions for induction of erythroid 
differentiation.  
PIGM-promoter activity was studied by employing luciferase reporter assays. 
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The nucleosome occupancy was determined by micrococcal nuclease protection 
assay and the positioning of the TSS was resolved by 5’-RACE.     
 
 
3.1.3 Results 
 
The -270C>G mutation directly abrogates PIGM transcription in a cell-type 
specific manner 
 
In order to gain insight on the degree of variability of PIGM expression, PIGM 
mRNA levels were first evaluated in haematopoietic cells derived from peripheral 
blood of normal donors.  
B lymphocytes, T lymphocytes and monocytes were obtained by FACS sorting 
after staining of peripheral blood mononuclear cells (PBMC) with the appropriate 
lineage-specific antibodies (CD19, CD3 and CD14, respectively) (Fig. 13A) while 
neutrophils were isolated after lysis of the red blood cells pellet derived from 
Ficoll centrifugation. The typical morphology of neutrophils was confirmed by 
MGG staining (Fig. 13C). 
A unimodal pattern of GPI expression was seen in B lymphocytes, T lymphocytes 
and monocytes obtained from normal donors, as assessed by FLAER staining 
(Fig. 13B). FLAER is a fluorescein-labeled modified proaerolysin that binds to 
GPI (180). 
While GPI expression in mature red blood cells is nearly normal, whether 
erythoid precursors in IGD also express high levels of GPI was not investigated. 
To address this, I generated erythroid precursors using a method suitable for in 
vitro generation of nucleated erythroid precursor cells from PBMC (see Chapter 2, 
2.10). PBMC constitute one of the sources of CD34+ progenitor cells that in the 
appropriate culture conditions have the capacity to commit into erythroid 
progenitor cells. Given that in vitro erythroid differentiation slightly varies from 
sample to sample, I describe below a representative example of a normal culture. 
Erythroid differentiation was monitored by FACS analysis of the cell surface 
markers CD36, CD71 and GlyA (see Fig. 8) at days 0, 7 and 10 of the liquid 
culture (Fig. 14). At day 0, 18.9% of cells were CD36+/CD71-/GlyA- and after 7 
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days in the appropriate erythroid culture conditions, CD36+ cells expanded to 
25.9%. At this stage, almost all CD36+ cells expressed the non-erythroid specific 
transferrin receptor, CD71, with 70.3% also expressing GlyA, an erythroid-
specific marker of late precursor and mature cells. By re-plating the CD36+ cells 
for an additional period of three more days in Phase II medium, all cells became 
CD71+ and gained GlyA expression (89.5%). The stage of maturation of the 
erythroid precursor cells corresponded to the morphological modifications as 
assessed by microscopic examination of MGG stained cytospins (Fig. 14). 
Accordingly, at day 7, erythroid precursor cells presented a large nucleus, 
characteristic of basophilic erythroblasts, and later in differentiation the nucleus 
was reduced in size and chromatin became more condensed. These cells are called 
polychromatic-erythroblasts. 
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Fig. 13 – Isolation of the haematopoietic cells derived from peripheral blood of a 
normal donor and assessment of GPI expression. Peripheral blood mononuclear cells 
were identified according to physical properties SSC (side scatter) vs. FSC (forward 
scatter) and doublets were excluded by double gating on FSC-W (width) and FSC-A 
(area). A – Cells were stained with CD19, CD3 and CD14 antibodies. T lymphocytes 
(CD3+) were gated on the double negative CD19-CD14- fraction; B lymphocytes 
corresponded to CD19+ cells and monocytes corresponded to CD14+ cells. B - Flow 
cytometric profile of T lymphocytes, B lymphocytes and monocytes stained with FLAER. 
The unimodal pattern of expression was observed in all cell types, with the majority being 
GPI+ as compared to unstained control. Numbers above the gates indicate the frequency 
of positively stained cells. C - Neutrophils were obtained by RBC lysis and morphology, 
characterised by a multi-lobed nucleus, was assessed by May-Grunwald-Giemsa (MGG) 
staining. 
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Fig. 14 - In vitro erythroid differentiation from a peripheral blood sample. Peripheral 
blood mononuclear cells were identified according to physical properties SSC (side 
scatter) vs. FSC (forward scatter). Doublets were excluded by double gating on FSC-W 
(width) and FSC-A (area) and dead cells were excluded by DAPI staining. Erythroid 
differentiation was monitored by flow cytometry analysis using CD34, CD36, CD71 and 
GlyA antibodies. CD71 and GlyA expression were assessed on CD36+ cells. Erythroid 
precursor cells were isolated by magnetic separation after staining with CD36-PE 
antibody and incubation with anti-PE beads. Morphologic characteristics of selected cells 
were assessed by MGG staining. Cytospins are shown to illustrate the morphologic 
changes as erythroid cells mature from basophilic erythroblasts with a large nucleus (Day 
7) through polychromatic-erythroblasts with a nucleus reduced in size accompanied by 
condensation of chromatin (Day10). 
 
 
After isolation of the various haematopoietic cell types from samples collected 
from different donors, PIGM mRNA levels were evaluated. PIGM expression was 
variable amongst different cell types. PIGM mRNA levels were highest in 
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neutrophils followed by T lymphocytes and B lymphocytes with monocytes 
expressing slightly less PIGM mRNA. In purified CD36+ erythroid precursor 
cells, PIGM levels decreased as cells underwent differentiation. At day 7, mRNA 
levels were comparable with those in the monocytes and later in differentiation, at 
day 10, decayed approximately by 2.5-fold (Fig. 15).  
 
 
 
Fig. 15 - PIGM mRNA expression in haematopoietic primary cells derived from 
normal donors. B lymphocytes (B lymph), T lymphocytes (T lymph) and monocytes 
were isolated after staining with CD19, CD3 and CD14, respectively (see Fig. 13A). 
Neutrophils were isolated by lysis of the red cells (see Fig. 13C) and CD36+ erythroid 
precursor cells (see Fig. 14) were isolated by magnetic separation. B lymphocytes: n=7, T 
lymphocytes: n=5, Monocytes: n=7, Neutrophils: n=3, Ery Day 7 n=4, Ery Day 10 n=3. 
Expression values were normalised to GAPDH and results are presented as mean ± SEM, 
*** p<0.001. 
 
 
The reduction in the mRNA levels of PIGM seen during erythropoiesis was in 
agreement with RNA-seq data obtained from mouse fetal liver erythroid precursor 
cells isolated at different stages of differentiation (154). As shown in Fig. 16, the 
number of reads mapping to PIGM and to the erythroid-specific gene GATA-1, 
were reduced in later stages of fetal erythropoiesis (R4 and R5). 
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Whether changes at the mRNA expression levels mirrored changes at the protein 
level in these cells could not be assessed due to the lack of good quality anti-
PIGM antibody.   
 
 
 
Fig. 16 – RNA-seq analysis in mouse fetal liver erythroid precursor cells. Fetal liver 
cells were double-labeled for erythroid-specific TER119 (GlyA equivalent in humans) 
and non erythroid-specific transferrin receptor (CD71) and then sorted by flow-
cytometry. R2 – proerythroblasts and early basophilic erythroblasts, R3 – early and late 
basophilic erythroblasts, R4 – polychromatophilic and orthochromatophilic erythroblasts 
and R5 – late orthochromatophilic erythroblasts and reticulocytes. Gene expression 
values were calculated as Reads Per Kilobase of Exon Model Per Million Mapped Reads 
(RPKM); RPKM values from R3, R4 and R5 were normalised with respect to R2 and 
expressed as a fold change relative to R2 (154). Data was retrieved from the Gene 
Expression Omnibus database under the accession number GSE27893.  
 
 
Having seen that mRNA levels of the housekeeping gene PIGM are variable in 
haematopoietic cells of normal donors, the next step was to establish in 
haematopoietic cells from IGD patients the relationship between PIGM mRNA 
levels and cell surface GPI expression.  
For this purpose, PBMC of an affected child, collected before NaBu treatment and 
cryopreserved for several years, were used. Accordingly, cells from 2C 
(homozygous MUT from Family 2, see Fig. 9) were stained with antibodies 
against CD19, CD3, CD14 and FLAER and then the haematopoietic cell 
populations were examined according to expression of GPI into two fractions: 
GPI positive (GPI+) and GPI negative (GPI-). For the purpose of direct 
comparison, cryopreserved PBMC from the father of the affected child, 2E 
(heterozygous for the -270 substitution), were also analysed.  As also described in 
(87), I found that haematopoietic cells from heterozygous individuals presented 
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normal levels of cell surface GPI. In cells from the affected child, the B 
lymphocytes showed a bimodal distribution in which the majority of the cells 
(70.9%) were GPI negative while a small proportion (29.1%) was GPI positive. 
Normal GPI expression was seen in 89% of the T lymphocytes with the remainder 
(11%) being GPI negative. GPI expression on monocytes in both homozygous and 
heterozygous individuals was unimodal and normal, with all cells staining with 
FLAER (Fig. 17).    
 
 
 
 
Fig. 17 – GPI expression profile of haematopoietic cells isolated from individuals of 
Family 2. Histograms show GPI expression as assessed by FLAER. The gating strategy 
used to identify CD3+ T lymphocytes (left), CD19+ B lymphocytes (middle) and CD14+ 
monocytes (right) was described above (Fig. 13A). Dotted line – unstained; blue solid 
line – heterozygous individual 2E; red solid line – homozygous MUT individual 2C.  
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Fig. 18 – In vitro erythroid differentiation from PBMC of individuals from Family 2 
and a normal control, at day 7. A - Erythroid differentiation was monitored by flow 
cytometry analysis using CD34 (not shown), CD36 and GlyA antibodies. Left – normal 
donor; middle – heterozygous individual, 2E; right – homozygous MUT individual, 2C. B 
– Flow cytometric profile of the GPI-linked antigen CD59. Dotted line – unstained; green 
solid line – normal donor; blue solid line – 2E; red solid line – 2C. Double positive 
CD36+/GlyA+ erythroid precursor cells were sorted by flow cytometry. C - CD36+ 
erythroid precursor cells and CD36- control cells were tested for α-globin expression by 
qRT-PCR. Expression values were normalised to GAPDH. n=1 
 
 
Erythroid precursor cells from individuals 2E and 2C were also generated in vitro 
from cryopreserved PBMC, following the approach described above. Briefly, 
erythroid differentiation was monitored by analysis of CD34, CD36 and 
glycophorin A (GlyA) expression. The last constitutes a specific marker of late, 
mature erythroid cells. To further characterise these cells, expression of the 
erythroid-specific α-globin gene was also assayed by qRT-PCR in WT, 
Chapter 3 – Results 
 
65 
heterozygous (2E) and homozygous MUT (2C) CD36+ cells at day 7 of 
differentiation (Fig. 18).  
 
In 2C and 2E, as assessed by GlyA expression, a higher frequency of  CD36+ cells 
were more mature than the CD36+ cells derived from a normal donor (Fig. 18A). 
This was consistent with the 3-fold higher expression levels of α-globin in  total 
CD36+ cells from 2E and CD36+ 2C than in normal donor CD36+ cells. As 
expected, α-globin was not expressed in CD36- cells (Fig. 18C).  
In order to evaluate whether the -270C>G erythroid precursor cells (2C) 
expressed normal levels of GPI, staining with the GPI-linked antigen CD59 was 
carried out. Contrasting with the bi- or tri-modal pattern seen in PNH erythroid 
cells (84), the result showed a unimodal pattern of CD59 expression in 
CD36+GlyA+ cells from 2E and 2C, interestingly higher than in CD36+GlyA+ 
normal cells. Staining with FLAER was not tested since it cannot bind to 
erythrocytes or platelets. 
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Fig. 19 - PIGM mRNA expression in haematopoietic cells isolated from PBMC of 
individuals from Family 2. The gating strategy used to identify CD19+ B lymphocytes, 
CD3+ T lymphocytes and CD14+ monocytes was described above (see Fig. 13A). CD36+ 
erythroid precursor cells were generated in vitro from PBMC and collected at day 7 (see 
Fig. 14). Haematopoietic cells were sorted according to expression of GPI into two 
fractions: GPI negative (GPI-) and GPI positive (GPI+). 2E – heterozygous individual; 
2C – homozygous MUT individual. When samples were available, PIGM mRNA 
expression was assessed in two biological replicates. Expression values were normalised 
with respect to GAPDH. 
 
 
After isolation of the cells belonging to the lymphoid, myeloid and erythroid 
haematopoietic lineages, PIGM mRNA expression was measured (Fig. 19). 
Regarding the B lymphocytes of the affected child (2C), PIGM mRNA levels 
were at least 10 fold lower in GPI- B lymphocytes than in their GPI+ counterparts 
and in B lymphocytes from the heterozygous individual (2E). PIGM mRNA levels 
Chapter 3 – Results 
 
67 
were approximately 20 times lower in the homozygous GPI- T lymphocytes than 
in their correspondent GPI+ T lymphocytes and 40 times lower than in the 
heterozygous T lymphocytes. Noteworthy, PIGM mRNA expression in the GPI+ 
monocytes and in the GPI+ erythroid precursor cells was 4 and 5 times higher, 
respectively, in the homozygous individual (2C) than in the heterozygous (2E). 
Curiously, heterozygous GPI+ monocytes expressed 2 times less PIGM mRNA 
than homozygous GPI- B lymphocytes.  
Due to scarcity of primary samples these results derived from one extraction (2C 
monocytes, and CD36+ erythroid cells) or from two biological replicates (B 
lymphocytes and T lymphocytes). 
 
Given the small number of primary cells from individuals of Family 1, PIGM 
expression was evaluated in lymphoblastoid B cell lines (LBCLs) derived from 
the same individuals. In parallel, measurements were also performed in LBCLs 
derived from individuals of Family 2 and normal individuals. In both families, 
PIGM levels in cells carrying the -270C>G mutation (1B and 2C) were less than 
1% of those in normal homozygous (1A and 2D) and heterozygous (2E) B cells 
(Fig. 20A). PIGM mRNA levels correlated with GPI expression at the cell 
surface, as assessed by staining with FLAER (Fig. 20B). Moreover, in LBCLs 
from both families, expression of PIGX mRNA varied less than 2-fold with no 
significant changes between cells from the homozygous affected children (1B and 
2C), homozygous WT (1A), heterozygous (2E and 2D) and normal controls (N1 
and N2) (Fig. 21), suggesting that PIGX does not compensate for the deficiency in 
PIGM.  
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Fig. 20 – PIGM mRNA and GPI levels in EBV-transformed lymphoblastoid B cells 
(LBCLs) derived from individuals of Family 1 and Family 2. A - PIGM mRNA levels 
in LBCLs derived from the homozygous affected children (1B and 2C), homozygous 
normal individuals (1A and 2D), heterozygous individuals (2E) and normal controls (N1 
and N2); see Fig. 9). Expression values were normalised to GAPDH and results are 
presented as mean ± SEM of 3 independent measurements, * p<0.05. B - GPI expression 
in LBCLs as assessed by staining with FLAER. Family 1: dotted line – unstained; solid 
orange line – homozygous MUT 1B; solid purple line – heterozygous 1A; solid black line 
– N2. Family 2: dotted line – unstained; solid red line – homozygous MUT 2C; solid blue 
line – heterozygous 2E; solid black line – N2. 
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Fig. 21 – PIGX mRNA expression levels in LBCLs derived from the homozygous 
affected children (1B and 2C), homozygous normal individuals (1A and 2D), 
heterozygous individuals (2E) and normal controls (N1 and N2); see Fig. 9). Expression 
values were normalised to GAPDH and results are presented as mean ± SEM of 3 
independent measurements. 
 
 
Altogether these results show that in IGD haematopoietic cells and cell lines, the 
relationship between PIGM mRNA levels and efficient synthesis and expression 
of GPI is different between cell types. 
 
My findings also suggest that in the erythroid cells and monocytes the -270GC 
rich motif is not essential for PIGM transcription.  
To further investigate the impact of the pathogenic mutation in erythroid cells, I 
performed a transactivation assay. Almeida et al, 2006 (87) showed that in LBCLs 
and in the non-haematopoietic cell line HeLa, the activity of a 2Kb-PIGM 
promoter construct harbouring the -270C>G mutation (MUT) is reduced by 80-
90% and 66%, respectively, in relation to normal WT promoter activity. I found, 
that whilst in HeLa cells the mutation caused a reduction to less than 50% of the 
WT promoter activity, in the K562 erythroid cells, the MUT promoter was nearly 
as active as the WT promoter (Fig. 22) thus further corroborating my observation 
in primary erythroid cells, i.e., that the pathogenic mutation does not decrease 
transcription of PIGM in erythroid cells. 
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Fig. 22 – Luciferase reporter assay in K562 (A) and HeLa (B) cells. 48 hours after 
transfection cell lysate was assayed for luminescence for a period of 100ms. 
Luminescence values were normalised to renilla and results are presented as fold change 
relative to 2Kb-WT promoter ± SEM of 3 independent experiments measured in 
triplicate, ∗ p<0.05. 
 
 
The finding that the -270C>G mutation does not abrogate PIGM promoter activity 
(Fig. 22) and GPI expression in the erythroid cells (Fig. 18B), pointed towards 
potential mechanisms accounting for intact PIGM transcription in this cell type. 
Before proceeding with the exploration of different hypotheses such as the role of 
cell-type specific TFs in the erythroid-specific transcriptional regulation of PIGM, 
I studied the architecture of its promoter in erythroid cells. 
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PIGM promoter architecture influences differential expression of PIGM  
 
Chromatin accessibility, that is determined by factors like DHSs and histone 
marks, is known to influence TF binding at the gene regulatory regions and 
therefore to impact on gene expression. Conversely, we recently showed that 
disruption of Sp1 binding influences the chromatin accessibility at the PIGM 
promoter. By employing a restriction enzyme accessibility assay (REAA) we 
showed that the MUT PIGM core promoter was highly protected and 
approximately 6-fold less accessible to digestion than the core promoter in normal 
B cells, associated with nucleosomal compaction and transcriptional repression. 
Treatment with NaBu, prompted nucleosome relaxation, histone re-acetylation 
and PIGM transcription by restoring Sp1 binding (38). 
 
Following this observation, nucleosome occupancy in the core promoter of PIGM 
was evaluated in erythroid, epithelial and B cell lines. For that purpose, a 
micrococcal nuclease protection assay, adapted from (181) was employed. This 
method takes advantage of the micrococcal nuclease (MNase) enzyme that 
preferentially digests the DNA linker region of chromatin between individual 
nucleosomes, hereafter called mononucleosomes. Optimal MNase concentration 
was monitored in an agarose gel (see Appendix A, Fig. A3) and subsequently 
used to obtain the mononuclesome units. After DNA purification and by placing 
primers along 600bp of the core and proximal promoter of PIGM, nucleosome 
occupancy was determined by qRT-PCR in which 100bp amplicons overlapped in 
50bp. High amplification PCR rates corresponded to protected, well positioned 
nucleosome regions whereas low amplification rates corresponded to more open 
and sensitive to digestion, less positioned regions.  
The results showed that in the WT LBCL N2, nucleosome occupancy was higher 
than in K562 cells or epithelial HeLa cells, particularly, in the region 
encompassing the -270GC rich motif and the putative TSS. To ensure these 
findings were specific to PIGM, nucleosome occupancy at the core promoter of 
the housekeeping gene GAPDH was assayed in parallel. Nucleosome occupancy 
at the GAPDH promoter was uniformly low in all cell types tested (Fig. 23A).    
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Fig. 23 – Effect of nucleosome occupancy on PIGM transcription. A – Nucleosome 
occupancy in the core and proximal promoter of PIGM. i to 2 represent the primers used 
for amplification, overlapping in 50bp. Nucleosome occupancy was determined by 
calculating the ratio of digested to undigested chromatin for equivalent DNA amounts. 
GAPDH promoter was used as negative control. B – PIGM mRNA expression levels in 
K562, HeLa and normal LBCL N2. Expression values were normalised to GAPDH and 
results are presented as mean ± SEM of 3 independent extractions, * p<0.05. 
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Since nucleosome protection at the PIGM promoter was higher in B cells than in 
erythroid or HeLa cells, its influence on PIGM transcription was evaluated by 
qRT-PCR analysis. Indeed, PIGM mRNA expression was lower in B cell lines 
than in K562 and HeLa cells (Fig. 23B), showing a clear link between 
nucleosome compaction and transcriptional output and suggesting that the 
differentially organised nucleosomes at the PIGM promoter impact on PIGM 
transcription in a cell type-specific manner.  
 
To further dissect the architecture of the PIGM promoter, an attempt was made to 
determine with precision the TSS. In principle the presence of a TSS in erythroid 
cells upstream of the -270GC motif can potentially ‘bypass’ the pathogenic 
mutation and ensure intact PIGM transcription in these cells. 
 
In the past years, several methods have been used to capture capped mRNAs and 
map the 20-30 nucleotides of the complementary DNA, thus defining TSSs 
(reviewed in (21)). One of these methods is 5’-Rapid Amplification of cDNA 
Ends (5’-RACE). Briefly, after isolation of capped mRNA, its 5’-end is tagged 
and reverse-transcribed into cDNA following annealing with an oligo(dT) 
sequence. The second cDNA strand is then synthesised and the double-stranded 
cDNA (dscDNA) is amplified in a PCR reaction by using specific primers. As a 
control, dscDNA is tested for detection of the abundant β-actin mRNA and in 
parallel a PCR reaction is carried out by using primers specific for the gene of 
interest. The PCR product is then cloned into a vector backbone and sequenced by 
using specific primers for the gene of interest (see Chapter 2, 2.13). 
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Fig. 24 – Gel electrophoresis of the 5’-RACE-PCR. Electrophoresis in a 2% agarose 
gel of β-actin dscDNA PCR (left) and PIGM dscDNA PCR (right). 1 – WT LBCL (N2), 
2 – Jurkat, 3 – HL60, 4- Fibroblast, 5 – K562, 6 – SH-SY5Y, 7 – HeLa, 8 – HeLa 
(commercial), NC – negative control, L - ladder. The β-actin positive control PCR 
generates an amplicon of approximately 400bp.  
 
 
The size of the PCR amplicon derived from the amplification with the β-actin 
primers was consistent with the predicted size (approximately 400bp). However, 
in the PCR reaction using primers targeting PIGM, the result in the majority of the 
cell lines was not clear, suggesting unspecific amplification or the presence of 
more than one TSS (Fig. 24). After several attempts to optimize the PCR 
conditions (by altering the annealing temperature and also by using DMSO, as it 
disrupts base pairing thus facilitating strand separation), the results obtained were 
similar (data not shown). Following cloning of the PCR product from K562, WT 
LBCL and HeLa into the pJET vector and transformation of competent cells, the 
plasmid DNA was sequenced. The results showed a very small number of 
sequences mapping to PIGM. While in the erythroid cell line K562, two of the 
one hundred sequences aligned with PIGM, in the WT B cell line none of the 
sequences obtained from the one hundred colonies aligned with the gene. In HeLa 
cells the 5’-RACE reaction was more efficient as approximately 30% of the 20 
sequences analysed matched with PIGM gene and some inclusively matched 
between them (Fig. 25). 
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Although inefficient, these results showed that in the cells analysed so far, the 
TSSs are positioned downstream at the -270GC motif, excluding the possibility of 
transcription initiation upstream of the pathogenic mutation. 
 
 
 
 
Fig. 25 – Schematic representation of the TSSs mapped at the PIGM promoter in 
K562 (K) and HeLa (H) cells. In K562 the TSS localised -72bp upstream of the ATG 
and in HeLa four TSSs were identified with the following positions, -72, -97, -137 and -
152bp upstream of the ATG. Black arrow – putative TSS (87). Grey bar – -270 Sp1 
binding site. 
 
 
Furthermore, CAGE (Cap Analysis Gene Expression) data deposited in the online 
database ENCODE revealed the presence of two clusters of TSSs at the promoter 
in both the B cell line GM12878 and the erythroid K562 cells. Each cluster 
consists of several TSSs, suggesting that transcription initiation might take place 
at different positions. Nevertheless, both clusters localised downstream at the -
270GC motif, and were similar between the erythroid and B cells (Fig. 26). 
Taken together, these results show that all TSS are downstream of the -270 motif 
position and thus cannot account for intact PIGM transcription in erythroid cells. 
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Fig. 26 – CAGE analysis of PIGM (strand -1) in the B cell line GM12878 (red) and in 
K562 (blue) retrieved from the ENCODE database. The TSSs are grouped in clusters 
in which the height of the peaks is proportional to the number of matched sequences. The 
coordinates for the -270GC motif are chr1:160,001,799 – 160,001,804 (green arrow). 
Both groups of TSSs are localised downstream of the -270GC motif. The method allows 
for single nucleotide resolution (21).  
 
 
3.1.4 Discussion 
 
GPI moieties are structures indispensable for anchoring of proteins at the cell 
surface which in turn, are required for the maintenance of several functions of the 
cell. PIGM constitutes the catalytic component of the GPI MT-I (68) whereas 
PIGX is believed to be responsible for maintaining the stability of the complex 
(69). The GPI MT-I is essential for the GPI biosynthesis as repression of PIGM 
transcription abrogates GPI expression.  
Since PIGM is a housekeeping gene, it is constitutively expressed in all cell types 
and it is fundamental for the basic functions of the cell (182). The concept of 
housekeeping gene has been recently revisited by Eisenberg et al, 2013 (183), in 
which the authors emphasise that a housekeeping gene has to be expressed at a 
constant level across cell types. Here, I challenge the concept proposed by the 
-270GC 
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authors as I observed that expression of PIGM varies considerably between 
different primary cells and between normal individuals (Fig. 15).  
Very interestingly, my results show that haematopoietic cells have different basal 
mRNA levels. For instance, whereas PIGM levels in the monocytes of the 
children with IGD were sufficient for normal GPI expression, in the B 
lymphocytes those levels were not sufficient and GPI was not produced (Fig. 19). 
Assessment of PIGM protein levels would have been useful to understand the 
basis of these differences. 
 
In erythroid lineage cells, PIGM mRNA levels decreased as normal erythroid 
precursor cells underwent differentiation in vitro (Fig. 15). Although the result 
seems plausible due to the fact that gene expression is “shut-down” as erythroid 
cells proceed towards late stages in the erythropoiesis, it has to be taken into 
account that the analysis was not performed in well-defined, pure, CD36+GlyA+ 
populations but in whole CD36+ erythroid precursor cells that were heterogeneous 
in terms of CD71 and GlyA expression. Nevertheless, in primary murine fetal 
erythroid precursor cells sorted at different stages of differentiation according to 
Ter119 and CD71 expression, the same result was described. As seen by RNA-
seq, PIGM expression decreased as erythroid cells become more mature (Fig. 16). 
 
However, erythroid precursor cells defined as CD36+GlyA+, homozygous or 
heterozygous for the pathogenic -270C>G mutation expressed normal levels of 
the GPI-linked antigen CD59 (Fig. 18B), clearly demonstrating that in this well-
defined erythroid precursor population the level of PIGM mRNA even in 
homozygous mutant cells is not only comparable (or in fact somewhat higher) 
than in normal cells (Fig. 19) but it is also sufficient for normal GPI expression. 
The finding that the homozygous or heterozygous erythroid precursor cells 
express slightly more CD59 than the normal cells is most likely related with 
normal variation between healthy donors. 
 
Nevertheless, there are two drawbacks in relation to these results: firstly, due to 
scarcity of primary samples I could only evaluate one patient sample and 
secondly, PIGM protein level assessment was not possible due to lack of suitable 
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antibody. Therefore, I could not provide direct evidence that variable PIGM 
mRNA expression translates into variable PIGM protein expression.     
 
Mutations in gene regulatory regions have been described in the literature and 
very frequently generate or abolish TF binding sites (TFBS). 
We have recently showed that in the B cells, the -270C>G mutation represses 
PIGM transcription by abolishing Sp1 binding and facilitating Polycomb 
recruitment. Here, I showed that in normal WT B cells, high levels of nucleosome 
protection and thus nucleosome occupancy in the region encompassing the -
270GC motif correlated with low levels of PIGM transcription, reinforcing the 
link between chromatin accessibility and transcriptional output. In contrast, in the 
erythroid cells the -270 GC-rich motif was not required for PIGM promoter 
activation, a finding supported by the luciferase reporter assays (Fig. 22) and the 
fact that the promoter region encompassing the -270GC motif was highly 
accessible for transcription (Fig. 23A and B). Further investigations, employing 
for instance a DNase footprinting assay, would have helped to reinforce the 
finding that the -270GC motif is transcriptionally accessible. Given the 
differences in chromatin status and transcriptional potential, I propose that the 
presence of the pathogenic C>G mutation is sufficient to tip the promoter into a 
repressive state in B but not erythroid cells, thus in part explaining the differential 
cellular phenotype in IGD.  
 
PIGM falls in the category of the genes with GC-rich promoters, which are 
commonly associated with multiple TSSs over a region of 50-100 nucleotides. By 
using ‘5-RACE, I have shown that in K562 cells the TSS localised -72bp 
upstream of the ATG and in HeLa four TSSs were identified (Fig. 25). Given the 
high percentage of false positives, possibly due to the inefficient PCR reaction, 
robust conclusions could not be drawn. However, by using CAGE data, two 
clusters of TSS upstream at the -270C>G mutation were annotated in both B and 
erythroid cells (Fig.26). Whether they correspond to alternative promoters is not 
known but so far the data revealed that the TSS of PIGM is positioned 
downstream of the pathogenic mutation. Therefore, I conclude that an alternative 
promoter operating upstream of the -270GC rich box cannot account for the intact 
transcription of PIGM in normal or patient erythroid cells. 
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Taken together, my results showed that in the erythroid cells, PIGM transcription 
is independent of the -270-Sp1 binding site. Understanding whether generic or 
erythroid-specific TFs can overcome the -270C>G mutation is the focus of the 
next chapters. 
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4.1 Exploring the role of the erythroid-lineage affiliated TFs 
GATA-1 and KLF1 in PIGM-associated IGD 
 
4.1.1 Introduction 
 
In PIGM-associated IGD, red blood cells express near normal expression of GPI, 
hence the lack of haemolysis and anaemia in patients (87). In the previous chapter 
I showed that in erythroid cells the -270GC-rich motif is not essential for PIGM 
promoter activity and transcription, hence the normal expression of GPI. The 
results suggested that in erythroid cells PIGM transcription is regulated in a cell-
type specific manner.   
 
cis-DNA elements control transcriptional regulation through the action of TFs 
bound to these elements. The role of the erythroid-restricted TFs GATA-1 and 
KLF1 as master regulators of erythroid transcriptional programmes (145, 175) and 
their implications in disease (170, 174, 184) has been documented in mice and in 
humans. Interestingly, in vitro experiments have suggested that regulation of 
erythroid specific genes by GATA-1 often occurs in co-operation with Sp1 (134, 
185) and  in addition, GATA-1 and Sp1 can physically interact through their zinc-
finger DNA binding domains (135, 168). Moreover, in vitro assays have shown 
that according to the erythroid promoter context, GATA-1 can interact either with 
Sp1 or KLF1 (165). KLF1, a TF predominantly expressed in erythroid cells, 
shares the same GC-rich binding sequence with the Sp family of TFs, with a 
preference for the 5’-CACCC-3’ DNA motif (186). 
 
The aim of this chapter is to investigate the mechanism(s) responsible for 
intact PIGM transcription and normal GPI expression in erythroid cells. 
Here, I hypothesised that the erythroid lineage-specific TFs GATA-1 and KLF1 
drive PIGM activity in IGD erythroid cells even in the presence of the pathogenic 
-270C>G mutation. 
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4.1.2 Experimental design 
 
To test the above hypothesis, the PIGM promoter was subjected to a bioinformatic 
analysis for putative TFs binding sites. The role of GATA-1 on PIGM 
transcriptional regulation was then assayed by ChIP analysis in the erythroid cell 
line K562 and in primary erythroid precursor cells followed by a genetic approach 
in which I employed knockdown and overexpression assays. KLF1 occupancy at 
the PIGM promoter was assayed by ChIP-qPCR in primary erythroid precursor 
cells.     
 
4.1.3 Results 
 
GATA-1 is not a transcriptional activator of PIGM 
 
By employing a bioinformatic analysis using the Transcription Element Search 
System (TESS) and the TFsearch 
(http://www.cbrc.jp/research/db/TFSEARCH.html) web tools, four putative 
GATA-1 binding sites were predicted at the -799bp, -712/-675bp and -520bp 
(from ATG) at the PIGM promoter (Fig. 27). Although the bioinformatics 
analysis has not predicted the presence of putative KLF1 binding sites, several 
CACCC-DNA motifs were identified upstream at the -270C>G mutation (-696bp, 
-578 and -291). The presence of four putative Sp1 binding sites (-160, -395/-380, -
582) in addition to the validated -270 Sp1 motif has been already described in 
Almeida et al, 2006 (87).  
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Predicted sites TESS TF Search (out of 100) 
GATA-1 (-799) 12 88.1 
GATA-1 (-712/-675) 16 94.3 
GATA-1 (-523) 10 90.4 
 
Fig. 27– Bioinformatic analysis of the PIGM promoter. Analysis was performed in the 
promoter region encompassing -2000 to +1 (ATG) using the bioinformatic tools TESS 
and TFsearch. A - PIGM promoter sequence showing the TFBS predicted form the 
analysis. The presence of four GATA-1 sites (bold) were predicted at the following 
positions -799, -712/-675 and -523. In addition to the -270 Sp1 motif, four putative Sp1 
sites, already described in Almeida, A. et al, 2006, were predicted (-582, -395/-380 and -
160). Three CACCC boxes were identified according to their sequence. ATG – 
translation initiation. -270 C>G mutation. Arrow – putative TSS. B – Table with 
GATA-1 binding scores. Cut-off score TFsearch = 85.0. 
 
 
High throughput ChIP-seq data deposited in the ENCODE database revealed 
GATA-1 binding at the PIGM promoter in the cell line K562 and in primary 
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erythroblasts derived from PBMC (Fig. 28), thus reinforcing the bioinformatics 
analysis. 
 
 
 
 
 
 
 
 
Fig. 28 – ChIP-seq analysis at the PIGM promoter retrieved from the UCSC genome 
browser on Human Feb.2009 (GRCh37/hg19) Assembly - ENCODE database.   GATA-1 
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binding was captured in primary erythroblast precursor cells derived from PBMC (top). 
GATA-1 binding at the PIGM promoter in K562 (bottom).  
 
 
Considering the great interest in dissecting GATA-1 occupancy at regions set 
apart by less than 200bp at the PIGM promoter, ChIP analysis followed by qPCR 
was carried out in which site-specific primers were designed to flank the predicted 
GATA-1 sites (Fig. 29). For that purpose, the well-studied erythroid cell line 
K562 was selected. GATA-1 was highly expressed in K562, whereas in cell lines 
with epithelial, myeloid, lymphoid or neuronal origin GATA-1 was not expressed 
(Fig. 30). 
 
 
 
 
Fig. 29 – Schematic representation of the PIGM promoter. Red – putative GATA-1 
binding sites; blue – putative Sp1 binding sites; light blue – Validated Sp1 binding site at 
the -270GC box. 1 to 8 and +6Kb designate the PCR amplicons. Two sets of primers 
were used to generate two amplicons (3 and 4) spanning the -270GC box.    
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Fig. 30 – GATA-1 mRNA expression levels in cell lines from epithelial (HeLa, 293T), 
neuronal (SH-SY5Y), erythroid (K562), myeloid (HL60), T lymphocytic (Jurkat) and B 
lymphocytic (LBCL N2) origin. Expression values were normalised to GAPDH and 
results are presented as mean ± SEM of 3 independent extractions, *** p<0.001.  
 
 
Typically, chromatin is prepared  and sonicated (see Chapter 2, 2.5) in fragments 
between 200bp-600bp (187) that are visualised on agarose gel. Following 
sonication (Appendix A, Fig. A4), chromatin immunoprecipitation was carried out 
with 5µg of GATA-1 antibody or respective IgG control and the promoter was 
scanned for GATA-1 binding. GATA-1 enrichment was compared to GATA-1 
binding at its own gene regulatory areas. GATA-1 is regulated by DNase I 
Hypersensitive sites (HSs) as described in Valverde-Garduno et al, 2004 (188). 
Whereas HS -3.5 and HS +14 are proximal to GATA-1, HS +15 is located more 
distally at the 5’end of the HDAC6 gene. Accordingly, I found that in K562 cells, 
GATA-1was enriched 36 and 27 fold at the HS -3.5 and HS +14, respectively, and 
less enriched at the HS-49 and HS+15.  
At the PIGM promoter, GATA-1 was moderately (7 fold) enriched at the 
predicted GATA-1 sites (amplicons 8, 7 and 6) when compared to the gene desert 
region, GW10.  
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Fig. 31 – GATA-1 occupancy at the length of the PIGM promoter in K562. HS -49, 
HS -3.5, HS +14 and HS +15 represented the DNase hypersensitive sites at GATA-1 locus 
used as controls. GW10 – negative control. Dashed line – IgG control. IgG and GATA-1 
enrichment were expressed as % of Input. Results are presented as fold enrichment over 
input IgG ± SEM of 5 independent experiments.  
 
 
To further validate this finding, the same analysis was performed in primary 
CD36+ erythroid precursor cells differentiated in vitro from PBMC.  
 
  
 
 
Fig. 32 – GATA-1 occupancy at the length of the PIGM promoter in primary 
erythroid precursor cells. Cells were differentiated in vitro from PBMC as shown in 
Fig. 14. HS -49, HS -3.5, HS +14 and HS +15 represented the DNAse Hypersensitive 
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sites at GATA-1 locus used as controls. Dashed line – IgG control. IgG and GATA-1 
enrichment were expressed as % of Input. Results are presented as fold enrichment over 
input IgG n=1. 
 
 
Erythroid differentiation was monitored by flow cytometry analysis as described 
before (see Results 3.1). Briefly, cells were analysed for CD34, CD36, CD71 and 
GlyA expression and isolated by magnetic separation after staining with CD36-PE 
antibody and incubation with anti-PE beads. Morphologic characteristics of 
selected cells were assessed by MGG staining. After selection of the CD36+ 
erythroid precursor cells, the remaining CD36- cells were used as a source of 
chromatin for optimisation of the appropriate sonication conditions (Appendix A, 
Fig. A4B). Following chromatin preparation of cross-linked CD36+ cells and 
immunoprecipitation with anti-GATA-1 antibody and respective IgG control, 
qPCR analysis was performed. In erythroid precursor cells isolated on Day 7, 
GATA-1 was exclusively enriched at the GATA-1 hypersensitivity site, HS-3.5 (6 
fold) and later in differentiation, at Day 10, it was also enriched at the HS+14 (38 
fold), suggesting a dynamic, time-coordinated, process. Remarkably, GATA-1 
was not enriched at the four predicted GATA-1 sites (amplicons 8, 7 and 6) at the 
PIGM promoter (2 fold enrichment) (Fig. 32).   
Regardless the differences seen between the erythroid cell line K562 and the 
erythroid precursor cells, the data suggested that the overall GATA-1 binding at 
the PIGM promoter was low.  
In order to dissect whether GATA-1 has indeed a functional role in the 
transcriptional regulation of PIGM, at least in K562 cells, a genetic approach was 
employed. To this end, GATA-1 knock-down (kd) K562 cells were generated by 
using short hairpin RNA (shRNA) lentiviral particles. This method of delivery 
allows stable integration of the shRNA and therefore long-term silencing of the 
gene of interest. shRNAs consist of a 19-22bp sense sequence identical to the 
target mRNA, followed by a short loop of 4-11 nucleotides, and an anti-sense 19-
22bp sequence. Following PolIII-mediated transcription, the shRNA is 
translocated to the cytosol where it is recognised by an enzyme called Dicer. The 
shRNA is then processed into a small-interfering RNA (siRNA) and once bound 
to the target RNA is incorporated into the RNA-induced silencing complex 
(RISC). Subsequently, the target RNA is degraded (189). In keeping with this, 
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GATA-1 mRNA target sequences were designed alongside with a scramble control 
by using a web tool (Mission®shRNA, Sigma – 
http://www.sigmaaldrich.com/life-science/functional-genomics-and-
rnai/shrna/shrna-search-and-order.html; see Chapter 2, 2.12). The synthesised 
oligonucleotide sequences were then annealed and cloned into the pLKO.1-GFP 
vector backbone (Appendix A, Fig. A5), which contains an ampicillin resistant 
marker for colony selection and a GFP reporter gene for selection of the 
transduced cells. Plasmid DNA was then digested to confirm the insertion of the 
shRNA (Appendix A, Fig. A6) and used to transfect, alongside with the helper 
viral vectors, 293T packaging cells that are able to produce the viral supernatant. 
Prior to transduction, the concentrated viral supernatant collected at 48h and 72h 
post-transfection was used for viral titration (Appendix A, Fig. A7). K562 cells 
were transduced with 4.5x105 units/ml of virus and 96 hours post-transduction, 
GFP cells were sorted and cultured in the appropriate medium to recover.  
Very interestingly, GATA-1 kd K562 cells lost their characteristic “red” colour as 
a result, most likely, due to down-regulation of Haemoglobin (Hb) genes. After 
expansion of the GFP cells, GATA-1 knockdown was assessed by measuring the 
mRNA and protein levels. As shown in Fig. 33, a reduction of 65% at the mRNA 
level in K562 GATA-1 kd cells resulted in a 20% down-regulation at the protein 
level, when compared with K562 scramble cells. As positive control for the effect 
of down-regulation of GATA-1 in K562, I used the γ globin gene (190). As 
shown, in K562 GATA-1 kd cells γ globin gene expression (γ exon2 and γ exon3) 
was reduced to less than 30% of the normal levels.  
Strikingly, in stable K562 GATA-1 kd cells, PIGM mRNA levels were 2 fold 
higher than in scramble control cells, indicating that GATA-1 might be a 
repressor rather than an activator of PIGM transcription. Whereas Sp1 levels were 
comparable between K562 scramble and K562 GATA-1 kd cells, PIGX mRNA 
levels also increased 2-fold, consistent with a co-ordinate effect of GATA-1 on 
the transcriptional regulation of both genes involved in the first mannosylation of 
the GPI core structure (Fig. 34). An attempt to generate a second GATA-1 kd 
K562 cell line was made but it was unsuccessful due to the low knockdown 
efficiency (data not shown). Therefore, whether GATA-1 kd results indeed in 
upregulation of PIGM and PIGX mRNA requires further confirmation. 
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Fig. 33 – K562 cells transduced with short hairpin (sh) RNA targeting GATA-1 and 
control scramble. A – FACS plots show the efficiency of transduction as measured by 
GFP. Untransduced cells were used as unstained control sample. B – GATA-1 mRNA 
expression in stable K562 scramble and K562 GATA-1 knock-down cells (K562 
shGATA-1). Expression values were normalised to GAPDH. Results are presented as fold 
mRNA ± SEM of 3 independent extractions, ∗ p<0.05. C – GATA-1 and β-actin protein 
expression. % of GATA-1 expression was determined by using ImageJ software.      
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Fig. 34 – mRNA expression in K562 scramble and K562 GATA-1 knock-down cells. 
Expression values were normalised to GAPDH. Results are presented as fold mRNA ± 
SEM of three independent measurements,∗ p<0.05.  
 
 
In an effort to better understand the role of GATA-1 in PIGM transcriptional 
regulation, a complementary  study in which GATA-1 is overexpressed, was 
carried out. For this purpose, the Flp/FRT site-specific recombination system was 
used. By employing this method, a single copy of the -270GC WT or MUT PIGM 
promoter, driving a GFP reporter gene, could be integrated in a site-specific 
manner into the genome of the cells. The Flp/FRT method takes advantage of the 
Flp recombinase (pOG44) that mediates recombination of two FRT (Flp 
recombination target) sites. The FRT sites, one integrated in the genome of the 
Flp-In cell line and the other present in the pCDNA5/FRT vector (see Chapter 2, 
2.9), constitute the binding and cleavage sites for the Flp recombinase.  
Firstly, a sequence of 910bp (from ATG) of the PIGM promoter, either WT or 
MUT at the -270GC-rich motif, was sub-cloned upstream of a GFP reporter gene 
in the modified pCDNA5/FRT vector backbone (see Appendix A, Fig A1). The 
pCDNA5/FRT vector, now containing the PIGM promoter-GFP cassette was co-
transfected with the pOG44 plasmid into the 293 Flp-In cells. Three weeks after 
transfection, recombinant, hygromycin resistant cells were obtained and expanded 
in the appropriate culture conditions. Thereafter, gDNA from both parental and 
recombinant cells was extracted and tested by using 3 primers-PCR (Fig. 35). 
Following confirmation of the recombination by PCR, the recombinant cell clones 
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were assessed for GFP expression by FACS but surprisingly, expression of GFP 
in those cells was very low and comparable to background levels (Fig. 36). 
 
 
 
 
Fig. 35 – Gel electrophoresis of the PCR products of parental and recombinant 293-
FRT amplified genomic DNA. L – ladder, 1 –Flp-In 293, 2 – 910WT PIGM-GFP cells, 
3 - 910MUT PIGM-GFP cells (clone #1), 4 - 910MUT PIGM-GFP cells (clone #2), 5 – 
non-template PCR control. Primers placed on the SV40, lacZeo and Hyg genes were used 
on the same PCR reaction. F1 and R2 generate an amplicon of approximately 600bp and 
F1 and R1 generate an amplicon of 400bp. 
 
 
Chapter 3 – Results 
 
93 
 
Fig. 36 – FACS analysis of 293T PIGM-promoter GFP recombinant cells. Cells were 
identified according to the physical properties SSC (side scatter) vs. FSC (forward 
scatter) and doublets were excluded by double gating on FSC-W (width) and FSC-A 
(area). Histograms shows GFP expression. Dotted line – unstained 293T cells; blue solid 
line – 910WT PIGM-GFP cells; red solid line – 910MUT PIGM-GFP cells; green solid 
line – 293T cells transiently transfected with the CMV-driven eGFP plasmid (positive 
control). 
 
 
In order to verify whether GFP was in fact transcribed, qRT-PCR analysis was 
carried out. Under the control of the -270 WT PIGM promoter, cells expressed 
four times more GFP than cells harbouring the MUT promoter (Fig. 37A). This 
result was further confirmed at the protein level by Western blot analysis (Fig. 
37B). Taken together these data suggested that GFP was expressed under the 
control of the PIGM promoter at low levels (as compared with the CMV driven 
plasmid).  
Furthermore, the same result was obtained with another subset of WT and MUT 
cell clones (data not shown). 
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Fig. 37 – 293T PIGM promoter-GFP recombinant cells. A - GFP mRNA expression in 
parental Flp-In 293 cells, 910WT PIGM-GFP and 910MUT PIGM-GFP recombinant 
cells. GFP expression values were normalised to GAPDH. Results are presented as fold 
mRNA ± SEM of 3 independent extractions, ∗ p<0.05. B – GFP protein expression in the 
recombinant clones by Western-blot. β-actin was used as loading control. 
 
 
Since GFP expression in 293 FRT recombinant cells recapitulated PIGM 
expression in WT and MUT B cell lines (see Results 3.1, Fig. 20A), 
overexpression of GATA-1 was finally performed in this cellular background. 
GATA-1 was previously sub-cloned in the MigR1-ratCD2 backbone vector and 
tested in HeLa cells by Western Blot (Appendix A, Fig. A8). Upon exogenous 
expression of GATA-1 in WT and MUT recombinant cells, GFP levels were 
assessed at 48h and 72 hours by qRT-PCR. Transfection efficiency was monitored 
by staining with rat-CD2 as exemplified in Fig. A9, Appendix A.  
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I found that upon GATA-1 transfection, GFP expression was comparable between 
WT and MUT cells, showing that the TF GATA-1 alone was not able to activate 
the PIGM promoter (Fig. 38). Whether in the presence of other erythroid-specific 
genes GATA-1 regulates the transcription of PIGM is not known. 
 
  
 
 
Fig. 38 – mRNA expression in – 293T PIGM promoter-GFP recombinant cells 
transiently transfected with MigR1-ratCD2 (control) or MigR1-hGATA-1 plasmids. 
48 hours after transfection, cells were collected and assayed for mRNA expression by 
qRT-PCR. Left panel – GATA-1 mRNA expression; right panel – GFP mRNA 
expression. Expression values were normalised to GAPDH and results are presented as 
fold mRNA expression (relative to control -910WT cells) ± SEM of 3 independent 
transfections, ∗ p<0.05. 
 
 
In summary, taken together the data suggested that the mega-erythroid lineage 
specific TF GATA-1 is not a transcriptional activator of PIGM and therefore 
could not account for active PIGM transcription in IGD erythroid cells. 
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KLF1 is a potential candidate in PIGM transcriptional activation 
 
Given the crucial role of KLF1 as a transcriptional activator of erythroid genes, 
the next step was to investigate whether this TF contributes for the normal 
transcriptional regulation of PIGM in IGD erythroid cells. Thus, KLF1 binding 
profile at the PIGM promoter was analysed by ChIP-qPCR. Since KLF1 is not 
expressed in K562 (191), the analysis was carried out in primary erythroid 
precursor cells derived from PBMC (see Results 3.1.3, Fig. 14).  
Whilst on Day 7 erythroblasts, KLF1 occupancy was comparable to background 
(2- fold enrichment), on Day 10, KLF1 showed a 4 and 5 fold enrichment at the -
270 upstream region (amplicons 8 and 6) but not at the -270GC box (amplicon 4). 
Notably, a CACCC box, the binding motif of KLF1, lies in the region of amplicon 
6, suggesting that KLF1 is a potential regulator of PIGM transcription in the 
erythroid cells. 
 
Taken together, these results show that KLF1 is likely be an important 
transcriptional regulator of PIGM; however, its effect would be independent of the 
-270 motif. 
 
 
Fig. 39 – KLF1 occupancy at the length of the PIGM promoter in erythroid 
precursor cells differentiated in vitro from PBMC (see Results 3.1.3, Fig. 14). HBA2 
locus was used as positive control. Dashed line – IgG control. IgG and KLF1 enrichment 
were expressed as % of Input. Results are presented as fold enrichment over input IgG ± 
SEM of 2 independent experiments. 
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4.1.4 Discussion 
 
In PIGM-associated IGD, red blood cells have near normal expression of GPI 
despite the presence of the -270C>G mutation, indicating the existence of a 
differential mechanism of transcriptional regulation in relation to other blood cells 
such as B cells in which the majority are GPI-deficient (as showed in Results 
3.1.3). To support PIGM expression in the presence of the -270C>G mutation, the 
erythroid master transcriptional regulators GATA-1 and KLF1 stood as two 
possible candidates. 
 
Due to its short sequence, GATA-1 consensus motif occurs with high frequency 
in mammalian genomes (192, 193) and therefore, annotation of GATA-1 sites 
does not always predict GATA-1 binding in vivo. Indeed, various studies have 
shown that few WGATAR motifs at several loci are occupied in vivo by GATA-1 
(194-197).  
In order to define the role of GATA-1 as regulator of PIGM transcription, its 
binding profile was first assessed at the gene promoter. We showed that in the 
erythroid cell line K562, GATA-1 was modestly enriched at the predicted sites at 
the PIGM promoter (Fig. 31) and the overall enrichment in primary erythroid 
precursor cells at two different stages of differentiation was very low as compared 
to GATA-1 occupancy at the DNase Hypersensitive sites (DHSs) on its own locus 
(Fig. 32) and to IgG control. Despite the low GATA-1 enrichment at the predicted 
sites, it has to be considered that GATA-1 can occupy distal regulatory regions 
(198, 199) and therefore regulate transcription through long range interactions 
(200). Nevertheless, the data in primary erythroid cells needs further 
confirmation. 
 
At the PIGM promoter two predicted GATA-1 binding sites (-712 and -675) lie 
within 50bp. Resolving TF occupancy at regions in such a close proximity 
constitutes one of the limitations of ChIP as the size of the immunoprecipitated 
fragments is usually within the range of 200bp. Nevertheless, new techniques 
derived from ChIP can bypass this limitation. For instance, ChIP-EXO is a 
technique based on the digestion of the sites flanking the TF-DNA complex with 
an exonuclease, followed by identification of the TFBS using deep-sequencing. 
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The advantages of this method are also related with the elimination of the 
uncrosslinked, unspecific DNA and with the achievement of resolution at single 
base level (201). Employment of this method or in alternative, performing in vivo 
mutagenesis of the nearby GATA-1 sites, could have provided better resolution in 
terms of GATA-1 occupancy at the promoter in K562 cells. 
 
I could not investigate the GATA-1 binding profile in primary erythroid precursor 
cells derived from IGD patients due to the insufficient number of cells obtained 
after differentiation and the amount of chromatin required for this type of analysis 
(usually from at least 3x105 cells). 
  
In the erythroid cell line, GATA-1 occupancy is not responsible for the 
transcriptional activation of PIGM. Supporting this, a knockdown assay showed 
that GATA-1 strongly repressed PIGM as a modest reduction in 20% of the 
GATA-1 protein levels (Fig. 33C), increased PIGM expression by two fold (Fig. 
34). In fact, it is known that GATA-1 not only participates in gene expression 
activation and consistent with its role as a repressor, it interacts with the NuRD 
complex, through FOG-1 (202, 203) and with the repressor complex LSD1-
CoREST, via Gfi-1b (203, 204). Moreover, recent studies have suggested that in 
later stages of erythropoiesis, GATA-1 mediates transcription repression through 
PRC2 as GATA-1 repressed genes are also enriched for the repressive histone 
mark H3K27me3 (161, 199). Employment of an experiment using a second target 
shRNA and validation of the results in primary cells would help to better define 
the role of GATA-1 as a repressor of PIGM transcription. 
As seen by others, in stable GATA-1 deficient cells, γ globin expression was 
reduced. In order to understand whether PIGM up-regulation results from a direct 
effect of GATA-1 knockdown, further studies are required. One possibility is the 
direct abrogation of the GATA-1 binding sites in the genome of the erythroid cell 
line K562 by using a genome editing technique such as the most recent system, 
CRISPR/CAS9 (205). 
The finding that PIGX expression was also up-regulated, raised the possibility that 
GATA-1 mediated transcriptional repression extends to more genes of the GPI 
biosynthetic pathway. GATA-1 mediated transcriptional repression possibly 
requires the contribution of other repressive elements. 
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The use of transient reporter assays to study gene regulatory elements has fallen in 
disuse. Although very indicative of gene regulatory elements, these studies are 
often misleading due to the concentration effect of the several copies of plasmid 
introduced in the cell and the lack of the appropriate chromatin configuration. 
These intrinsic characteristics of the transient reporter assay frequently lead to 
aberrant activity. Generating a stable transfection assay in which the -270C>G 
mutation was site-specific integrated in the genome of the cells was definitely the 
most suitable approach.   
In gain-of-function experiments in stable 293-GFP reporter cells, exogenous 
expression of GATA-1 was insufficient to activate the PIGM promoter and 
therefore to drive GFP expression as measured by qRT-PCR. GFP mRNA levels 
were comparable in WT and MUT cells, both highly expressing GATA-1. 
Whereas GATA-1 partners involved in gene repression are less clear, partners for 
gene activation have been well reported. GATA-1 mediated gene regulation often 
involves a combinatorial interaction with other transcription factors, such as 
KLF1 (206). Although GATA-1 can regulate gene expression independently of 
SCL/TAL-1 (161), gene expression mediated by the pentameric complex 
constituted by GATA-1/LMO2-LDB1-E2A/SCL-TAL-1 has been well studied 
(163, 164). More recently, other Krüppel-type zinc finger TF, ZBP-89, has been 
identified in TF regulatory complexes containing GATA-1 (207). All these factors 
are crucial either in early or late stages of normal erythropoiesis. 
This being said, lack of activation of the PIGM promoter in stable 293-PIGM 
promoter cells may reflect the absence of the erythroid-specific, GATA-1 
interacting factors in this cellular environment. Moreover, a controlled analysis of 
this system by testing the expression of GATA-1 target genes could not be 
assessed for the same reason.  
Post-translational modifications constitute another important aspect of correct TF 
function. Accordingly, it has been seen that an acetylation defective GATA-1 
mutant presents binding impairment in vivo (208) and recently, the importance of 
GATA-1 sumoylation has been demonstrated (209). Whether these modifications 
were correctly attainable in this system is not known.   
 
Altogether these findings exclude GATA-1 as major activator of PIGM 
transcription in erythroid cells, raising the possibility that KLF1 has a key 
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regulatory role. Interestingly, evidence exists supporting that PIG-Q, an element 
of the enzymatic complex that transfers the N-acetylglucosamine to 
phosphatidylinositol (see Introduction, Fig. 4), is a KLF1 target gene (206). This 
reinforces the idea that master erythroid TFs regulate the expression of genes 
belonging to the GPI biosynthetic pathway thus ensuring the normal function of 
the erythroid cells. 
 
Although the role of KLF1 could not be determined in detail, some evidence 
presented here suggest that it constitutes a potential activator of PIGM 
transcription, in a manner that is independent of the -270 motif and therefore 
could, at least in part, be responsible for intact PIGM transcription in IGD 
erythroid cells. 
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5.1 Exploring the role of the generic family of Sp transcription 
factors in PIGM-associated IGD 
 
5.1.1 Introduction 
 
In PIGM-associated IGD, the -270C>G mutation abrogates binding of the generic 
TF Sp1, causing selective histone hypoacetylation at the promoter of PIGM. 
Recently, we showed that in B cells, the pathogenic mutation that abrogates Sp1 
binding to the -270GC-rich motif imposes nucleosomal compaction and mediates 
Polycomb-dependent repression of PIGM (38).  
 
The generic TF Sp1, along with Sp2 and Sp3, belongs to the Specificity 
Protein/Kruppel-like Factor (Sp/KLF) family. Members of the Sp subgroup 
preferentially bind to DNA sequences highly enriched in GC-motifs. Although 
Sp1 was believed to regulate transcription of mainly housekeeping genes, studies 
showed that Sp1 can also regulate tissue-specific genes (165).  
The function of Sp1 is modulated by its expression levels (210) , its protein-
protein interactions and post-translational modifications (211), amongst others. 
 
The lack of Sp1 binding, as a result of the -270C>G mutation, and its impact on 
the transcriptional regulation of PIGM has been clearly demonstrated in B cells, 
explaining their GPI deficient phenotype seen in IGD. By contrast, my studies in 
IGD erythroid cells suggest that the -270C>G mutation has no impact on PIGM 
mRNA expression and GPI surface levels; therefore, in erythroid cells, PIGM 
transcription is independent of the -270GC box. In addition, I ruled out 
transcriptional regulation by the erythroid lineage-specific TF GATA-1 as a 
mechanism that rescues PIGM transcription in IGD erythroid cells (see Results 
4.1).  
 
In this chapter I investigated the role of Sp1 in PIGM transcription in normal 
and IGD erythroid cells. For this purpose, I addressed the following: i) is PIGM 
transcription Sp1- dependent or –independent in erythroid cells; ii) what is the 
functional role of the several putative Sp1 binding sites (different to the -270GC-
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rich box) at the PIGM promoter; iii) what is the role of the Sp-family members 
Sp2 and Sp3, which share the same DNA-binding domain with Sp1. 
 
5.1.2 Experimental design  
 
To dissect the role of the Sp family members in the transcriptional regulation of 
PIGM, I employed genetic (dominant negative Sp1-mutant), loss-of-function 
(shRNA) and pharmacological (MitA) assays. The binding profile of Sp1 and Sp2 
was assessed by ChIP-qPCR analysis in cell lines and primary erythroid precursor 
cells.    
 
5.1.3 Results 
 
Sp1 regulates PIGM transcription in both erythroid and B cells 
 
As employed in the knock-down (kd) assay described in Results 4.1, Sp1 mRNA 
was specifically targeted by the use of shRNA lentiviruses in K562 cells and 
homozygous (N1) and heterozygous (2D) WT LBCLs. In this case, the Sp1 kd 
efficiency was first evaluated by qPCR analysis in transiently transfected 293T 
cells. shRNA Sp1 lentivirus was used in transduction experiments when at least a 
50% reduction at the Sp1 mRNA level was achieved in 293T cells (data not 
shown).   
In the case of the WT homozygous LBCL, scramble- and Sp1 shRNA-transduced 
cells were sorted 96 hours post-transduction on the basis of GFP expression and 
were left to recover in the appropriate culture conditions.  
I found that in Sp1 kd WT LBCL, Sp1 levels were reduced to 35% of scramble 
control levels, commensurate with PIGM mRNA levels decreasing to 22% of 
control. Consistent with it being a Sp1-dependent gene (212, 213), dihydrofolate 
reductase (DHFR) mRNA levels were also drastically reduced (Fig. 40). 
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Fig. 40 – WT LBCL (N1) transduced with shRNA targeting Sp1 and control 
scramble. A – Cells were identified according to the physical properties SSC (side 
scatter) vs. FSC (forward scatter) of the cells and doublets were excluded by double 
gating on FSC-W (width) and FSC-A (area). FACS plots show GFP expression. 
Untransduced cells were used as unstained control sample. GFP+ cells were flow-sorted 
to high purity (>90%) B – mRNA expression in scramble and Sp1 kd WT LBCL. DHFR 
– positive control. Expression values were normalised to GAPDH and results are 
presented as fold mRNA relative to scramble cells, n=1. 
 
    
In order to evaluate whether this effect was applicable to the heterozygous 
LBLCs, knockdown of Sp1 was also carried out in the -270C>G heterozygous cell 
line, 2D. After 96 hours post-transduction, Sp1 mRNA levels were reduced to 
13% of those in control scramble cells (Fig. 41). Consistently, PIGM mRNA 
levels and DHFR mRNA levels were approximately reduced by 60-70%. 
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Fig. 41 – mRNA expression in the heterozygous LBCL scramble and LBCL Sp1 
knock-down cells (LBCL-shSp1). DHFR – positive control. Expression values were 
normalised to GAPDH and results are presented as fold mRNA (relative to scramble 
cells) ± SEM of 3 independent transductions.      
 
 
Taken together these results showed that in B cells PIGM transcription is 
activated by and depends upon Sp1. 
Surprisingly, in the erythroid GFP-expressing K562 cells, knockdown of Sp1, 
performed in parallel with knockdown in B cells, was inefficient as seen by its 
mRNA levels following transduction with two independent target shRNAs (Fig. 
42). Transduction efficiency was monitored by FACS analysis as described in 
Results 4.1, Fig. 33.  The reason for this is unclear but it may be related, at least in 
part, to the 4-fold higher Sp1 mRNA levels in K562 cells compared to B cells 
(Fig. 43). 
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Fig. 42 – mRNA expression in K562 cells transduced independently with two 
shRNAs targeting Sp1. Cells were transduced with scramble, shSp1#1 and shSp1#2 
lentiviruses and sorted 96 hours thereafter. Expression values were normalised to 
GAPDH and results are presented as fold mRNA relative to scramble cells, n=1. 
 
 
 
Fig. 43 – Sp1 mRNA expression in K562 and WT LBCL (N2) cells. Expression values 
were normalised to GAPDH and results are presented as mean ± SEM of 3 independent 
extractions, ∗ p<0.05. 
 
 
In order to overcome this limitation, I employed an alternative method to interfere 
with the function of Sp1 and test its role in PIGM transcription in erythroid cells. 
Specifically, I used a dominant negative (DN) form of Sp1 which lacks the N-
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terminus trans-activation domain but maintains its DNA-binding domain and 
therefore, once over-expressed in the cell, it competes with endogenous Sp1 for 
binding to its target genes (214). In addition, because the Sp1-mutant is not able to 
recruit the basal transcriptional machinery, transcription of the target genes 
decreases. After transferring this DN Sp1 cDNA from its original pEBGN-Sp1 
backbone into the MigR-GFP vector (see Chapter 2, 2.12) I used it to transduce 
K562 cells.  
After 48 hours post-transfection, GFP-expressing K562 cells were sorted and 
PIGM mRNA levels were analysed by qRT-PCR. By impairing endogenous, 
transcriptionally active Sp1 binding to its DNA cognate motifs, PIGM mRNA 
levels were reduced to 40% of its normal levels as was also the Sp1-dependent 
gene, DHFR (Fig. 44). These results show that just as in B cells, in erythroid 
K562 cells, Sp1 is also fundamental for PIGM transcription.  
 
 
 
 
Fig. 44 – mRNA expression in K562 cells transduced with MigR1-GFP (control) or 
MigR1-Sp1DN-GFP retroviruses. Cells were sorted 48 hours after transduction. 
Expression values were normalised to GAPDH and results are presented as fold mRNA ± 
SEM of 2 independent transductions. 
 
 
To further consolidate these findings, the erythroid and B cells were treated with 
Mithramycin A (MitA), an agent that inhibits TF binding to GC-rich motifs as are 
the TFs belonging to the Sp family (215-217).  
Chapter 3 – Results 
 
107 
After 24 hours of treatment at the indicated concentrations (0.5µM-1µM), cells 
were collected and assayed for PIGM mRNA and respective control genes.  
By increasing MitA concentration in the -270C>G heterozygous LBCL 2D, PIGM 
mRNA levels decreased in a dose-dependent manner reaching one third of its 
normal levels at 0.4µM as compared to DMSO treated control cells. DHFR levels 
were reduced 5-fold of its normal levels and consistent with an auto-regulatory 
transcriptional circuit, Sp1 expression was also drastically reduced (10-fold of 
normal mRNA levels) (Fig. 45A). 
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Fig. 45 – Effect of MitA on gene expression in the -270C>G heterozygous LBCL, 2D 
(A) and K562 cells (B) at the indicated concentrations, for 24hours. Expression values 
were normalised to GAPDH. Results are expressed as fold change mRNA (relative to 
DMSO-treated cells) ± SEM of 3 independent assays, ∗ p<0.05. 
 
In the erythroid cell line K562, PIGM mRNA levels first increased at lower MitA 
(0.05 – 0.3µM) concentrations and then reduced to 40% at the highest 
concentration of 1µM. Regarding Sp1 and DHFR, reduction of their expression 
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levels was achieved at the concentration of 0.3µM, to 35 and 74%, respectively 
(Fig. 44B). 
 
Through the genetic (shRNA), loss-of-function (dominant negative Sp1-mutant) 
and pharmacological (MitA treatment) approaches the role of Sp1 in the 
transcriptional regulation of PIGM in the erythroid cells was better elucidated.   
The investigations outlined here and in the previous section demonstrated that 
although Sp1 is required for PIGM transcription in erythroid cells, its effect is 
independent of the -270GC box.  
 
As the PIGM promoter contains several GC-rich boxes, the next step consisted of 
evaluating the binding pattern of the Sp-family members by ChIP-qPCR. 
 
 
Sp1 differentially occupies the GC-rich boxes at the PIGM promoter 
 
Sp TF occupancy at the length of the PIGM promoter was determined by ChIP-
qPCR using specific primers spanning the GC rich motifs.  
 
In agreement with the results obtained in B cells, Sp1 occupancy at the DHFR 
promoter was used as a positive control whereas in the erythroid K562 cells, the 
α−globin locus was preferred (3). As reported in our previous work (38), Sp1 
binds at the -270 GC-rich box in B cells (Fig. 46). A similar degree of Sp1 
occupancy was seen at upstream promoter regions where at least one GC-rich box 
(-582; amplicon 6) was predicted. In the downstream -160 GC-rich motif 
(amplicon 1), Sp1 occupancy was comparable with background levels (fold 
enrichment of 2). Remarkably, in the erythroid cell line K562, Sp1 was 6-fold 
enriched at the corresponding upstream GC-rich box (amplicon 6) but not at the -
270 GC-rich box (amplicons 4 and 3), suggesting differential, cell type-specific 
binding to this motif. 
To further validate this finding, the same analysis was performed in primary 
CD36+ erythroid precursor cells differentiated in vitro from CD34+ cells isolated 
from cord blood. The advantage in using cord blood as source of CD34+ cells is 
related with the high number of CD36+ cells obtained after differentiation. As 
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seen by the expression of the surface markers CD71 and GlyA, CD36+.cells were 
delayed in differentiation (Fig. 47A) when compared with cells derived from 
PBMC (Fig. 14). Nevertheless, ChIP analysis in the erythroid precursor cells also 
showed Sp1 binding selectivity, with Sp1 binding highly enriched at the upstream 
GC-rich box but not at the -270GC-box (Fig. 47B). The ChIP-seq data deposited 
at the ENCODE was not sufficient to distinguish with fine resolution Sp1 
differential occupancy (see Appendix A, Fig. A10). 
 
  
 
 
 
 
 
 
Fig. 46 – Sp1 occupancy at the length of the PIGM promoter in K562 and WT LBCL 
- N2. DHFR and HBA2 - positive control amplicons; +6Kb - negative control amplicon. 
Results are expressed as fold enrichment over Input ± SEM of at least 3 independent 
experiments. 
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Fig. 47 – Sp1 occupancy at the length of the PIGM promoter in primary erythroid 
precursor cells. A – Cells were sorted according to the physical characteristics (FSC and 
SSC) and cell surface expression of CD34, CD36, CD71 and GlyA markers at day 7. B – 
Sp1 occupancy. HBA2 - positive control amplicon; +6Kb - negative control amplicon. 
Results are expressed as fold enrichment over Input, n=1. 
 
 
Following these findings, the next step was to determine whether other members 
of the Sp family, namely, Sp2 and Sp3, could preferentially occupy the -270 GC-
rich motif and therefore contribute for PIGM transcription and normal expression 
of GPI in patient erythroid cells. The results I obtained with the available anti-Sp3 
antibody were inconsistent possibly due to it not being of sufficiently high quality 
for the purposes of ChIP assays. Nevertheless, the results I obtained in the ChIP of 
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Sp2 were very robust as seen by the high enrichment at the positive control region 
(Sp2 promoter), as described in (128). However, at the length of the PIGM 
promoter, including the -270 GC-rich box, Sp2 enrichment was uniform and 
slightly above the background (fold enrichment 2) in both WT LBCL and K562 
(Fig. 48). 
 
 
 
Fig. 48 – Sp2 occupancy at the Sp2 locus and at the length of the PIGM promoter by 
ChIP-qPCR in K562 (red) and WT LBCL - N2 (purple). Sp2 -2.5Kb and Sp2 pr 
(promoter) correspond to the amplicons used as negative and positive controls, 
respectively. Results from the two experiments (A and B) are expressed as fold 
enrichment over Input.  
 
 
Altogether these results show that the general transcription factor Sp1 regulates 
PIGM transcription in erythroid and B cells. Whilst in B cells, PIGM transcription 
depends of Sp1 occupancy at the -270GC box, in the erythroid cells Sp1-mediated 
transcriptional regulation of PIGM is independent of the -270GC rich motif. 
Moreover, Sp2 does not directly contribute for the transcriptional regulation of 
PIGM.  
Remarkably, these findings explain the normal GPI expression seen in patient 
erythroid cells, thus the lack of anaemia and intravascular haemolysis.    
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5.1.4 Discussion 
 
A point mutation at the promoter of the mannosyltransferase-encoding gene 
PIGM, disrupts a GC-motif and abrogates binding of the TF Sp1.  
The role of Sp1 in the transcriptional regulation of PIGM was first dissected by 
employing a knockdown assay. While in the B cells, the Sp1 mRNA levels were 
significantly reduced (Fig. 41), in the erythroid cells, Sp1 levels were comparable 
to those in control cells transduced with a scramble lentivirus (Fig. 42). The 
impossibility in generating Sp1—deficient K562 cells by shRNA might be the 
result, at least in part, of the higher levels of mRNA in these cells (Fig. 43). 
Failure to target by the two shRNA an Sp1 isoform that might be abundant in 
K562 cells might be another possible explanation for the inefficient knockdown of 
Sp1 in these cells.  
In contrast to K562 cells, in WT and heterozygous -270C>G B cells, efficient 
reduction of Sp1 drastically decreased PIGM expression.  
 
Regardless the inefficient Sp1 kd in the erythroid cells, the role of Sp1 in the 
transcription of PIGM was efficiently demonstrated by overexpressing a dominant 
negative Sp1-mutant. Accordingly, in the presence of Sp1 lacking of 
transactivation potential and failing in the recruitment of the basal transcriptional 
machinery, PIGM expression was reduced to levels lower than 50% (Fig. 44).  
Another manner to test Sp1dependency is by employing a pharmacological 
approach using Mithramycin A (MitA). MitA has been shown to bind to GC 
modules and thus inhibiting Sp binding, including Sp1, to the DNA and repressing 
gene expression (216). Diminished Sp1 DNA binding to GC-boxes by using MitA 
caused a reduction in the PIGM levels (Fig. 49). However, a higher concentration 
was required in erythroid than in B cells (1µM vs 0.4µM, respectively). Again, 
this might be related with the high levels of Sp proteins in the erythroid cells and 
therefore the requirement of more MitA for binding competition.  
Surprisingly, at lower doses of MitA in the erythroid cells, PIGM and DHFR 
expression increased whereas Sp1 expression decreased, suggesting the 
involvement of other TFs in the erythroid cells in counteracting the role of the Sp 
TFs or alternatively, suggesting that members of the Sp family repress PIGM (and 
DHFR) transcription.  
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Altogether these data showed direct involvement of Sp1 in mediating PIGM-
transcriptional regulation in both erythroid and B cells. 
 
Unexpectedly, the data showed that in erythroid cells, Sp1 was preferentially 
recruited at upstream GC boxes rather than at the -270GC box (Fig. 46). In B 
cells, Sp1 occupancy was high and extended at the length of the promoter with 
highest binding levels at the -270GC rich box, highlighting the importance of this 
motif in PIGM transcription in B cells. Recent in vitro mutagenesis studies have 
suggested that, in the context of the multi-functional TNIP1 gene, when multiple, 
nearby Sp1 sites are available for binding, the gene is more prone to repression as 
a result of repressive TFs forming a complex with Sp1 (218). In the context of 
PIGM, Sp1 binding at the length of the promoter in B cells and relative to other 
cell types, is indeed associated with a relative higher level of nucleosomal 
compaction configuration that leads to reduced transcription, as seen in Results, 
3.1.3. By contrast, in the erythroid cells, exclusive Sp1 binding at the upstream 
GC box results in a more open, nucleosome-free promoter configuration that 
ensures higher levels of PIGM transcription. 
ChIP-seq data deposited in the ENCODE database showed low resolution in terms 
of Sp1 binding at such nearby sites and therefore could not further support this 
finding. As mentioned before (see Results 4.1.3), employment of ChIP-EXO 
could have bypassed this limitation.    
 
Studies showing cell-type specific preferences for a given TF at the length of the 
same gene promoter have not been reported. The closest investigations come from 
a study in which a model to predict differential TF occupancy within a single-cell 
type was generated. Chromatin accessibility was not predictive of TF binding, as 
in regions where TFBS were accessible in both erythroid and B cell lines, TFs 
presented cell-type preferential binding. The study showed that TF binding has to 
be considered in the context of specific nucleotide sequence, heteromeric complex 
formation, post-translational modifications, and other allosteric alterations (39).  
 
In vitro studies have suggested that Sp1 competes with Sp3 for the same binding 
site (219, 220) and other studies have demonstrated that Sp1 and Sp3 selectively 
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bind to different Sp1/Sp3 site(s) on the same promoter, depending on the spatial 
availability (221). By recruiting different complexes, Sp1 and Sp3 can exert an 
active or repressive effect in transcription (222). If there is Sp1/Sp3 selectivity at 
the PIGM promoter could not be determined. Although conclusions can not be 
drawn, the possibility that Sp3 binds to the -270GC-rich motif, thus contributing 
to the normal expression of PIGM in the IGD erythroid cells, can not be excluded. 
However, my studies clearly show that Sp2 is not a direct regulator of PIGM 
transcription. 
    
Speculations apart, depicting unknown TFs bound at the gene regulatory regions 
can be achieved by reverse-ChIP techniques such as Proteomics of Isolated 
Chromatin segments (PICh) (223) or similar, like Chromatin Affinity Purification 
with Mass Spectrometry (ChAP-MS) (224). The former involves isolation of the 
protein –DNA complex by using a nucleic acid hybridisation method followed by 
mass-spectrometry. The nuclei acid probe targets the genomic locus of interest 
and subsequently all the proteins bound to that locus are identified according to 
their mass to charge ratio. Employment of this method would have allowed the 
identification of the TF(s) bound at the -270GC motif in the erythroid cells and 
therefore the study of their role on PIGM transcription. 
  
At the most proximal -160GC-box I found that Sp1 was not enriched in both 
erythroid and B cells (Fig. 46). By prediction, mutations in this putative Sp1 
binding site have no effect in PIGM transcription and therefore in GPI expression 
in these cells.  
 
In this chapter, I showed that Sp1 is required for PIGM transcription in erythroid 
and B cells. Very importantly, I demonstrated that Sp1 discriminates between GC-
boxes at the PIGM promoter in a cell-environment dependent manner. These 
finding explains the normal PIGM transcription and GPI expression in patient’s 
erythroid cells and consequently the lack of anaemia and intravascular 
haemolysis. 
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6.1 Investigating the genomic interactions of PIGM 
 
6.1.1 Introduction 
 
In the nuclear space, chromatin is not randomly distributed but presents instead a 
level of organization. Chromosomal territories (CT) represent the topological 
space occupied by chromosomes, are the highest-order of chromatin organization 
and can be cell-type specific (225). 
  
Preferential organization of the genes in the nuclear space has been proposed to 
associate with their transcriptional status. Accordingly, there are regions in the 
nuclear space where transcription is usually active (euchromatin regions like in 
the nucleolus) and others where it is not (heterochromatin regions). 
Transcriptionally active genes may loop out of their CT to create “hubs” of 
transcription or transcriptional factories, and come in close proximity of other in 
cis or in trans genes with which they interact. In transcriptional factories, are 
transcriptional units in which participating genes share of the use of TFs and 
active RNA PolII, that are essential for active gene transcription (226). Further 
studies in erythroid cells showed that in cis active genes co-localise in foci of 
active transcription, and once moved out transcription is abolished. Recruitment 
into the factories is most likely influenced by effectors of transcriptional 
regulation such as TFs, regulatory elements (enhancers) and epigenetic marks 
(227).   
 
This fascinating structural and functional organisation is supported by the findings 
that transcriptional regulation does not occur in a linear fashion and the regulatory 
elements do not necessarily regulate transcription of the nearby genes. Indeed, 
regulatory elements like enhancers contact the gene proximal region of the target 
gene by TF-DNA-mediated looping formation. 
 
DNA looping formation and the three-dimensional organisation of the genes in 
the nucleus is therefore relevant for transcriptional regulation and constitutes a 
layer of regulation that should be taken into account.  
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Long-range interactions can be detected and quantified by using the chromosome 
conformational capture (3C) methodology and its derivatives. The technique is 
based on the detection of intramolecular ligations following crosslink of the 
chromatin. The abundance of a given intramolecular ligation reflects the 
frequency of an interaction and therefore, the vicinity between two genomic loci 
(4). Circular chromosome conformational capture (4C) is a derivative of 3C. 
Whereas in the 3C both bait and interactor are known, in the 4C the approach is 
unbiased. 4C is based on the proximity ligation principle, in which interacting 
protein-DNA complexes are favoured and circularize under diluted conditions; it 
involves two steps of restriction digestion with appropriate enzymes and 
identification of the interacting genes by genomic screening (microarray analysis 
or high throughput-sequencing). Regarding the choice the restriction enzyme, 
some aspects have to be taken into account. The choice of a 4 or 6bp cutter 
depends of the size of the loci under analysis; the enzymes have to efficiently 
digest the chromatin at 37°C as high temperatures uncross-link the protein-DNA 
complexes; the enzymes that are sensitive to DNA methylation should be avoided 
as they may introduce a bias into the assay due to different DNA digestion 
efficiency. The 4C assay presents higher resolution than 3C and is highly accurate 
in the quantification of DNA interaction frequencies of a specific genomic area 
(228). 
 
In the previous chapters I elucidated the role of a cis-DNA element, in this case of 
the -270GC-rich box, in differential, tissue-specific transcriptional regulation of 
PIGM. In an attempt to better understand the complex regulatory network of 
PIGM, here I propose to investigate whether PIGM established in cis or in 
trans long range interactions with other genes as part of the same 
transcriptional unit. Furthermore, I intend to investigate the impact of lack 
Sp1-binding at the PIGM-promoter in IGD cells in this process.  
 
6.1.2 Experimental design 
 
In order to identify PIGM-interacting genes, 4C assay was employed in uncross-
linked (controls) and cross-linked WT- and MUT (IGD)- LBCLs followed by 
Chapter 3 – Results 
 
119 
high-throughput sequencing. Bioinformatic analysis was performed by the 
Computational Genomics Analysis and Training (MRC Functional Genomics 
Unit, Oxford). 
The results presented below are still preliminary. 
 
6.1.3 Results 
 
PIGM and neighbour genes are part of a transcriptional unit 
 
Following previously optimization, ApoI (6-bp cutter, R^AATTY) and NlaIII (4-
bp cutter, CATG^) were the restriction enzymes of choice. Following sequential 
digestion intercalating with two steps of intramolecular ligation, the libraries for 
the WT and MUT cells were prepared (see Chapter 2, 2.6 and schematic 
representation below). Controls included digestion efficiency by qRT-PCR and 
specificity of the PCR amplification by DNA sequencing. 
 
 
 
 
Fig. 49 – Schematic representation of the 4C assay. Following digestion and 
intramolecular ligation, PCR amplification of the fusion sequences is performed by using 
tail to tail PIGM specific primers. Adapted from (228).  
 
Ligation junctions were captured by high-throughput sequencing and data was 
aligned to the reference genome and then compiled as heat-maps. The specificity 
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of a given interaction is supported by the identification at the fusion of the partner 
genes of the ApoI/NlaIII sites. Therefore, interactions are revealed as fusion 
sequences between the bait, i.e., PIGM and the interacting partner. 
 
In the WT uncross-linked cells (Fig. 51B), the majority of the PIGM interactions 
were localised at the PIGM locus, most likely as a result of re-ligation. In the 
cross-linked samples (Fig. 51A), high intensity contacts (seen as peaks) were 
established with the following neighbour genes: IGSF9, SLAMF9, KCNJ10, 
KCNJ9, IGSF8 and ATP1A2. Less intense contacts were established with CASQ1, 
DCAF8 and NCSTN genes. 
Regarding the MUT cells, in the uncross-linked state (Fig. 51D) the number of 
captures was less than in the WT uncross-linked cells but still at the PIGM locus 
(overall MUT cells were somehow more resistant to digestion). In the MUT cross-
linked sample (Fig. 51C), the 4C profile was similar to the MUT UNX or WT 
UNX, suggesting inefficient cross-link. However, as uncross-linked samples were 
less resistant to digestion than cross-linked samples, this indicated that the MUT 
cross-linked profile represented a real loss of interactions and it was not the result 
of inefficient cross-link. 
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Fig. 50 – Heat map showing the average contact intensities of PIGM. A – cross-linked 
and B – uncross-linked WT LBCL (N2); C – cross-linked and D – uncross-linked MUT 
LBCL (2C). Window size varies from 4Kb to 200Kb.The colour scheme (grey to red) 
represents the frequency of the contact intensities.  
 
 
The results in B cells suggest a common regulatory network shared between 
PIGM and the interacting partners, as part of a transcriptional unit. Given that in 
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the MUT cells the contacts are lost and preliminary data showed alignment of the 
interactions with known Sp1-binding sites, active gene expression, promoter state 
and open chromatin (ENCODE), the results further suggest that Sp1 could be 
involved in mediating the cis-interactions by DNA-loop formation. 
 
 
6.1.4 Discussion 
 
PIGM-associated IGD is a disorder characterised by abdominal vein thrombosis 
and epilepsy. The complexity of the disease translates the diverse GPI phenotype 
seen in patient cells, as a result of differential transcriptional regulation of PIGM. 
In B cells, PIGM transcription is dependent of Sp1 binding to the -270GC box. 
Using as a model LBCLs derived from a patient and a normal donor B cells, I 
tested whether PIGM is part of a transcriptional unit, sharing with genes in the 
close proximity similar mechanisms of regulation and whether in the absence of 
Sp1 binding to the PIGM promoter and lack of active transcription, the regulatory 
network where these genes are embedded, is disrupted.    
Preliminary data resulting from 4C analysis showed cis-interactions established 
between PIGM and the following genes: IGSF9, SLAMF9, KCNJ10, KCNJ9, 
IGSF8 and ATP1A2. Those interactions were captured with high frequency, 
suggesting that in the nuclear space these genes are indeed in close proximity with 
PIGM. 
KCNJ9 and KCNJ10, both part of a subfamily of inward rectifier potassium 
channels constitute two of the high-frequent PIGM-interacting genes. 
Interestingly, SNPs in the region encompassing the KCNJ9/KCNJ10 genes have 
been associated with temporal lobe epilepsy (229), suggesting their role in the 
maintenance of the brain function. It is very tempting to speculate that lack of 
appropriate PIGM transcription can influence their expression, constituting an 
explanation for some of the IGD characteristics (such as epilepsy). Furthermore, 
IGSF8 and ATP1A2, two other genes depicted from the analysis, have been 
suggested to participate in the maintenance of the neural network in the adult 
brain. ATP1A2 is associated with a rare neurological disorder that is Alternating 
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Hemiplegia of Childhood (AHC), characterised by recurrent attacks of hemiplegia 
(230, 231). SLAMF9 is involved in the signalling lymphocytic activation (232).  
In view of the functional aspects of the PIGM-interacting genes the results point 
towards a regulatory link between these genes and PIGM that once disrupted 
possibly contribute for the phenotype of the disease. Further validation of the 
ligation junctions would require 3C analysis by using primers targeting both 
PIGM and the interacting gene as well as DNA-FISH, using specific DNA-probes 
to detect co-localization/proximity. Determining whether the captures are 
functional by quantifying gene expression using RNA-seq is also essential. Lastly, 
in order to consolidate these findings occupancy of Sp1 at H3K4me marked 
promoter regions of the interacting genes needs to be carried-out by ChIP. Those 
results will reinforce the role of Sp1 as an “anchor” in mediating PIGM-loop 
interactions. 
Furthermore, I speculate that NaBu treatment of the MUT cells restores the 
interactions seen in the WT cells.  
 
Although preliminary, these findings suggest that PIGM is part of a transcriptional 
unit in which genes important for the brain function are involved, possibly sharing 
a common mechanism of Sp1-mediated transcriptional regulation. Sp1-mediated 
chromatin looping has been reported in the enhancer-promoter HO-1 (heme 
oxygenase 1) gene in renal cells (129) . 
 
Altogether these results add another level of complexity at the PIGM locus and 
contribute for the knowledge of such a particular disease. Further, they reveal the 
importance in identifying genes contained in transcriptional units as a unique 
contribution for the better understanding of disease. 
 
 
 
 
 
 
 
Chapter 4 – Discussion and concluding remarks 
 
124 
Chapter 4 – Discussion and concluding remarks 
 
 
Appropriate regulation of gene expression is essential for the maintenance of the 
cellular function. In recent years, genome-wide studies have delivered an 
enormous amount of data in relation to the structure and function of regulatory 
elements and mechanisms of gene transcription. This data mostly results from 
high-throughput studies including RNA-seq, ChIP-seq, DNase-seq, Hi-seq and 
others. From the integration of gene expression data, TF occupancy, chromatin 
accessibility and epigenetic marks, novel regulatory elements have been identified 
(29) suggesting the presence of even more complex regulatory interactions within 
the mechanisms of gene regulation. 
However, these tools become less useful when studying regulation of gene 
expression at the level of a single gene and particularly in a cell-type specific 
context. 
  
PIGM-associated IGD constitutes a very interesting model to study the impact of 
a cis-acting mutation in gene expression (de)regulation at the cell- and tissue-
specific level. Cis-regulatory mutations are usually screened after coding 
mutations have been excluded. In striking contrast to the other genes required for 
the GPI biosynthesis, PIGM is so far the only gene of the pathway in which a 
functional mutation in a regulatory region has been reported. This may be related 
with the fact that mutations are not always compatible with life and therefore 
create a “gap” in the number of studies available. Interestingly, inherited 
mutations in other genes of the GPI biosynthetic pathway are coding and are 
associated with a more severe phenotype that in PIGM-associated IGD. This may 
be related to the fact that regulatory mutations are often hypomorphic, i.e., do not 
totally abrogate expression and even if low, the amount of protein/enzyme that is 
produced is functional and can be sufficient in a certain cellular environment to 
reach the required threshold. On the other hand, a coding mutation, even if it is 
missense, may produce an aberrant and/or completely dysfunctional protein.    
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The -270C>G pathogenic mutation disrupts binding for the generic TF Sp1 in the 
core promoter of PIGM. As we recently published, impaired TF binding is 
associated with selective histone hypoacetylation, nucleosomal compaction, 
Polycomb recruitment and imposition of bivalent histone methylation marks. 
These events ultimately lead to a down-regulation of PIGM mRNA and deficient 
GPI expression at the cell surface in IGD B cells. Contrasting with PNH, another 
well-characterised disorder of the GPI pathway, GPI expression at the surface of 
the erythroid cells is near normal thus the absence of anaemia and intravascular 
haemolysis in patients. Similarly, in the group of Inherited GPI disorders, patient 
erythroid cells possibly express normal levels of GPI as deficiency has not been 
reported. As within this group most disorders result from coding mutations I 
hypothesize that in those where the catalytic domain of the enzyme is affected, the 
deficient enzyme is somehow re-activated in the erythroid environment or its 
activity is sufficient for minimal expression. The molecular events driving normal 
GPI expression in the erythroid cells of patients with PIGM-associated IGD were 
not known and constituted the overall aim of this thesis.  
 
 
Sp1 may discriminate between GC-boxes along the promoter of housekeeping 
genes 
 
 
In PIGM-associated IGD, GPI deficiency results from transcriptional deregulation 
of PIGM. For instance, in the B lymphocyte lineage GPI- cells express less PIGM 
mRNA than GPI+ cells (Fig.19). 
In WT B cells the PIGM promoter architecture is more compacted than in the 
erythroid cells, and therefore in the former the gene is more prone to 
transcriptional repression (Fig. 23A and B). Associated with this, Sp1 binds along 
the GC-boxes at the promoter, most highly at the -270GC box in B cells (Fig. 46).  
By contrast, in erythroid cells, the pathogenic mutation had no impact at the 
transcriptional level, as mutant primary erythroid precursor cells expressed PIGM 
mRNA (Fig. 19) and the GPI-linked antigen CD59 (Fig. 18B) as compared to 
their heterozygous counterparts. Moreover, in the erythroid cell line the TSS is 
positioned downstream at the -270GC motif (Fig. 25), excluding the possibility of 
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transcription initiation upstream of the pathogenic mutation and differential core 
promoter usage.  
The most striking finding of my investigations was the absence of Sp1 binding at 
the -270GC-box in the erythroid cell line K562 (Fig. 46) further confirmed in 
primary erythroid precursor cells (Fig. 47). This result revealed that Sp1-mediated 
transcriptional regulation of PIGM in erythroid cells is independent of the -270GC 
box, thus explaining the normal GPI+ phenotype seen in patient mature red cells. 
 
Although numerous studies have focused on cell type-specific gene regulation, 
there is a lack of investigations aiming to dissect cell type-specific TF binding 
preferences at gene regulatory regions. The studies reporting differential, cell 
type-specific TF preferences are usually focused in motif-comparisons between 
genes and not on motifs on the same gene (34, 39, 40). Based on the results of my 
studies in normal and IGD erythroid cells I propose that discriminative binding to 
GC boxes is the result of an erythroid cell-specific configuration of the PIGM 
promoter (see proposed model, Fig. 51). Accordingly, protein-protein interactions 
established upstream at the promoter between erythroid specific TFs (possibly 
KLF1) may limit the spatial availability and by nucleating the transcriptional 
machinery potentiate PIGM transcription. Whereas KLF1 is a possible direct 
PIGM transcriptional activator, GATA-1 is most likely involved in PIGM 
repression.  
Another possible scenario might involve reduced Sp1 binding affinity to the -
270GC box possibly due to those interactions established upstream at the 
promoter, so altering Sp1 specificity or sequence affinity. Additionally, 
investigating how the levels of Sp1 and its post-translational modifications affect 
Sp1 availability and binding at the promoter in the erythroid cells could have been 
important to better dissect the regulatory mechanism driving PIGM transcription.  
 
In addition, PIGM mRNA levels in the erythroid cells suggested a low basal level 
in normal conditions as compared to the B lymphocytes (Fig. 15). Nevertheless, 
the amount of protein that is produced is sufficient for normal enzymatic function 
and therefore for the normal cellular processes. Comparing PIGM activity in the 
eryhroid cells with that in the B cells would contribute for the better 
understanding of the differential threshold and as a consequence, of the disease. 
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Thus, I speculate that the role of the -270GC box is to potentiate PIGM 
transcription in cells where higher levels are needed, like in B cells. 
  
In patients with PIGM-associated IGD, cells belonging to the monocyte lineage as 
well as T cells expressed normal GPI levels whereas the B lymphocytes were 
mostly deficient (Fig. 17). Deciphering the regulatory mechanism of PIGM in 
these cell lines is beyond the scope of this thesis. Whether in the monocytes and T 
cells, PIGM expression is independent of the -270GC box, is not known. 
Nevertheless, I speculate that in the monocytes, in which the PIGM basal levels 
are also low, Sp1 is not recruited at the -270GC box.  
 
An interesting observation is that the erythroid precursor cells contrast with the 
red blood cells (RBC) isolated from peripheral blood of patients in respect to 
CD59 expression. While the in vitro differentiated erythroid precursor cells 
express normal levels of CD59 (Fig. 18B), the red blood cells isolated from 
peripheral blood present some degree of heterogeneity, with some cells expressing 
less CD59 (Fig. 13). This might be related with gene expression shut-down in 
RBC combined with the fact that in the erythroid culture system used in here cells 
were collected at the proerythroblast stage and the PIGM mRNA levels were still 
elevated.  
 
By disrupting erythroid-specific transcriptional networks, Sp1-binding mutations 
have been shown to affect gene expression in erythroid cells (93, 139). Here we 
show that the Sp1 binding mutation is not disadvantageous to the erythroid cells 
as a result of lack of Sp1 binding in the normal conditions. Additionally, the 
complexes between generic and erythroid-specifc TFs recruited upstream at the 
promoter are most likely fundamental for normal expression.  
 
In view of the importance of generic TF binding in housekeeping gene regulation, 
understanding whether Sp1 discriminates between GC-boxes at the regulatory 
regions of other housekeeping genes, usually enriched in GC-motifs, would 
doubtless provide invaluable information. As regulatory mutations not always 
underlie an evident phenotype and might have an impact at the cell-type specific 
level, this link may be difficult to study in a genome-wide type of approach.  
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I speculate that this finding is applicable to other housekeeping genes. 
Discrimination between GC-boxes might constitute a mechanism of regulating 
different threshold levels in different cell types, thus always ensuing sufficient 
mRNA levels. 
  
 
The -270GC box may be bound by TFs other than Sp1 
 
Having seen that KLF1 (erythroid TF that shares the DNA binding domain with 
Sp1 with similar affinities) was not recruited at the -270GC box, but it was instead 
recruited at the upstream promoter region of PIGM (Fig. 39), I hypothesise that in 
the erythroid cells, PIGM transcription is most likely driven by a combination of 
generic and cell-type specific TFs, like Sp1 and KLF1, respectively, anchored at 
the proximal promoter upstream at the -270GC box. Evidence exists supporting 
that Sp1 and KLF1 synergistically interact to regulate gene expression of 
enzymatic proteins (233). Moreover, a gene of the biosynthetic GPI pathway 
(PIGQ) is a KLF1 target in the eryhroid cells (206), suggesting that erythroid 
specific TFs regulate expression of housekeeping genes belonging to the GPI 
pathway.    
Whether transcriptional regulation of PIGM involves recruitment of the upstream 
regulators nearby the TSS by DNA-looping formation is not known. Studies 
supporting the existence of short-range interactions in mediating gene regulation 
have been reported (234).  
 
The role of Sp3 in competing with Sp1 for the DNA-binding domain can not be 
excluded. Also Sp4, mainly expressed in neuronal cells, may contribute for the 
regulatory mechanism driving PIGM expression in the neuronal tissue of the 
affected children. The importance of Sp proteins in the regulation of neuronal 
genes has been reported (101, 235). Specifically, in the case of PIGM-associated 
IGD, treatment of the affected children with the HDAC inhibitor NaBu, mediated 
histone re-acetylation and Sp1 recruitment. The role of Sp3 and Sp4 in PIGM 
transcription in the erythroid cells remains unknown.  
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It should be also noted that GC-boxes serve as binding motifs not only for Sp but 
for other TFs too. In gene promoter regions, Sp1 binding sites are frequently 
adjacent or can overlap with GC-binding sites for the transcription factor Egr1 
(236). In megakaryocytes for example, Sp1 and Egr1 can differentially regulate 
transcription through the same DNA binding site (237). The role of Egr1 has been 
also described in cell differentiation along the monocyte lineage and interestingly, 
in neuronal plasticity. ChIP-seq data suggests that Egr1 is a potential candidate of 
PIGM transcription (Fig. 28).   
 
Regarding the T cells, studies have shown the importance of GATA-3 not only in 
their development but also survival (155). As GATA-3 shares the same DNA-
binding domain with GATA-1, is possible that GATA-3 activates PIGM 
transcription through the identified GATA sites in T cells.  
 
The use of induced pluripotent stem (iPS) cells to produce cells from different 
tissue sources, has constituted a relevant tool when patient samples are not 
available. iPS cells could be used to generate neuronal or haematopoietic cells (in 
larger amounts) harbouring the -270C>G mutation, in which the regulatory 
mechanism could be studied in more detail, therefore contributing for the more 
comprehensive knowledge of the disease.  
 
 
The importance of studying cis-regulatory mutations in the appropriate cell-
type 
 
Mutations in a Sp1 binding site, differentially affecting gene expression according 
to the cell type have not been reported. This may be related with the fact that most 
studies focus in a particular cell-type, in which there is an obvious link between 
the regulatory mutation and impact in gene expression. As a consequence, results 
might have been disregarded.  
 
Here we showed that disruption of Sp1 binding affects PIGM transcription and 
consequently, GPI expression in a cell-type specific manner. Moreover, 
preliminary studies suggested that disruption of Sp1 binding might have a 
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functional effect in neighbouring, interacting genes that can contribute to the 
phenotype of the disease.  
 
Studying the impact of a functional mutation in gene expression in a broader cell 
context may be particularly relevant for the accurate diagnosis of diseases sharing 
very similar characteristics. In this context, determining the interactions that are 
disrupted by the functional mutation may also provide invaluable information for 
the purpose of better understanding the complex regulatory mechanism behind the 
disease and therefore to help to design more efficient therapies.   
 
The work presented here unveils new questions that remain to be answered. For 
instance, it is not known whether PIGM-associated IGD patients present somatic 
mutations that could contribute for the deficient phenotype or instead, to the 
normal expression of GPI. Additionally, dissecting PIGM transcriptional 
regulation at the HSC level and during haematopoietic lineage specification could 
provide valuable information in terms of TF binding usage and therefore 
contribute for the better comprehension of the distinct GPI phenotypes seen in the 
haematopoietic tissue.  
 
Very importantly, the work presented in this thesis constitutes one, if not the first, 
report of cell-type specific binding preferences of a generic TF, providing novel 
insights into tissue-specific transcriptional control of a housekeeping gene.  
Remarkably, these results can contribute for the better understanding of diseases 
caused by single point mutations that abrogate TFBS and additionally, they shed 
light on the importance of studying regulatory mutations at the individual cell-
type level. 
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Fig. 51 – Proposed mechanism of transcriptional regulation of PIGM in 
erythroid and B cells. In WT erythroid cells, Sp1 is not recruited at the -270GC 
box, occupying instead the upstream GC box. In the WT B cells, Sp1 is recruited 
at the upstream box and also at the -270GC box. Whereas in the WT B cells, 
recruitment of the transcriptional machinery is mediated through Sp1-bound at the 
-270 GC box, in the erythroid cells, lineage-specific and generic TFs drive PIGM 
transcription. As a consequence, in the presence of the mutation, PIGM 
transcription is reduced in the B cells but it is not affected in the erythroid cells. 
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Fig. A1 – pcDNA5/FRT vector used in the stable luciferase reporter assays. The 
pcDNA5/FRT vector lacks the CMV promoter and contains a GFP reporter gene 
downstream at the PIGM promoter.  -910bp of the WT and MUT PIGM promoter were 
cloned between KpnI and NcoI restriction sites. 
 
 
 
Fig. A2 – MigR1 vector used for overexpression. Sp1-mutant cDNA fragment was 
cloned between BglII and EcoRI in the MigR1-GFP backbone. hGATA-1 cDNA 
fragment was cloned in the EcoRI site in the MigR1-ratCD2 vector backbone.  
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Fig. A3 – Mononuclease digestion at the indicated units monitored by gel 
electrophoresis (2% agarose gel).    
 
 
 
 
Fig. A4 – Optimization of the sonication conditions. A – Chromatin from WT LBCL 
(N2) sonicated for 15(1), 20(2), 22(3) and 25(4) min and chromatin from K562 sonicated 
for 22(5) and 25(6) min. Fragments are below 500bp. B - Chromatin from CD36- cells 
sonicated for 15(1), 20(2), 25(3) and 27(3) minutes. A period of 27 min was used for 
subsequent sonication of CD36+ cells. 
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Fig. A5 – pLKO1-modified GFP vector used in the lentivirus transductions. shRNA 
oligonucleotides were cloned between EcoRI and AgeI restriction sites. 
 
 
 
Fig. A6 – Digestion of the pLKO.1 shRNA plasmids. Approximately 100ηg of each 
plasmid were digested with EcoRI and NcoI. Digestion was monitored in a 2% agarose 
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gel. L – ladder; lane 1 – pLKO.1-GFP empty (control), lanes 2 – 6 pLKO.1-shRNA. The 
pLKO.1 empty vector contains a 1.9kb stuffer that is released upon digestion. 
 
 
Fig. A7 – Virus titration in 293T cells. Cells were transduced with 2µl, 20µl, 100µl and 
200µl of viral supernatant and then assayed for GFP expression by FACS. Viral titre 
(transducing units per ml) was determined according to the formula described in (238): 
TU ml-1 = (F*N*D*1000)/V, where F = percentage of GFP fluorescent cells, N = number 
of cells at the time of transduction (100.000), D = fold dilution of vector sample used for 
transduction and V = volume (µl) of diluted vector sample added into each well for 
transduction. The average titer was then calculated.  
 
 
 
  
Fig. A8 – Western-Blot showing exogenous hGATA-1 expression in HeLa cells, 48 
hours post-transfection. GATA-1 from murine was also tested in parallel. 
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Fig. A9 – Evaluation of the transfection efficiency of the MigR1-ratCD2 plasmid in 
Flp-In 293 cells by FACS (solid black line). 
 
 
 
 
 
 
Fig. A10 – Sp1 ChIP-seq analysis at the PIGM promoter retrieved from the UCSC 
genome browser on Human Feb.2009 (GRCh37/hg19) Assembly - ENCODE database. 
Sp1 binding was captured in a LBCL (GM12878) and K562. The -270GC box is 
highlighted in green.  
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Appendix B – Inherited GPI Deficiency 
 
Below are described the main genetic and clinical aspects of the group of rare 
inherited autosomal diseases of the GPI pathway.  
 
 
PIG-A 
As previously described, somatic mutations in PIG-A result in PNH. Although it 
has been suggested that germline mutations in PIG-A are lethal (239, 240), a 
recently identified X-linked disorder contradicts this supposition. Patients with a 
nonsense mutation on PIG-A (c.1234C>T) have a reduction, but not absence, of 
GPI biosynthesis and present anomalies such as cleft palate, neonatal seizures, 
contractures and central nervous system (CNS) malformations (104). 
 
PIG-L 
Compound heterozygous mutations in PIG-L, the enzyme that catalyses the de-N-
acetylation of GlcNAc-PI in the cytoplasmic side of the ER, have been associated 
with the multisystemic disorder CHIME (coloboma, heart defects, icthyosis, 
mental insufficiency and ear defects) syndrome. The heterozygous missense 
mutation c.500T>C (p.Leu167Pro), located in the catalytic domain of the enzyme, 
was found in all six previously described CHIME patients. By employing FACS 
analysis in fibroblasts- and in EBV-transformed lymphoblastoid -cell lines 
derived from two patients, the authors observed a slight reduction (between 2- to 
4-fold) in both CD59 cell-surface marker and FLAER, a modified pro-aerolysin 
that binds to GPI, when compared to normal controls. As discussed, the decrease 
in GPI expression suggests that the alteration mildly affects the function of the 
enzyme and GlcN-PI properly de-N-acetylated is flipped into the luminal side of 
the ER. Despite the lack of data in primary cells, the study confirms the 
pathogenicity of PIG-L mutations and reveals their impact at the multisystem 
level (105). 
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PIG-V 
Homozygous or compound heterozygous mutations in PIG-V, the second 
mannosyltransferase encoding-gene of the pathway are known to cause HPMR 
syndrome, characterized as the name implies, by mental retardation and elevated 
levels of the GPI-anchored protein ALP in serum. Cell surface analysis of CD16 
and FLAER in granulocytes from HPMR patients showed a remarkable decrease 
of GPI expression and rescue experiments performed in PIG-V deficient CHO 
(Chinese hamster ovary) cells, revealed that only PIG-V WT cDNA was able to 
restore GPI expression, as measured by CD59 and CD55 (78). More recently, the 
mechanism for release of ALP in HPMR has been demonstrated. Briefly, by 
employing pulse-chase metabolic labelling in PIGV-deficient and –rescued cells, 
the authors showed that the secretion of ALP functionally depends on the 
cleavage of the GPI attachment signal by the GPI transamidase complex. 
Moreover, they demonstrated that efficient cleavage is determined by the presence 
of the intermediate GPI containing at least one mannose residue. 
Given the fact that half of the patients with HPMR are negative for PIG-V 
mutations, it was also suggested that defects in later genes of the GPI biosynthetic 
pathway, such as PIG-B, PIG-O and PIG-F, may also cause HPMR syndrome, 
contrary to defects in early GPI genes, such as PIG-L and PIG-W, in which 
immature GPI is not mannosylated (241). Indeed, a new study has recently 
recognized PIG-O as the second gene associated with HPMR (103).  
 
PIG-N 
Subsequently in the biosynthetic pathway of the GPI complex is PIG-N, the 
ethanolamine phosphate transferase 1-encoding gene. A study performed in mice 
by Hong Y. et al, has shown that the addition of the first ethanolamine (Etn-P) is 
not crucial for GPI anchor attachment as disruption of Pig-n only partially affects 
expression of the GPI-AP Thy-1 (73). On the other hand, a missense mutation in a 
highly conserved residue of PIG-N in humans underlies the drastic reduction (10 
fold) of CD59 in fibroblasts from patients with PIG-N deficiency. Patients present 
with various abnormalities including developmental delay, cardiac, genitourinary 
and gastrointestinal defects, as well as severe neurological impairment with 
chorea and seizures, leading to early death (113). Despite the scarce 
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immunophenotypic analysis, the study demonstrates the vast implications 
associated with PIG-N deficiency and reinforces the importance of GPI-APs in 
development. 
  
PIG-O 
As mentioned above, PIG-O mutations have been reported as the genetic cause of 
HPMR, independently of mutations in PIG-V. Accordingly, patients with PIG-O 
deficiency present with neurological abnormalities (microcephaly and seizures) 
and elevated levels of serum ALP.  
Compound heterozygous mutations, underlying GPI deficiency at the surface of 
granulocytes, have been identified in patients belonging to unrelated families. 
PIG-O mutations have been functionally assayed in in vitro experiments by 
transfecting two mutant PIG-O cDNAs in PIG-O-deficient cells. Whereas some 
PIG-O mutations affect protein stability, others severely impair enzyme activity 
reducing GPI-APs at the cell surface (103, 242). 
 
PIGT 
 
Very recently, mutations in PIGT, one of the subunits of the transamidase 
complex, have also been described. The homozygous mutation c.547A>C in PIGT 
is the causative defect of a previously unidentified syndrome characterised by 
distinct facial features, intellectual disability, hypotonia and seizures, in 
combination with abnormal skeletal, endocrine and ophthalmologic findings. Cell 
surface analysis of CD16 and FLAER in granulocytes and NK cells as well as 
CD59 in monocytes, revealed decreased expression of these GPI-APs in patients 
when compared with normal controls. Additional studies using morpholinos (MO) 
mediated suppression of pigt in zebrafish embryos, showed defects at the 
gastrulation level and in rescue experiments the presence of PIG-T homologous 
mRNA, but not mutated PIGT mRNA, rescued the abnormal phenotype.  
Together, the results demonstrate for the first time an association between 
mutations in PIGT and human disease (114).     
Recently, mutations in PIGT have been associated with PNH in the absence of 
mutations in PIGA. A deleterious splice site mutation simultaneously with a 
somatic mutation in a myeloid stem cell on PIGT reduces the expression of GPI in 
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the haematopoietic cells and causes haemolytic anaemia. The data suggests that 
defects in transferring intact, fully assembled GPI anchor to proteins causes PNH 
(115).  
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